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ABSTRACT 
Patrick T. Bradshaw: Post-diagnosis weight change, physical activity and survival among 
women with breast cancer: a longitudinal study with missing data 
(Under the direction of Marilie D. Gammon) 
 
Nearly forty thousand women per year are diagnosed with breast cancer and there are 
currently over 2 million female breast cancer survivors in the United States.  Whether 
survival after breast cancer diagnosis is influenced by modifiable lifestyle factors, including 
post-diagnosis weight change and physical activity, is unclear.  These associations were 
examined using data from a population-based follow-up study of 1,508 women diagnosed 
with first primary in situ or invasive breast cancer between August 1, 1996 and July 31, 1997 
in Long Island, New York.  During baseline and follow-up interviews, women self-reported 
their height, weight, recreational physical activity levels and other factors.  Additional 
information on clinical factors was ascertained through medical records and the New York 
State Cancer Registry.  Vital status was determined using the National Death Index; through 
the end of 2005, 308 women were deceased, with 164 due to breast cancer. Approximately 
one-third of the subjects did not complete the follow-up interview. To address the issue of 
potentially non-ignorably missing data, I developed a selection model for survival analysis 
with time-varying covariates.  A sensitivity analysis using the data on post-diagnosis weight 
change illustrated that a standard analysis resulted in reduced statistical efficiency and 
differences in magnitude of effect when compared to the selection model.  Mortality was 
positively associated with both post-diagnosis weight loss and weight gain, regardless of the 
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time since diagnosis or pre-diagnosis body size.  More detailed analyses showed that 
previously reported associations of mortality with pre-diagnosis body mass index (BMI) and 
adult weight change were attenuated after accounting for post-diagnosis weight change, 
while associations with post-diagnosis weight change remained.  Mortality was inversely 
associated with recreational physical activity, regardless of pre-diagnosis activity levels, 
timing of post-diagnosis activity, or pre-diagnosis BMI.  Since weight gain and reduction in 
physical activity are common after breast cancer diagnosis, these findings that suggest weight 
maintenance and physical activity enhance survival among breast cancer survivors may be 
especially important. 
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 CHAPTER 1 
BACKGROUND 
Epidemiology of Breast Cancer Incidence 
In 2005 the greatest number of new cancer cases among women was breast cancer with over 
260,000 new cases, accounting for nearly a third of all cancers diagnosed that year (1).  A 
sharp increase in yearly incidence rates of invasive breast cancer was observed between 1980 
and 1987, due in part to improved use of mammographic screening and overall breast cancer 
awareness, but the yearly increases in incidence became much more stable between 1987 and 
2002 (2).  Age is the factor most strongly associated with breast cancer incidence with the 
median age at diagnosis between 1987 and 2002 being 61 years and most new breast cancer 
diagnoses occurring among women over 40 years.  Breast cancer incidence rises across the 
entire age range reaching its apex by 75-79 years, however it increases with age more rapidly 
before menopause than after (3).  This pattern is likely reflective of the hormonal 
mechanisms that are believed to play a role in breast carcinogenesis (4) as endogenous 
estrogen exposure is higher during the reproductive years.  A positive association between 
breast cancer incidence and socioeconomic status has also been noted (5) as more affluent 
women have a higher risk of being diagnosed. 
Etiology of Breast Cancer 
The vast majority of breast cancers are adenocarcinomas which arise from the glandular 
tissue of the breast (6).  In situ breast cancers are those malignancies that are confined to the 
ducts or lobules of the breast and are less common than invasive cancers, those that infiltrate 
the surrounding stroma.  Hormones such as estrogen and progesterone are believed to play a 
  2 
significant role in the etiology of breast cancer given their effect on cellular proliferation (7).  
Estrogen receptor (ER) positive or progesterone receptor (PR) positive tumors have relatively 
large numbers of the respective hormone receptors and are thought to generally have a better 
prognosis and specifically respond more favorably to hormone therapies compared to ER 
negative or PR negative tumors (8).   
Breast Cancer Risk Factors 
As estrogen plays a significant role in mammary cell carcinogenesis many established risk 
factors for breast cancer are related to reproductive characteristics, such as early menarche 
(5), later age of menopause (5, 7), age at first birth (5), parity (9) and lactation history (10).  
Early menarche or later age of menopause increases the length of time a woman’s body is 
exposed to endogenous estrogens and consequently increases her risk for breast cancer.  In 
addition to their hormonal impact, pregnancy and lactation are thought to reduce risk by 
affecting differentiation of mammary cells, making them less susceptible to the DNA damage 
required for carcinogenesis (5).  Use of exogenous hormones, such as oral contraceptives 
(11) or hormone replacement therapy (12) has also been associated with increased risk of 
breast cancer. 
Many modifiable lifestyle factors have been evaluated for their association with 
breast cancer risk, notably alcohol consumption (13) and certain dietary behaviors (14).  
Alcohol intake has been consistently positively associated with breast cancer risk (6); the 
plausible mechanism is that alcohol increases in estrogen exposure (15) as well as folate 
antagonism (16), the latter thought to increase risk through impairment of DNA methylation 
and repair (17).  The associations with dietary factors are less consistent (14, 18), however 
the evidence is intriguing for several exposures: intake of cooked and smoked meats has been 
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associated with an increase in the risk of breast cancer (14) while folate intake may be 
associated with a lower risk (17).  
Factors related to energy balance, such as anthropometric measures of body size and 
physical activity levels, have been consistently associated with breast cancer risk and are 
emerging as important issues in cancer prevention.  The relationship between body size and 
breast cancer risk varies by menopausal status with greater body size conveying a reduction 
in risk for premenopausal women while increasing risk for postmenopausal women (19, 20).  
Specifically, the reduction in relative risk for premenopausal women of heavier weight or 
higher body mass index (BMI, the ratio of weight in kg to squared height in meters) category 
is on the order of 40% while heavier or larger postmenopausal women have approximately 
25% greater relative risk of breast cancer (21, 22).  The association with adult weight gain 
has proven even more consistent than associations with BMI or body weight, with effects of 
similar magnitudes observed in cohort studies even when null associations for BMI or body 
weight were observed (20-22).  The association of breast cancer risk with anthropometric 
measures of fat distribution, such as waist-to-hip ratio (WHR), have been less consistent 
among premenopausal women but generally support a positive association with risk among 
postmenopausal women (20).  Physical activity has also shown fairly consistent associations 
with breast cancer risk, with relative risks ranging between 0.80 and 0.20 comparing the most 
physically active to least physically active in cohort and case-control studies (23).  A 
plausible mechanism for these associations exists as energy balance is related to endogenous 
exposure to estrogen and insulin, both mitogenic hormones that are believed to increase the 
risk of breast cancer by functioning as tumor promoters (24, 25).  The epidemiologic 
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evidence and specific biologic mechanisms surrounding the observed associations between 
body size, physical activity and breast cancer risk will be discussed in detail below.   
Epidemiology of Breast Cancer Survival 
Breast cancer claimed the lives of an estimated 40,410 women in 2005 accounting for 15% of 
the female cancer related deaths that year, second only to lung cancer.  Survival after a 
diagnosis of breast cancer has improved over the last three decades with 88% of women 
surviving to 5 years by the year 2000 (1).  Between 1990 and 2002 the death rate from breast 
cancer has decreased by 2.3% annually, which is believed to be due to earlier detection and 
improvements in treatment (2).  As of 2004 there were over 2 million female breast cancer 
survivors in the United States (3) and there has been growing interest in identification of 
modifiable prognostic factors in an effort to improve morbidity and mortality. 
Established Prognostic Factors 
The most reliable predictors of breast cancer survival include age, socioeconomic status, 
race, pathological features of the tumor and clinical characteristics.  Younger age is 
associated with poorer prognosis (26, 27), reflective of the fact that tumors of younger 
women often have histopathologic characteristics associated with poorer prognosis (28).  
Despite the fact that incidence rates for breast cancer are higher among white women, 
African-American women are less likely to survive, with approximately one-quarter dying 
within five years of diagnosis compared to only ten percent of Caucasian women (3).  This 
association has been thought to be driven by socioeconomic status as women of lower 
socioeconomic status tend to have poorer outcomes after diagnosis of breast cancer 
regardless of race (29).  
Pathological features such as tumor size, metastases to axillary lymph nodes and 
stage at diagnosis are strongly associated with breast cancer recurrence and survival, since 
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higher stage, greater tumor size and involvement of axillary lymph nodes generally signal 
more advanced or aggressive disease.  Tumor size is one of the most important prognostic 
indicators of breast cancer survival (30) as studies have shown that women with tumors with 
a diameter of 2 centimeters (cm) or less have better survival compared to those with tumors 
greater than 2 cm (26).  The metastatic involvement of axillary lymph nodes is also a 
significant predictor of survival (31) as involvement of a greater number of lymph node 
metastases indicates a more advanced disease that has spread to other areas of the body.  
Women with lower stage of disease have a markedly better prognosis, with 100% of those 
with in situ breast carcinomas surviving 5 years post-diagnosis, but only 88.6% of all women 
with invasive tumors surviving as long (3).  Among women with invasive breast cancer, 5-
year survival rates for those with localized tumors are high (98.0%) with 5-year survival 
progressively decreasing for those presenting with regional and distant carcinoma (83.5% 
and 26.7%, respectively).  
Clinically, treatment regimen is associated with survival with surgery, radiation 
therapy, chemotherapy and hormone therapy among the standard options (32-36).  Hormonal 
therapy, specifically the use of anti-estrogenic drugs such as Tamoxifen, is commonly used 
and has proven to provide a significant improvement in survival (37).  A recent review of 
randomized clinical trials reports a 31% reduction in the annual death rate among women 
with ER+ tumors on tamoxifen (38), lending additional evidence to the effect of estrogen on 
both breast cancer risk and survival.  Other reports note that response to treatment can be 
influenced by tumor characteristics, with hormone receptor negative tumors (ER- or PR-) 
being less responsive to the effects of endocrine therapy (39).  Chemotherapy is also a very 
effective treatment as it has been shown to reduce the annual death rate by 38% for women 
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younger than 50 years and 20% for women older than 50 years of age (38).  Radiation 
therapy is used in conjunction with surgery and chemotherapy, where it has proven effective 
at reducing local and regional recurrence and improving breast cancer related survival (40), 
however a recent review has reported an increase in vascular-related deaths (41).  Tumor 
markers associated with treatment efficacy include expression of the p53 tumor suppressor 
gene (42) and HER-2/neu overexpression (43) but their association with survival has not 
been definitively established.  Although clinical factors are important indicators of prognosis, 
they have been shown to explain only about 20% of the variability in breast cancer mortality 
(44).   
Although established risk factors for breast cancer would seem to be plausible 
prognostic indicators, to date, few modifiable lifestyle factors have shown consistent 
associations with breast cancer recurrence and survival (45, 46).  Estrogen exposure does 
appear to influence prognosis, as evidenced by the successful use of anti-estrogenic drugs for 
treatment (35); further some studies, although not all, have observed an increase in breast 
cancer mortality among recent users of oral contraceptives or hormone replacement therapy 
(47).  Additional evidence for the deleterious effect of estrogen on survival is noted from the 
literature on reproductive history and survival, which been extensively studied given the 
hormonal changes associated with pregnancy and since these factors have been consistently 
associated with incident breast cancer.  The reproductive factor most consistently associated 
with survival is recent birth, with studies finding that women who give birth within 1-5 years 
before diagnosis have a significantly reduced chance of survival (48-52).  Several studies 
have also noted that parity is inversely associated with survival  with an increase in mortality 
associated with a greater number of births (48, 50, 51, 53).  The prognostic value of other 
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reproductive characteristics, such as gravidity, age at menarche, age at first birth, 
breastfeeding history and abortion history is less clear (51, 54).  Alcohol consumption has not 
been associated with survival (55) and the results for smoking have been inconclusive (56).  
Studies of diet and breast cancer survival have not yielded consistent results, however a 
recent review of the available evidence suggests that increasing fat intake may be related to 
poorer survival while increasing fruit, vegetable, micronutrient and fiber intake may reduce 
mortality (55).  Of the modifiable behaviors that are hypothesized to affect breast cancer 
survival, factors related to energy balance appear to hold great promise (45).  Many of the 
factors associated with positive energy balance, particularly elevations in hormones that 
promote tumor growth and decrease apoptosis, are believed to influence survival by 
encouraging the development of existing tumors among patients diagnosed with breast 
cancer (57).  
Energy Balance and Breast Cancer: Biologic Mechanisms 
Energy balance represents the state of equilibrium between energy intake and expenditure 
and is determined by the interaction between diet, body size and composition, genetics and 
physical activity (58, 59).  Positive energy balance indicates a condition in which energy 
intake exceeds energy expenditure and is reflected by an increase in adipose tissue; a high 
level of body fat is believed to be a significant cause of morbidity and mortality in the 
developed world (60-62).  
Obesity and Carcinogenesis 
Adipose tissue, especially visceral fat, is metabolically active (63) and has a number of 
physiological corollaries that are believed to influence the etiology of several cancers, 
including breast (figure 1).  The association between obesity and sex hormones and related 
binding proteins, especially estradiol and sex hormone binding globulin (SHBG), are thought 
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to play a significant role in mammary carcinogenesis (64).  Aromatization of androgens in 
adipose tissue yields estrone which is subsequently converted to estradiol, the most 
metabolically active estrogen (65).  This pathway represents the primary source of estrogen 
for postmenopausal women, in contrast to premenopausal women where ovarian production 
of estradiol overshadows adipose-mediated formation (66).  In addition, estrogen production 
in premenopausal women is tightly regulated through feedback loops, however adipose-
mediated estrogen production is largely unregulated making it a significant source of 
estrogen exposure, particularly among postmenopausal women (66).  The availability of 
estradiol to target tissues is primarily determined by the amount of circulating SHBG.  
Approximately half of the estradiol in the blood is bound to SHBG, the remainder bound to 
albumin or freely circulating (66).  A common consequence of obesity-related 
hyperinsulinemia is a reduction in SHBG resulting in an increase in bioavailable estrogen 
allowing more free or albumin-bound estradiol to bind with estrogen receptors (64).  The 
combined effect of unregulated estradiol exposure and reduction in SHBG results in a greater 
than two-fold increase in free estradiol among obese postmenopausal women compared to 
women of normal weight (66).  Recently McTiernan and colleagues found that body mass 
index (BMI) was positively associated with estrone, estradiol, free estradiol, free testosterone 
and prolactin and negatively associated with SHBG among healthy postmenopausal women 
(67).  As noted previously, sex hormones are powerful mitogens which stimulate cellular 
proliferation therefore increasing the likelihood of a DNA mutation during cell division and 
encouraging replication of aberrant cells (68); breast tissue is especially sensitive to the 
effects of these hormones (69, 70).  There is also some evidence that estrogen metabolism 
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generates free radicals which may inflict DNA damage thereby initiating carcinogenesis (71, 
72).  
Obesity is also positively associated with increased levels of insulin and insulin like 
growth factors (73, 74) which can encourage proliferation of both normal and cancerous 
mammary cells (19, 24, 74).  Insulin, a peptide hormone secreted by the beta cells of the 
pancreas, functions primarily to regulate blood glucose levels and inhibit breakdown of 
adipose tissue.  An increase in fat mass is associated with elevated levels of serum free fatty 
acids through several mechanisms that encourage lipolysis:  visceral adipose tissue is less 
sensitive to the antilipolytic effect of insulin and more sensitive to the lipolytic effects of 
catecholamine (75) and it is also known to secrete a variety of cytokines including the 
lipolysis stimulating tumor necrosis factor alpha (TNFα) (76).  This increase in free fatty 
acids is thought to inhibit insulin’s effect on glucose uptake and oxidation (77) thereby 
resulting in a state of insulin resistance (78), and a subsequent compensatory increase in 
insulin secretion by the pancreas in an effort to maintain glucose homeostasis.  This increase 
in insulin precipitates a decrease in insulin-like growth factor binding proteins (IGF-BPs) and 
a successive increase in bioavailable insulin-like growth factor I (IGF-I) (78).  Both insulin 
and IGF-I, as well as TNFα, bind to membrane-bound receptors on cells that stimulate 
cellular proliferation and inhibit apoptosis, thereby providing a mechanism for tumor 
development (79).  This biologic pathway is especially relevant to breast cancer (80, 81) as 
mammary cell carcinomas typically exhibit an overexpression of insulin receptors (82) and 
IGF-I receptors (83) making them very susceptible to the proliferative effects of these 
hormones.  It is important to note that there are a number of genetic factors associated with 
obesity that may influence these relationships.  Genetic variations associated with regulation 
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of food intake, glucose metabolism and lipid metabolism are potentially important factors in 
explaining the relationship between obesity and breast carcinogensis (59). 
Physical Activity and Carcinogenesis 
The biologic pathways through which physical activity influences cancer risk are less 
understood than those for obesity, however several plausible mechanisms have been 
discussed in the recent literature (23, 84-87) and are illustrated in figure 2.  Perhaps the most 
obvious mechanism through which physical activity may influence cancer risk is through its 
effect in reducing adipose tissue (58, 88), especially metabolically active visceral fat (23), 
thereby reducing the associated hormonal milieu that favors tumor initiation and promotion, 
discussed previously.  In addition to this obesity-mediated pathway, physical activity has 
several independent effects on hormone and growth factor levels that are believed to 
influence carcinogenesis (89, 90). Independent of body size, higher levels of physical activity 
are associated with lower levels of estrogens and androgens and higher levels of SHBG 
among women (91-95).  This impact of physical activity on sex hormone exposure may be 
due to a synergistic effect with adiposity as suggested by a recent clinical study showing that 
among women who lost weight, physical activity further increased SHBG and reduced total 
and free estradiol and estrone concentrations beyond those changes expected due to weight 
loss alone (95).  Regular strenuous physical activity is also believed to reduce lifetime 
estrogen exposure through disruption of the normal menstrual cycle.  Frequent intense 
physical activity can suppresses the secretion of lutenizing hormone by curbing secretion of 
gonadotropin-releasing hormone through several pathways (96).  These exercise-induced 
alterations in the menstrual cycle are associated with delay of onset of menarche among 
adolescent females (97) as well as amenorrhea and menstrual irregularities for 
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premenopausal women in general (98), all of which are established protective factors for 
hormone-related cancers such as breast. 
Physical activity is associated with an increase in insulin sensitivity by increasing 
expression of the insulin-stimulated GLUT-4 glucose transporter in the plasma membrane of 
skeletal muscle (99-103) and by reducing the level of free fatty acids, which have been linked 
to impaired insulin function (104).   This increase in insulin sensitivity precipitates a decrease 
in insulin secretion, which is a possible mechanism for the observed increase in IGF-BPs 
(105) and decrease in IGF observed among physically active women (106).  The ability of 
physical activity to mediate these metabolic hormones and growth factors (80, 81, 107) 
suggests another potential pathway for the observed protective effect of this exposure.  This 
reduction in IGF may yield additional cancer protection as it may reduce sex hormone 
exposure by encouraging an increase in SHBG production by the liver (23). 
While hormonal pathways offer the most convincing explanations for a protective 
effect of physical activity on carcinogenesis, other physiological effects of exercise may 
prove beneficial as well.  Moderate physical activity may improve the immune response over 
both sedentary and exceptionally active individuals (108), possibly by promoting killer-cell, 
macrophage and cytokine activity (109, 110).  Although it is possible for cancerous cells to 
be eliminated through an immune response, the specific effect of exercise on the 
anticarcinogenic actions of the immune system remains unclear (109).  Moderate physical 
activity has also been shown to upregulate antioxidant enzyme activity (111), which may 
protect against DNA damage, although extreme levels of activity may increase the level of 
oxidative stress on the body (112).  A moderate level of physical activity appears to be 
optimal for both immune and antioxidant systems, however the overall cancer protective 
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effect of exercise is likely due to an interaction between several different pathways that are 
affected by varying levels of activity (23), making specific dosing recommendations unclear. 
Epidemiology of Obesity and Breast Cancer 
Direct measures of body composition, such as percent body fat, are rarely measured directly 
in epidemiologic studies of cancer given the expense and logistical issues required for these 
assessments (113).  Anthropometric measurements such as height, weight and body 
circumferences are easily gathered and reasonably accurate, even when self-reported (114) 
and can reflect elements of body composition relevant to disease etiology.  BMI, the ratio of 
weight in kilograms to squared height in meters, is the currently accepted anthropometric 
measure of general adiposity (114).  Correlations between BMI and densitometry-measured 
body fat have been noted to range from 0.55 to 0.85 (114), although studies have shown 
significant variations in body fat within levels of BMI, which appear to be related to body 
build, physical activity and race or ethnicity (115, 116).  As a measure of general adiposity 
BMI also does not reflect the location of excess fat mass, which may be a more relevant 
factor in disease etiology and prognosis.  Nevertheless, the ease of use, accuracy and general 
association with adiposity make it a useful tool in population-based epidemiologic research 
(113).  Body circumference measurements and their index measures (such as waist-to-hip 
ratio (WHR), the ratio of the waist circumference to hip circumference) are similarly easy to 
obtain and do reflect fat patterning (114), as the WHR is a common measure of central 
adiposity, with higher values indicating a greater deposit of metabolically active visceral fat 
tissue (117).  Unfortunately these measures are not always practical, and accuracy can 
depend upon the skill of trained personnel to consistently identify proper locations for 
measurement (114).  An alternative anthropometric measure of adiposity is adult weight gain, 
which may be more relevant than BMI as weight gain after adolescence is primarily 
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associated with accumulation of adipose tissue so this measure may be more associated with 
the etiologically relevant exposure than BMI (118).  Anthropometric measures of body 
composition such as these have shown consistent associations with breast cancer incidence 
and survival, likely reflecting the effect of energy balance on the carcinogenic process. 
Obesity and Breast Cancer Incidence 
Body size seems to have differential effects on breast cancer risk based on menopausal 
status, with obesity appearing to decrease risk among premenopausal women while 
increasing risk for postmenopausal women (21).  These effects reflect the fact that excess 
adipose tissue has the potential to disrupt endogenous estrogen production among younger 
women yet represent a significant source of sex hormones after menopause, through 
mechanisms discussed previously.  A pooled analysis of seven prospective cohort studies 
reported that premenopausal women with a BMI greater than 31 kg/m2 had a relative risk 
(RR) of breast cancer of 0.54 (95% confidence interval (CI): 0.34-0.85) compared to women 
with a BMI below 21 kg/m2 (22).  This analysis also reported a positive association between 
BMI and risk of breast cancer among postmenopausal women: postmenopausal women with 
BMI above 28 kg/m2 had a RR of 1.26 (95% CI: 1.09-1.46) compared to women less than 21 
kg/m2.  Similar associations were found in this study when weight was used as the measure 
of body size.  One recent meta-analysis of thirteen case-control and cohort studies across the 
world reported a RR of 1.12 comparing normal-weight (BMI less than 25 kg/m2) to 
overweight (BMI between 25 kg/m2 and 30 kg/m2) postmenopausal women (119).  A 
separate meta-analysis of eight prospective studies of postmenopausal breast cancer found a 
RR of 1.19 (95% CI: 1.05-1.34) for a 5 kg/m2 increase in BMI (120); this association was 
significantly attenuated (RR: 1.02, 95% CI: 0.89 to 1.17) after adjustment for serum sex 
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hormones, further corroborating the hypothesis that adiposity’s effect is at least partially 
through the estrogen pathway.  
The potential metabolic consequences of central obesity have lead researchers to 
examine breast cancer risk associated with anthropometric measures that reflect the pattern of 
visceral adiposity, such as waist circumference or WHR.  Waist circumference and WHR 
have been inconsistently associated with an increased risk of breast cancer among 
premenopausal women in case-control studies (20), however most cohort studies do support 
a positive association (21).  An analysis using data from the Nurses’ Health Study I showed 
an elevated risk associated with highest quintile of WHR compared to the lowest for all 
women (RR: 1.22, 95% CI: 1.12-2.99), while the association was stronger for women who 
never used hormone replacement therapy (RR: 1.85, 95% CI: 1.25-2.74).  Data from the 
Iowa Women’s Health Study suggests that this association is strongest among women with a 
family history of breast or ovarian cancer (121, 122) although a recent update in this 
population shows this interaction is not as strong as previously reported (123). 
Changes in body size over time, especially in adulthood, also appear to play a 
significant role in the association between body composition and breast cancer risk as results 
from several studies show (21).  In general, an increase in body size has been associated with 
a slight decrease or null effect on premenopausal breast cancer risk (124-128), similar to the 
associations observed for BMI.  Weight change appears to have a more profound effect on 
postmenopausal breast cancer as it has been consistently associated with increased risk, and 
weight loss with reduced risk (20).  A case-control report by Eng and colleagues (129) 
examined the effect of changes in body mass over the life course on risk of incident breast 
cancer among postmenopausal women on Long Island, New York.  The authors found that 
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postmenopausal women who gained more than 15 kg since age 20 years had a significant 
increase in risk of breast cancer (odds ratio (OR): 1.60, 95% CI: 1.11-2.26) compared to 
women who maintained their weight from age 20.  This study also showed that women who 
reduced weight over their lifetime had a decrease in the estimated risk of breast cancer (OR: 
0.55, 95% CI: 0.32-0.96) suggesting that weight loss is associated with decreased risk.  
Huang and colleagues’ findings from the Nurses’ Health Study suggest that an increase in 
risk for postmenopausal breast cancer associated with weight gain may be stronger among 
women who never took hormone therapy compared to those who have (126), an interaction 
that has been corroborated by other reports (130, 131).  These findings indicate that never 
users of HRT may be more susceptible to adipose-driven perturbations in estrogen levels 
than women with a history of HRT use.  Recently a cohort analysis by Harvie and colleagues 
from the Iowa Women’s Health Study reported that compared to women who consistently 
gained weight over their adult lives, women who maintain their weight from age 18 to 30 and 
lost weight between 30 and menopause had a reduced risk of postmenopausal breast cancer 
(RR: 0.36, 95% CI: 0.22-0.60) as did those who maintained or lost weight from age 30 to 
menopause but lost weight after menopause (RR: 0.48; 95% CI: 0.22-0.65) (132).  These 
results indicate that even recent weight change can have a significant impact on breast 
carcinogenesis, which may hint at the possible prognostic implications of weight change 
post-diagnosis. 
Obesity and Breast Cancer Survival 
Obesity Near Diagnosis and Survival.  Obesity at diagnosis and weight gain pre-
diagnosis have been established as indicators of poorer prognosis as discussed by several 
recent reviews (57, 133-135).  Of the 26 studies reviewed by Rock and Demark-Wahnefried 
(134), 17 reported an association between greater body size and decreased survival or 
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increased rates of recurrence while 36 of the 51 discussed in an updated review by Goodwin 
found similar associations (57).  Elevations in risk have generally been moderate with RRs 
and HRs comparing extremes of body size ranging from approximately 1.5 to 2.5 (57), 
however extremes as high as nearly sixfold have been noted (136).   A 1995 meta analysis of 
30 studies by Goodwin and colleagues reported a HR for death over 10 years comparing 
overweight to normal weight women of 1.56 (95% CI: 1.38-1.76) while the HR for 
recurrence over 5 years was 1.91 (95% CI: 1.52-2.40) (137).  Although poorer prognosis with 
increasing body size is seen all women, Goodwin’s 2005 review reports that the findings in 
the literature support a somewhat greater increase in risk among premenopausal women and 
among women with hormone receptor positive cancers (57).  Additionally, there is evidence 
that the relationship between BMI and prognosis is nonlinear, with underweight and 
overweight women having greater risk than women of normal body size (138). 
More recently using data from a study of 1,254 young women (age 20 to 54) from 
Atlanta and New Jersey who were diagnosed with invasive breast cancer, Abrahamson and 
colleagues found an moderate increase in risk of all-cause mortality for women who were 
obese at diagnosis (BMI 30 kg/m2 or above) compared to normal weight women (BMI 18.5-
24.9 kg/m2), reporting a hazard ratio (HR) of 1.48 (95% CI: 1.09-2.01) (139).  The 
association with WHR was similar (HR comparing highest to lowest quartiles: 1.52, 95% CI: 
1.05-2.19), suggesting the effect may be driven by central adiposity.  Most recently, an 
analysis of 1,508 women diagnosed with breast cancer between 1996 and 1997 on Long 
Island, New York examined prognosis in relation to BMI in the year prior to diagnosis as 
well as changes in BMI during adulthood up to diagnosis (140).  Among premenopausal 
women, comparing obese (BMI 30 kg/m2 or above) to normal weight women (BMI 18.5 
  17 
kg/m2 -24.9 kg/m2) the authors report a marked increase in risk of breast cancer specific 
death (HR: 2.85, 95% CI: 1.30-6.24), with a similar magnitude of association for all-cause 
mortality.  The increased risk for postmenopausal women was more moderate, yet still 
significant, with obese women having nearly twice the risk of breast cancer related death 
compared to normal weight women (HR: 1.88, 95% CI: 1.04-3.34).  This data also suggested 
that significant adult weight gain (>16 kg since age 20) confers an increased risk of breast 
cancer related death among premenopausal women compared to stable-weight women (HR: 
2.09, 95% CI: 0.80-5.48) as does a greater than 12.7 kg gain from age 50 years to diagnosis 
for postmenopausal women (HR: 2.95, 95% CI: 1.36-6.43). 
Changes in Body Size After Diagnosis of Breast Cancer.  Weight gain after 
diagnosis in breast cancer patients is well documented, with the amount ranging from 
approximately 1 kg to more than 10 kg within the first two years (57).  Several reviews (57, 
141) as well as recent reports (142-145) have identified younger age, lower pre-diagnosis 
BMI, premenopausal status, later disease stage, use of systemic chemotherapy, and time 
since diagnosis as major factors associated with increases in post-diagnosis bodyweight.  
Behaviorally, alterations of dietary behavior due to psychological distress or physical 
discomfort appear to be associated with weight gain (146, 147), however associations with 
low physical activity levels have been inconsistent (144, 148-151).  Demark-Wahnefried and 
colleagues also report that women who gained weight while on chemotherapy showed a loss 
of lean body mass (148), which has potential implications for reduction in basal metabolic 
rate.  Unfortunately, this finding is consistent with the fact that women who gain weight after 
breast cancer diagnosis rarely return to their pre-diagnosis body size (152, 153). 
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Post-diagnosis Changes in Body Size and Breast Cancer Survival.  The 
relationship of breast cancer prognosis with post-diagnosis changes in body size is far less 
studied than the prognostic value of pre-diagnostic body size.  Only a handful of studies, 
most published over a decade ago have directly examined the relationship between weight 
gain post-diagnosis and survival with inconsistent results (152, 154-160).  Most have 
reported no association of prognosis with relatively small increases in weight (155-157), 
however several have noted an association when examining larger changes in weight or BMI, 
often in subgroup analyses (152, 154, 158).  Camoriano and colleagues report a negative 
prognostic effect of weight gain among premenopausal women (HR comparing gain of 5.9 
kg to less than 5.9 kg: 1.62, 95% CI: 1.01-2.62), but no association among postmenopausal 
women (p=0.25, no HR reported).   
Of the most recent reports, summarized in table 1, Kroenke and colleagues recently 
reported data from the Nurses Health Study cohort that showed that among never smokers, 
weight gain post-diagnosis was related to increased risk of death and recurrence of cancer 
(158).  Among never smokers, those gaining between 0.5 and 2.0 kg/m2 over the follow-up 
period had 35% greater risk compared to those who did not gain (HR: 1.35, 95% CI: 0.93-
1.95) while those gaining more than 2.0 kg/m2 had even greater risk (HR: 1.64, 95% CI: 
1.07-2.51).  The most recent study by Nichols et al. found sizeable increases in risk among 
women with weight gains of 10 kg or more compared to those who maintained 2 kg of their 
pre-diagnosis weight: (all-cause mortality HR: 1.70, 95% CI: 1.21-2.41; breast cancer 
specific mortality HR: 1.78, 95% CI: 1.01-3.14; cardiovascular disease mortality HR: 1.73, 
95% CI: 0.83-3.62).  A null report was published by Caan et al. who found modest, and 
statistically insignificant associations between women who gained >10% of their pre-
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diagnosis weight compared to those who maintained within 5% for both all-cause mortality 
(HR: 0.7, 95% CI: 0.4-1.2) and breast cancer recurrence (HR: 0.8, 95% CI: 0.5-1.2). 
Studies with null findings were limited by small sample size (155-157) and short 
follow-up (155, 157), or likely biased samples and poor timing of exposure assessment (159) 
possibly explaining the lack of associations.  Given the limited evidence to date, additional 
investigation of the effect of weight change on prognosis is needed before weight 
management guidelines for breast cancer survivors can be defined. 
Epidemiology of Physical Activity and Breast Cancer 
Assessment of physical activity in epidemiologic studies of cancer is challenging as direct 
measures such as accelerometers, pedometers and calorimeters are not applicable to case-
control designs, fail to measure specific activities or fail to capture activity at an etiologically 
relevant time period, and are often too expensive for cohort studies (161).  Use of 
questionnaire-based physical activity assessments is standard practice in observational 
epidemiology given the relatively low cost and ease of administration.  Physical activity 
questionnaires seek to assess some combination of the type, frequency, intensity and duration 
of activity levels throughout various domains of an individual’s life (occupational, leisure, 
domestic duties, transportation) (162).  Although questionnaire data may yield only crude 
categorizations of physical activity levels, data from detailed assessments can be summarized 
into an intensity score representing the multiple of energy expended while at rest, the 
metabolic equivalent score (MET) (162, 163).  The MET is only an estimate of relative 
energy expenditure and the true value for an individual would vary by a number of factors 
including intensity of activity, body composition and other physiological variables.  
Although qualitative differences in assessment tools and assessment at an etiologically 
relevant time frame of exposure make it difficult to compare results across studies the 
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literature overwhelmingly supports a protective effect for physical activity on incident breast 
cancer (163). 
Physical Activity and Breast Cancer Incidence 
The relationship between physical activity and incident breast cancer has been studied 
extensively and the overall findings have been discussed in several reviews (163-166).  The 
most recent was a systematic review by Monninkhof and colleagues (167) that evaluated the 
evidence from 19 cohort and 29 case-control studies.  Among the case-control studies 
examined, 4 of the 6 that assessed total physical activity (168-173) reported protective effects 
(which the authors define as relative effect measures below 0.80) while 14 of the 28 studies 
reporting on leisure time activity (165, 168-170, 172-195) found reduced risk associated with 
greater physical activity.  Results for cohort analyses were more equivocal than for the case-
control studies:  the 3 studies reporting associations for total activity were in complete 
disagreement (one protective (196), one null (197), one harmful (198)) and only 8 of the 17 
reports of leisure time activity (187, 197, 199-213) found a protective effect of greater 
activity levels.  A larger proportion of studies report a protective effect of increased leisure 
time activity among postmenopausal women than premenopausal women, and several reports 
have indicated that initiation of exercise after menopause is associated with a reduction in 
risk (200, 205, 208).  The authors observed that most studies examining effect modification 
by body size failed to find differences suggesting that physical activity has independent 
effects on carcinogenesis, a conclusion also reached in the review by Patel and Bernstein 
(163).  After consideration of the variation in physical activity questionnaires, as well as 
formal statistical tests of heterogeneity of effect across study design (case/control) and 
menopausal status (premenopausal/postmenopausal), Monninkhof and colleagues felt it 
prudent to avoid calculation of a summary effect measure, although they noted that among 
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studies deemed “protective,” reductions in risk ranged from 21% to 52% among the case-
control studies and 21% to 80% among the cohort studies.  Ultimately these authors conclude 
that the current weight of evidence of a protective effect strong for postmenopausal women 
and inconclusive for premenopausal women. 
Physical Activity and Breast Cancer Survival 
The psychosocial and physiological effects of physical activity among female breast cancer 
survivors have been mentioned in recent reviews of exercise interventions in cancer patients 
(214, 215).  During breast cancer treatment, physical activity has been associated with 
improvements in treatment-related side effects such as fatigue (216-219), nausea (220) and 
quality of life (219), as well as body size (149, 221).  Studies of post-treatment physical 
activity have also noted improvements in immune function (222, 223); these improvements 
in body size and immune function due to exercise may be especially relevant to prognosis.  
Although these findings are encouraging, important limitations with these trials include low 
statistical power due to small sample size as well as lack of common and universally 
meaningful outcome measures (215, 224, 225).  Perhaps the greatest issue with current 
intervention studies of survival is that outcomes focusing on short term measures such as 
physiological and psychological parameters (224) instead of survival or recurrence. 
There are only a handful of studies examining the effect of physical activity, either 
pre- or post-diagnosis, on breast cancer recurrence and survival, as outlined in table 2.  Two 
separate studies (226, 227) of 412 and 603 female breast cancer patients failed to find 
associations with pre-diagnosis physical activity and breast cancer prognosis.  The smaller 
study by Rohan and colleagues reported a HR of 0.98 (95% CI: 0.50-1.94) for breast cancer 
related death comparing those expending more than 4000 kcal/week in recreational physical 
activity to those expending 0 kcal/week (227).  Borugian and colleagues examine 
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associations with breast cancer mortality across levels of seven different types of recreational 
physical activity (climbing stairs, walking, sports, exercise, jogging, swimming, gardening), 
with five levels each (none, few times a year, few times a month, once a week, more than 
once a week) with most associations at or near unity (228).  Abrahamson and colleagues 
report on all-cause mortality in a follow-up study of 1,264 women diagnosed with invasive 
breast cancer (229).  The authors find a reduction in risk of death across extreme quartiles of 
physical activity expressed as MET hours per week (HR: 0.78, 95% CI: 0.56-1.08), an effect 
that appears to be limited to women who were overweight or obese near diagnosis (HR: 0.70, 
95% CI: 0.49-0.99).   
Recently, several studies have been published examining the effect of post-diagnosis 
levels of physical activity and survival.  Holmes and colleagues report a beneficial effect of 
leisure-time physical activity on breast-cancer prognosis using data from the Nurses’ Health 
Study (230).  Comparing those women with 24 or more MET-hours per week of physical 
activity two years after diagnosis to those with fewer than 3 MET-hours per week, reduction 
in risk of overall death (HR: 0.65, 95% CI: 0.48-0.88), breast cancer related death (HR: 0.60, 
95% CI: 0.40-0.89) and recurrence (HR: 0.74, 95% CI: 0.53-1.04) were noted with 
significant trends for overall and breast cancer survival.  There was no finding of effect 
modification for dichotomized physical activity across levels of menopausal status or stage, 
however results suggested the protective effect among women with hormone-receptor 
positive tumors was stronger (HR: 0.50, 95% CI: 0.34-0.74) compared to women with 
hormone-receptor negative tumors (HR: 0.91, 95% CI: 0.43-1.96, p for interaction: 0.08).  
Pierce et al. (231) report that women with high post-diagnosis physical activity and high fruit 
and vegetable consumption have longer survival compared to those with in the lowest 
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categories of both exposures (HR: 0.53, 95% CI: 0.31-0.98).  The analysis by Holick et al. 
(232), in the largest study to date, reported effects for both all-cause mortality (HR: 0.44, 
95% CI: 0.32-0.68) and breast cancer-specific mortality (HR: 0.51, 95% CI: 0.29-0.89) 
comparing women expending >21.0 MET-hours/week to those expending < 2.7 MET-
hours/week.  The strongest effect was noted by Irwin et al. (233) who found that women 
expending >9.0 MET-hours/week had 33% the risk of death from any cause (HR: 0.33, 95% 
CI: 0.15-0.73) compared to inactive women (0 MET-hours/week), although the effect for 
breast cancer-related deaths was not as strong (HR: 0.65, 95% CI: 0.23-1.87).  Although 
several of these studies report inverse associations between post-diagnosis physical activity 
and survival, the most recent study by Sternfeld et al. (234) reported largely null associations 
between post-diagnosis physical activity and both recurrence and survival after breast cancer 
diagnosis.  Of note is the fact that to date, all of the studies of post-diagnosis physical activity 
and survival have been limited to women who were enrolled at least 2 years post-diagnosis.  
Failure to include women who died within the first several years of diagnosis (or who may be 
otherwise unable to enroll) is certain to result in a biased sample.  Additionally, exposure 
assessment occurred only once, at enrollment, and therefore only measured activity levels 
well after treatment was concluded, and did not capture the longitudinal patterns of physical 
activity that may be important in the survival experience. 
The limited evidence and variance in methodology between these studies make it 
difficult to draw a general conclusion regarding the effect of physical activity on breast 
cancer prognosis.  Notably, the two studies that found the strongest effects were large 
population-based epidemiologic analyses while the null results came from much smaller 
studies.  Assessment of physical activity at a biologically relevant point is clearly important 
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for answering the question most relevant for survivors who must make decisions regarding 
lifestyle modifications after diagnosis and treatment.  Although the level of pre-diagnosis 
physical activity is thought to be correlated with post-diagnosis level after treatment (235, 
236) the use of pre-diagnosis assessments in two null reports (226, 227) could be a factor in 
their findings.  The results from the recent reports of post-diagnosis activity are encouraging, 
but these studies did not evaluate the longitudinal pattern.  Much work remains in the 
evaluation of the effect of physical activity on breast cancer survival before a consensus can 
be reached. 
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Summary 
Given the weight of the evidence, the association between energy balance and breast cancer 
development is convincing.  Biologically, excess adipose tissue and physical inactivity are 
associated with a hormonal environment that encourages cellular proliferation and possibly 
DNA damage required for carciogenesis.  Epidemiologic studies have established obesity and 
weight change as risk factors for postmenopausal breast cancer, while they appear to be 
somewhat protective for premenopausal women.  Increased levels of physical activity also 
appear to be associated with a decrease in risk of breast cancer for postmenopausal women, 
yet the evidence is less clear for breast cancer risk before menopause.   
These facets of energy balance have also shown promise as potential prognostic 
indicators after diagnosis of breast cancer.  Factors associated with positive energy balance, 
especially elevations in the hormones estrogen, insulin and IGF-1, are believed to negatively 
influence survival after breast cancer diagnosis by encouraging promotion of cancerous cells 
through similar mechanisms believed to increase breast cancer risk.  Studies examining pre-
diagnostic weight and breast cancer outcomes show that heavier women have less favorable 
prognosis, even among women with recent weight loss.  Of special interest to breast cancer 
survivors is the effect of post-diagnostic lifestyle changes, such as weight modification and 
increasing physical activity, on survival.  Recent work on the effect of post-diagnostic 
changes in body weight provides evidence that weight loss reduces mortality, perhaps more 
so among subgroups.  Reports of the effect of physical activity on survival have recently 
increased, but the evidence has been somewhat conflicting.  Overall, the evidence for a 
protective effect of post-diagnostic alterations in factors associated with energy balance is 
alluring, but much work remains.  Further examination of these relationships, especially in 
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large epidemiologic studies, may yield information with significant clinical and public health 
impact. 
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Table 1.1.  Recent studies of the effects of post-diagnosis changes in body size and breast cancer prognosis. 
Author, Year 
Sample 
Size 
Median Length 
of Follow-up 
Outcome 
Measure 
Measure of 
Change in 
Body Size Summary of Results 
Camoriano et al., 1990 
(152) 545  6.6 years R, OS 
weight change 
above/below 
median  
premenopausal: 
HR recurrence: 1.5 (p=0.17) 
HR all-cause mortality: 1.62 (p=0.04) 
postmenopausal: only reported NS (p=0.25) 
Costa et al., 2002 (155) 106 
4.9 months 
(mean) R, OS 
any percent 
body weight 
increase log-rank test p=0.08 
Kroenke et al., 2005 (158) 5,204 9 years R, OS, BCM 
change in BMI: 
0-0.5 kg/m2, 0.5-
2.0 kg/m2, >2.0 
kg/m2 
Among never smoking women, 
comparing >2.0 kg/m2  to  
0-0.5 kg/m2 increase: 
OS HR: 1.59 (95% CI: 1.12-2.27) 
BCM HR: 1.64 (95% CI: 107-2.51) 
R HR: 1.53 (95% CI: 1.04-2.24) 
Caan et al., 2008 (159) 
1,689 (in 
final 
analysis) 83.9 months 
R, OS, BCM 
(pre-diagnosis 
BMI only for 
BCM) 
Weight change: 
>10% loss/gain, 
5-10% loss/gain, 
maintain ±5% 
(ref) 
For >10% weight gain: 
OS HR: 0.7 (0.4-1.2) 
R HR: 0.8 (0.5-1.2) 
Nichols et al., 2009 (160) 3,993 6.3 years 
OS, BCM, 
CVDM 
Weight change: 
> 10kg loss, 10-
2kg loss, 
maintain ±2kg 
(ref), 2-6 kg 
gain, 6-10 kg 
gain, >10 kg 
gain 
For > 10kg increase: 
OS HR: 1.70 (1.21-2.41) 
BCM HR: 1.78 (1.01-3.14) 
CVDM: 1.73 (0.83-3.62) 
 
Abbreviations:  BCM: breast cancer mortality, OS: overall survival, R: recurrence of breast cancer; CVDM: cardiovascular disease mortality, BMI: body 
mass index, HR: hazard ratio, CI: confidence interval. 
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Table 1.2.  Recent studies of the effects of post-diagnosis physical activity and breast cancer prognosis. 
Author, Year 
Sample  
Size 
Median Length  
of Follow-up 
Outcome  
Measure Physical Activity Measure Summary of Results 
Holmes et al., 2005 (230) 1,264 96 months (BCM) OS, BCM, R 
MET-hours per week for 
leisure-time physical 
activity, 2 years post-
diagnosis, categorized as <3, 
3-8.9, 9-14.9, 15-23.9, >=24 
Comparing >= 24 MET-h/wk to <3 
MET-h/kw: 
OS HR: 0.65 (95% CI: 0.48-0.88) 
BCM HR: 0.60 (95% CI: 0.40-0.89) 
R HR: 0.74 (95% CI:0.53-1.04) 
Pierce et al., 2007 (231) 1,490 Average 6.7 years OS 
Various categorizations of 
MET-minutes/week 
measured once at follow-up 
(avg. 2 years, max 4 years 
post-diagnosis) 
Compared to low fruit and veg, and 
low physical activity, women with 
high fruit and veg intake and high 
physical activity, HR: 0.53 (95% CI: 
0.31-0.98). 
Holick et al., 2008 (232) 4,482 5.5 years OS, BCM 
MET-hours week at follow-
up (average ~6 years post-
diagnosis): <2.7 (ref), 2.8-
7.9, 2.0-20.9, >=21.0 
Compared to <2.7 MET-hours/week, 
those with > 21.0 MET-hours/week: 
OS HR: 0.44 (0.32-0.68) 
BCM HR: 0.51 (0.29-0.89) 
Irwin et al., 2008 (233) 933 6 years OS, BCM 
MET-hours week 2 years 
after diagnosis: 0 (ref), 0.1-
9.0, >9.0 
Compared to 0 MET-hours/week, 
women with >9 MET-hours/week: 
OS HR: 0.33 (0.15-0.73) 
BCM HR: 0.65 (0.23-1.87) 
Sternfeld et al., 2008 (234) 1,970 87 months OS, BCM, R 
Quartiles MET-hours/week: 
overall, mod/vig activity, 
moderate only, vigorous 
only  
Total MET-hours/week, quartile 4 vs. 
quartile 1: 
OS HR: 0.76 (0.48-1.19) 
BCM HR: 0.87 (0.48-1.59) 
R HR: 0.91 (0.61-1.36) 
 
Abbreviations:  BCM: breast cancer mortality, OS: overall survival, R: recurrence of breast cancer, MET: metabolic energy expenditure, HR: hazard ratio, 
CI: confidence interval. 
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Figure 1.1.  Hypothesized biological mechanisms for the relationship between adiposity and breast cancer survival among breast 
cancer patients. 
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Figure 1.2. Hypothesized biological mechanisms for the relationship between physical activity and breast cancer survival among 
breast cancer patients.
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CHAPTER 2 
RESEARCH METHODS 
Overview 
To evaluate the effects of post-diagnosis changes in body size and physical activity levels on 
survival after breast cancer diagnosis I used data from the follow-up study of the Long Island 
Breast Cancer Study Project (LIBCSP).  The parent LIBCSP study was a population-based 
case-control study of newly diagnosed cases of breast cancer in Nassau and Suffolk counties 
on Long Island, New York.  This follow-up study includes data from 1,508 women 
diagnosed with in situ or invasive breast cancer between August 1, 1996 and July 31, 1997 in 
Nassau and Suffolk counties in Long Island, New York.  Baseline data from the original case 
control study as well as the follow-up interviews conducted approximately five years post-
baseline included anthropometric and lifestyle characteristics as well as sociodemographic 
and medical factors relevant to breast cancer prognosis.  Breast cancer specific mortality and 
all-cause mortality through December 31, 2005 were determined from data from the National 
Death Index.  Self-reported physical activity and anthropometric data from the follow-up 
interview were related to the outcomes in a time-to-event analysis.  Of the 1,508 breast 
cancer cases who participated in the baseline case-control interview, follow-up interview data 
was available for only 1,033 women, yielding a large percentage of missing data.  To address 
this issue I applied a selection model from the biostatistics literature that allows for 
examination of the effects of varying the assumptions underlying the missing data on the 
observed relationship between changes in body size and physical activity levels and 
mortality. 
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Parent Study 
This study uses data from the follow-up to the Long Island Breast Cancer Study Project 
(LIBCSP), a population-based case-control study of breast cancer in Nassau and Suffolk 
counties in New York.  The LIBCSP has been described in detail in the recent literature (1) 
but relevant details will be reviewed here.  Potential cases for this study were English-
speaking women with in situ or invasive breast cancer who were diagnosed between August 
1, 1996 and July 31, 1997.  These potential cases were identified through pathology 
departments of participating hospitals and their physicians were contacted to confirm the 
diagnosis and obtain permission to contact the patients for participation in the study.  Initially 
2,271 women were identified as potentially eligible cases with physician consent ultimately 
obtained for 1,837 (80.9%) of these women.  Potential controls were English-speaking 
women selected from the population of current residents of Nassau and Suffolk counties with 
no history of diagnosis of breast cancer.  
Written informed consent was obtained from all study subjects prior to participation 
in the case-control interview.  Questionnaires were administered at baseline by trained study 
personnel and included assessments of reproductive, occupational, residential and medical 
histories, as well as sociodemographic, anthropometric, lifestyle, and environmental 
exposures (2).  A total of 1,508 (82.1%) of the eligible case women completed the main 
study questionnaire taking an average of 101 minutes to complete the interview.  After the 
main interview study subjects were asked to self-administer a modified Block-style food 
frequency questionnaire, with 1,481 (98.2%) cases complying. Additionally, case subjects 
were asked to sign a medical record release to allow study personnel to gather data regarding 
clinical characteristics relevant to the breast cancer diagnosis, such as stage, tumor size and 
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hormone receptor status.  A total of 1,493 (97.7%) of the case women signed the release 
forms and subsequently 1,402 records were abstracted. 
Follow-up Study 
Study Population 
During the parent case-control study 94 women refused to be contacted at a later date for 
participation in the follow-up study.  For those who agreed to participate in the follow-up, the 
case subjects or their proxy were contacted by mail approximately 5 years after initial 
diagnosis of breast cancer and informed consent was obtained via telephone follow-up calls.  
Of the 1,414 women who initially agreed to participate in the follow-up study, 60 
subsequently refused at the initial mail contact, 65 refused when contacted by telephone, 18 
refused due to illness, 22 were unable to complete the interview, 55 were lost to follow-up 
and 96 were deceased with no identifiable proxy to complete the interview.  Of the remaining 
1,098 subjects who agreed to the follow-up interview, 65 were only able to provide 
information on their first course of treatment for their original breast cancer diagnosis. 
Ultimately 1,033 case subjects (68.5% of the original 1,508 women) actually completed the 
follow-up interview (3).  The follow-up interview ascertained information similar to that 
gathered in the baseline questionnaire but relevant to the time period since diagnosis 
including treatment, reproductive history, smoking and alcohol use, and as well as body size 
and physical activity. 
Description of Cohort of Women with Breast Cancer 
Descriptive statistics at diagnosis for the 1,508 case women have been previously published 
(1) and are summarized briefly in table 1.  The median age at time of diagnosis for the case 
women was 58 years with a range from 25-98 years.  The majority of case women were 
postmenopausal at time of diagnosis, white and of non-Hispanic ethnicity.  Nearly all women 
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reported having been married and most had at least one child.  Most had no history of a first-
degree family relative with breast cancer.  Less than one-third reported ever having used 
hormone replacement therapy.  For those reporting height and weight (n=1,491) mean BMI 
at baseline was 26.5.  Among all breast cancer cases in this study the average MET-hours per 
week of recreational physical activity from age at menarche to reference date was 27.7 (4).  
Most women were diagnosed with invasive breast cancer with small tumors (less than or 
equal to 2 cm), with no nodal involvement and with either ER- or PR-positive tumors.  Over 
60% of the cases reported having radiation therapy or hormone therapy during their treatment 
regimen, while less than half reported that they received chemotherapy after diagnosis.  
Outcome Assessment 
The outcome for this study, date and cause of death, was determined by the National Death 
Index (NDI) (5), a centralized database of death records maintained by the National Center 
for Health Statistics which is considered the standard source of mortality data for 
epidemiologic research (6).  A text-formatted data file including first and last name, city, 
state, date of birth, social security number, gender, and marital status along with the unique 
LIBCSP subject identifier was sent to the NDI offices to be matched with their records to 
obtain the corresponding date and cause of death for each subject.  Subjects without a match 
returned were assumed to be alive on the final date available in the NDI database.  For 
women who were determined to be deceased from the NDI records I constructed two event 
indicators: (1) breast cancer related death (breast cancer listed as primary or secondary cause 
of death) and (2) death from any cause which, combined with time of death, represent be the 
two outcomes for this analyses.  An initial match of the LIBCSP case records to the NDI was 
conducted in 2004 (7) and an update was completed in early 2008, yielding a total of 308 
deaths as of December 31, 2005 with 164 of these attributed specifically to breast cancer. 
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Exposure Assessment 
Body Size.  Body mass index (BMI) is calculated as the ratio of weight in kilograms 
to squared height in meters. At baseline the initial questionnaire (2) collected self-reported 
data on height in inches and body weight in pounds at age 20 years and at 1 year prior to the 
reference date (date of diagnosis for cases).  The baseline questionnaire also collected weight 
in pounds by decade of life from 20 years through 70 years of age.  The follow-up 
questionnaire contained similar questions asking self-reported height, body weight in pounds 
one year after diagnosis, current weight, maximum weight since time of diagnosis and 
minimum weight since time of diagnosis.  Measures of BMI and weight change at each 
corresponding time point were calculated from these variables; details will be discussed 
under variable definition.  
Physical Activity. Recreational physical activity was measured using a modification 
of the instrument developed by Bernstein and colleagues used in previous studies of physical 
activity and breast cancer risk (8).  The baseline questionnaire included a screening question 
asking “Have you ever participated in any physical activities or exercises on a regular 
basis—that is for at least 1 hour per week for 3 months or more in any year?” (2) with those 
subjects answering affirmatively considered having ever participated in physical activity.  
These subjects were then asked to list each activity separately and then answer more detailed 
questions for each one:   
(1) “In what activity did you (first/next) participate on a regular basis?” 
(2) “Looking at the calendar, at what age did you start (ACTIVITY) regularly?” 
(3) “At what age did you stop (ACTIVITY)?” 
(4) “For how many years did you (ACTIVITY) regularly?  For how many months 
each year did you do this?” 
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(5) “On average, about how many hours per week did you actually (ACTIVITY)?” 
Eng (4) describes in detail the procedure used for calculating physical activity 
variables from this data, which will be summarized here.  For the subjects with detailed 
physical activity data the number of months per year of each activity was converted to 
number of hours per week.  Where an activity was reported without a corresponding 
duration, 12 months per year was imputed for non-seasonal activities while the average 
number of months per year was imputed for seasonal activities.  For each activity a metabolic 
equivalent of energy expenditure (MET) score was assigned using a database derived from 
previously published values (9).  The MET is a standard unit of energy expenditure for 
physical activity research (10) and is defined as the energy expended while sitting quietly, 
approximately one kilocalorie per kilogram of bodyweight per hour.  When an activity 
reported by the study subjects did not have a corresponding MET-score published then a 
similar activity with a published MET value was chosen.  For each activity the MET value 
was then multiplied by duration of activity in number of hours per week, which was added 
across all activities for each subject for each year of life since menarche to arrive at a 
measure of the total number of MET-hours per week for each subject. 
In the follow-up questionnaire subjects were asked if they had participated in any 
physical activities or exercises on a regular basis for at least 1 hour a week for 3 months or 
more in any year since the date of diagnosis.  If an affirmative answer was recorded then 
detailed questions regarding type, duration, frequency and age at commencement were asked, 
similar to the baseline questionnaire, for up to 12 separate activities with the time period 
queried relevant to the time since the reference date (diagnosis) for the case-control study.  
 58 
The average number of MET-hours per week in the 5 years since diagnosis was calculated in 
the same manner described above for the baseline measure. 
Behavioral, Clinical and Histopathologic Covariates.  The baseline and follow-up 
questionnaires were administered by trained study staff and ascertained a number of lifestyle 
measures (1, 2).  The baseline questionnaires collected detailed data on reproductive and 
menstrual history, smoking, alcohol intake, hormone therapy and oral contraceptive use.  
Diet was measured using a self-completed modified semi-quantitative Block food frequency 
questionnaire (FFQ) that contained approximately 100 line items corresponding to different 
foods or food groups and included measures of portion size and frequency of consumption.  
This data was used to calculate a broad set of dietary measures including frequency of 
consumption of standard portions of various foods as well as a comprehensive set of 
micronutrient intakes, macronutrient levels and total energy intake.  Total energy are 
potential confounders for these analyses. 
At baseline, clinical and histopathological variables were established from medical 
chart abstraction and included disease stage, treatment modality, ER/PR status and other 
relevant tumor characteristics.  The follow-up interview also included questions regarding 
treatment modality in an attempt to ascertain this variable for those women who were pre-
treatment or had yet to complete a course of treatment at the time of enrollment on the study 
(1).  During the follow-up study medical records were abstracted for 598 women and the 
details regarding treatment regimen were compared to that self-reported in the follow-up 
interview.  Kappa coefficients comparing self-report and medical records were high for all 
three treatment modalities examined: radiation therapy κ=0.97, chemotherapy κ=0.96 and 
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hormone therapy κ=0.92 (7).  Data on tumor size was ascertained through the New York 
State Cancer Registry. 
Results from Previous Analyses 
Several published manuscripts, based on data from the parent case-control study, include 
results that are relevant to the proposed project.  A recent report by Eng et. al. (11) examined 
the effect of changes in body mass over the life course on risk of incident breast cancer in the 
LIBCSP.  The authors report that among postmenopausal women, those who gained more 
than 15 kg since age 20 years had a significant increase in risk of breast cancer (OR: 1.6, 
95% CI: 1.11-2.26) compared to women who maintained their weight at age 20.    This study 
also showed that women who reduced weight over their lifetime had a decrease in the 
estimated risk of breast cancer (OR: 0.55, 95% CI: 0.32-0.96) suggesting that modification of 
body size is associated with decreased risk.   
In a separate report of the effect of lifetime physical activity in this cohort Eng (4) 
showed that postmenopausal women who ever regularly exercised had a notable decrease in 
risk of breast cancer compared to women who never regularly exercised (OR: 0.81, 95% CI: 
0.65-1.01).  This study also showed that postmenopausal women who were active for at least 
6.4 hours per week had a similar decrease in risk of breast cancer (OR: 0.73, 95% CI: 0.54-
0.99).  Both studies by Eng and colleagues suggest that changes in body mass as well as 
physical activity levels are associated with breast cancer risk, which make it plausible that 
changes in these factors would also be related to survival post diagnosis.   
Using the data from the LIBCSP follow-up study, Cleveland et al. report that women 
who are obese one year prior to diagnosis (BMI >= 30.0 kg/m2) have an increased risk of 
breast cancer related death compared to ideal weight women for both premenopausal (HR: 
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2.85, 95% CI: 1.30-6.23) and postmenopausal cases (HR: 1.88, 95% CI: 1.04-3.34) with 
similar associations observed for all-cause mortality.  Also, among women who were 
premenopausal when diagnosed with breast cancer, those who gained more than 16 kg 
between age 20 and 1 year prior to diagnosis had a markedly greater risk of death from all 
causes (HR: 2.45, 95% CI: 0.96-6.27) and breast cancer (HR: 2.09, 95% CI: 0.80-5.48) 
compared to women whose weight remained stable.  A similar association was observed 
among postmenopausal women diagnosed with breast cancer who gained more than 12.7 kg 
after age 50 up to the year before diagnosis compared to those whose weight remained stable 
(all-cause mortality HR: 2.69, 95% CI: 1.63-4.43; breast cancer mortality HR: 2.95, 95% CI: 
1.36-6.43).  Body size was also found to modify the relationship between smoking and 
survival in this cohort as Sagiv and colleagues found (12).  The authors report that the 
association between current active smoking (compared to never smokers) and increased risk 
of death from all causes was stronger among women who were obese at diagnosis (HR: 2.10, 
95% CI: 1.03-4.27) than overweight (HR: 1.10, 95% CI: 0.52-2.35) or normal weight women 
(HR: 1.00, 95% CI: 0.54-1.86) with similar associations observed for breast cancer specific 
mortality.  Examining dietary exposures that may be relevant to the relationship between 
energy balance and mortality, Fink et. al. (3) report that intake one year prior to diagnosis of 
46 or more half-cup servings per week of fruits and vegetables is associated with an increase 
in survival among women diagnosed with invasive breast cancer compared to those who ate 
fewer than 18 half-cup servings a week (HR: 0.68, 95% CI: 0.42-1.09).   In a separate report, 
Fink and colleagues also found an approximately 40-50% reduction in risk of all-cause and 
breast cancer specific death comparing extreme quintiles of intakes of flavones, isoflavones 
and anthocyanidins (13).   
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Data Analysis 
Variable Definitions for Outcome and Exposures 
All-cause and Breast Cancer Specific Mortality.  A variable corresponding to 
length of time from baseline interview to either date of death or date of last follow-up 
(December 31, 2005) was created.  Dichotomous indicator variables were created to indicate 
if the time variable indicates death from any cause and death from breast-cancer related cause 
or if the subject was alive (or died from a non-breast cancer related illness) at the associated 
time point. 
Changes in Body Size.  Changes in body size from baseline (one year before 
diagnosis) to the various follow-up assessments were categorized into groups corresponding 
to weight loss (>5% loss from pre-diagnosis weight), maintenance (within 5% of pre-
diagnosis weight) and gain (2 groups, 5-10% gain from pre-diagnosis weight and >10% gain 
from prediagnosis weight).  These cutpoints were determined in accordance with other recent 
reports (14) as well as to coincide with public health recommendations (15).  For 
examination of effect modification, weight gain was combined into a single group (>5% gain 
from pre-diagnosis weight) in order to avoid sparse categories. 
Physical Activity Levels.  Physical activity levels, expressed in MET-hours/week 
were categorized as 0 MET-hours/week (inactive), 0.1-9.0 MET-hours/week and >9 MET-
hours/week.  This categorization was again chosen to correspond to previous reports (16, 17), 
facilitating comparison of our results with them as well as providing meaningful categories, 
as the highest category corresponds roughly to 2-3 hours a week of brisk walking.  With the 
issue of a significant amount of missing data, it is important to remember that a priori 
cutpoints for both body size and physical activity are necessary as the distribution of the 
 62 
missing data is unobserved, and therefore empirically-derived cutpoints are therefore 
inappropriate. 
Missing Data: Background 
Although outcomes are available on all 1,508 case subjects, only 1,033 women (68.5%) 
participated in the follow-up interview, yielding a large proportion of missing data for post-
diagnosis body size and physical activity.  Data on missing exposures and covariates is 
common in population based research and basic methods used to address this issue have been 
recently reviewed in the epidemiology literature (18).  Missing data may arise from several 
different processes defined by the relationships between the probability that the data is 
missing, other covariates and the unobserved value of the missing variable.   
In their classic text, Little and Rubin (19) propose a taxonomy that describes the 
mechanisms that may lead to missing data.  Data is considered missing completely at random 
(MCAR) if the probability that data is missing is independent of both observed and 
unobserved data.  Under this mechanism the observed data essentially constitutes a random 
sample of values from all subjects.  If data is MCAR then a complete-case analysis, where 
the analysis is performed on all subjects with completely observed data, will yield valid 
estimates.  If the probability that data is missing depends only upon observed variables then 
the mechanism is termed missing at random (MAR).  Under this scenario a complete-case 
analysis will yield biased estimates, however analytic methods that account for the 
probability of missingness conditional on observed variables, such as multiple imputation 
and weighted estimating equations, are appropriate.  The most problematic situation arises 
when the probability that data is missing depends upon unobserved values of the missing 
variable, for example if the probability that income is reported is dependent upon the 
unobserved value of income.  When the probability that a variable is missing depends upon 
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its unobserved value, and possibly observed variables, the mechanism is referred to as not 
missing at random (NMAR).  In MCAR and MAR the missing data mechanism is considered 
ignorable (its consideration is not required in the modeling process), while under NMAR the 
missing data mechanism is non-ignorable (one must account for the distribution that 
determined if a data element was missing).  Valid estimation under non-ignorable 
missingness requires an approach that simultaneously incorporates a model for the 
probability that data is missing, a model for the distribution of the values of the missing 
variable and a model relating the variable to the outcome of interest. 
The concern in this project is that follow-up data on weight change and physical 
activity may be non-ignorably missing.  As described previously, many women were 
deceased at the time of the follow-up interview while a substantial number were ill or 
otherwise unable to complete the interview.  If post-diagnosis weight changes or levels of 
physical activity of these women contributed to their death or inability to complete the 
interview then this would create a mechanism of non-ignorable missingness for these 
variables and a complete case analysis, imputation or a weighted estimation approach would 
yield biased estimates of the association between these variables and survival. 
Proportional Hazards Models Under Complete Data 
This analysis utilizes proportional hazards regression to relate the exposures of interest to 
survival.  Proportional hazards regression is a statistical approach that allows for regression 
modeling of the rate of an event occurrence as a function of one or more variables (20-22).  
Here I sketch out the version of the proportional hazards model used here under the 
assumption that all data is completely observed.  This brief description will be extended into 
the selection model in the next section, with the more formal derivation discussed in chapter 
3.  Assume we have data on a sample of n independent subjects and for subject i we observe 
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the variable yi representing the observed follow-up time for subject i and indicator δi which 
equals 1 if yi corresponds to an event (e.g. death), and 0 if it represents a censored 
observation.  To define the piecewise exponential model, we divide the time axis into J 
discrete intervals (sj-1, sj] for j=1, …, J with s0 = 0 and sJ greater than the maximum of the 
{yi} .  Each subject provides a series of longitudinal measurements for of p completely 
observed covariates indexed by observation j by x
ij
 for j = 1, …, J, some elements of which 
may be constant (such as a fixed covariate measured only once, at baseline).  The piecewise 
exponential hazards model is then defined with the hazard function: 
 !(yi | xij ,"1,! j ) = ! j exp xij#"1( ) for y $(s j%1, s j ]  (1) 
where β1 is the p × 1 vector of coefficients on the vector of covariates xij and λj represents the 
baseline hazard within interval j.  The piecewise exponential proportional hazards model is 
similar to the Cox proportional hazards model except the baseline hazards are explicitly 
defined to be constant within each interval (sj-1, sj].  The advantages of the piecewise 
exponential model are that it allows for the shape of the baseline hazard to change across the 
time interval and facilitates estimation of the hazard ratios from a familiar distribution 
without regard to tied failure times that are sometimes problematic for the standard Cox 
proportional hazards model (21, 22).  Note that here, for convenience, it is assumed that the 
covariate measurement times correspond to the intervals of the piecewise exponential model, 
but this is not a requirement; this assumption will be relaxed in chapter 3. 
Selection Models for Survival Data with Missing Covariates 
Herring et. al. (23) propose a general technique that extends the fixed-time Cox proportional 
hazards model when some covariates may be missing, and allows for the missing data 
mechanism to be potentially non-ignorable.  It is this method that I extended to allow 
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covariates that vary over time.  This modeling paradigm, called a selection model, requires 
the specification of the joint distribution of three processes: (1) the probability that data is 
missing, (2) the distribution of the variable with missing values and (3) the relationship 
between said variable and the outcome, time to death.   
In addition to the covariates xij defined previously, consider zij a vector of length q of 
additional covariates, some of which may be missing at some point in time.  Corresponding 
to each variable in zij is an indicator of missingness for that variable contained in the vector 
rij=(rij1, …, rijq) where rijl=1 if zijl is missing and 0 otherwise, for l=1,…, q.  The selection 
model allows specification of the joint distribution of (ri, yi, zi | xi) with the goal of obtaining 
unbiased estimates of the regression parameters.  In general, the complete data joint 
distribution of (ri, yi, zi | xi) may be expressed as a series of conditional densities: 
p(ri , yi ,zi | xi ,!,",#) = pr (ri | yi ,zi ,xi ,#) $ py (yi | zi ,xi ,!) $ pz (zi | xi ," )  (2) 
The parameters φ and α index the distribution of the missing data mechanism and the 
missing covariates and are nuisance parameters which are not of inferential interest. 
Distribution of the missing data process.  Accounting for the nonignorability of the 
missing data mechanism requires specification of a model for the missing data mechanism ri, 
which is assumed to be dependent upon the unobserved value the corresponding variable 
would have taken if it were observed.  As shown in Ibrahim, Lipsitz and Chen (24) and 
Stubbendick and Ibrahim (25) modeling the missing data mechanism ri as a series of one 
dimensional conditional distributions is effective at reducing the number of nuisance 
parameters while maintaining correlation between the longitudinal observations and allowing 
for non-monotone patterns of missingness (25, 26).  For the joint distribution of ri, we 
specify a distribution for each rijl sequentially conditioning over the other missingness 
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indicators at measurement j, previous missingness indicators for all variables at all 
measurements prior to j, the corresponding vector of completely observed and possibly 
missing covariates, xij and zij, respectively, event time yi and vector of parameters φjl: 
 
p
r
(ri | yi ,xi ,zi ) = p(riJq | riJ1,…,riJ (q!1),ri(J !1),…,ri1,xiJ ,ziJ , yi ,"Jq ) #!
# p(riJ1 | ri(J !1)1,…,ri11,xiJ ,ziJ , yi ,"J1) #!
# p(ri(J !1)q | ri(J !1)1,…,ri(J !1)(q!1),ri(J !2),…,
ri1,xi(J !1),zi(J !1), yi ,"(J !1)q ) #!
# p(ri(J !1)1 | ri(J !2)1,…,ri11,xi(J !2),zi(J !2), yi ,"(J !1)1) #!
# p(ri1q | ri11,,…,ri1(q!1),xi1,zi1, yi ,"1q ) #!# p(ri11 | xi1,zi1, yi ,"11)
 (3) 
Sequentially conditioning on previous measurements approximates a correlation structure 
similar to what would be obtained using random effects models without the need to specify 
the random effect (25, 27).  A series of logistic regressions may be used to model these 
conditional distributions as each rijl is dichotomous.  The contribution to the complete-data 
likelihood for subject i corresponding to the missing data mechanism is thus given by 
equation (3). 
Distribution of the observed failure times.  The distribution of observed failure times 
conditional on observed and unobserved covariates is given by the proportional hazards 
model defined in equation (1), but explicitly including the potentially missing variables zij.  
The hazard function is then: 
 !(yi | xij ,zij ,"1,"2 ,! j ) = ! j exp xij#"1 + zij#"2( ) for y $(s j%1, s j ]  
where now β2 is the q × 1 vector of coefficients on the vector of covariates zij.  The density 
for the observed failure time yi is then: 
 py (yi | xij ,zij ,!1,!2 ," j ) = " j exp(xij#!1 + zij#!2 )( )
$i
exp(%&i (yi ))
exp(xij #!1 +zij #!2 )  
for yi  ∈ (sj-1, sj] with cumulative hazard function: 
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! j (yi ) = (yi " s j"1)# j exp(xij$%1 + zij$%2 ) + (sg " sg"1)#g exp(xig$%1 + zig$%2 )
g=1
j"1
&
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. 
We further let λ=(λ1,…,λJ)′ denote the J × 1 vector of baseline hazards λj and let Δij be an 
indicator of if subject i died or was censored in interval j (i.e. yi  ∈ (sj-1, sj]).  The ith 
contribution to the complete data likelihood for the piecewise exponential model is then: 
 
py (yi | xi ,zi ,!1,!2 ,") = " j exp(xij#!1 + zij#!2 )( )
$ij%i
j=1
J
& '
exp ($ij) j (yi )exp(xij#!1 + zij#!2 ){ }.
 (4) 
If we define tij = min(yi, sj+1) - sj if yi ≥ sj and 0 if yi < sj to be the length of the overlap from 
the beginning of interval j to the end of the interval or until failure time yi, then it can be 
shown that the likelihood function given by equation (4) is equivalent to one where Δijδi 
follows a Poisson distribution with mean tij λ(yi | xij, zij, β1, β2, λj). 
Distribution of missing data. For the joint distribution of the missing covariates zi we 
again follow the strategy suggested by Lipsitz and Ibrahim (28), Ibrahim et al. (24) and 
Stubbendick and Ibrahim (25) by specifying a sequence of one dimensional conditional 
distributions.  We specify a model for each zijl sequentially conditioning over the other z 
variables at measurement j, all z variables at previous times, the corresponding vector of 
completely observed covariates, xij, event time yi, and α=(α11,…,αJq)′ where each αjl is a 
vector of parameters indexing the distribution for each covariate l for measurement j.  The 
joint distribution of the z variables for subject i is then:  
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p
z
(zi | yi ,xi ) = p(ziJq | ziJ1,…, ziJ (q!1),zi(J !1),…,zi1,xiJ , yi ," Jq ) #!
# p(ziJ1 | zi(J !1)1,…, zi11,xiJ , yi ," J1) #!
# p(zi(J !1)q | zi(J !1)1,…, zi(J !1)(q!1),zi(J !2),…,zi1,xi(J !1), yi ," (J !1)q ) #!
# p(zi(J !1)1 | zi(J !2)1,…, zi11,xi(J !2), yi ," (J !1)1) #!
# p(zi1q | zi11,,…, zi1(q!1),xi1, yi ,"1q ) #!# p(ri11 | xi1,zi1, yi ,"11)
 (5) 
Expression of the distribution of covariates this way allows considerable flexibility in 
choice of distribution for each zijl, accommodating continuous and categorical variables, as 
well as offering a convenient way to account for intra-subject correlation without 
specification of a random effect.  Once again, one should strive for a parsimonious 
specification of this joint distribution to avoid specification issues.  Equation (5) then 
represents the ith contribution to the marginal likelihood for z. 
Substituting equations (3), (4) and (5) into equation (2), yields the complete data 
likelihood: 
 
 
!(!
1
,!
2
,",#,$) = p(ri , yi ,zi | xi ,!1,!2 ,",#,$)
i=1
n
%
= p
r
(ri | yi ,zi ,xi ,$)py (yi | zi ,xi ,!1,!2 ,")pz (zi | xi ,# )
i=1
n
%
 
with densities p
r
(!) , p
y
(!)  and p
z
(!)  defined above.  Previous work with similar models has 
made use of the expectation-maximization (EM) algorithm to obtain the parameter estimates 
(23).  However here I propose a Fully Bayesian (FB) approach using vague priors on the 
parameters β1, β2, λ, α, and φ, which will produce estimates equivalent to the frequentist 
analysis using EM.  The FB framework is also less computationally demanding than the EM 
framework for this model. 
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The joint posterior distribution of the parameters is proportional to the product of the 
conditional distribution of the observed data given the parameters and the joint prior 
distribution of the model parameters p(!
1
,!
2
,",#,$) : 
 p(!
1
,!
2
,",#,$ | y,r,x,z)% p(yi ,ri ,xi ,zi | !1,!2 ,",#,$)dzi( )
zi
& '
i=1
n
( p(!1,!2 ,",#,$)  (6) 
If non-informative priors are specified for (β1, β2, λ, α, φ) then the posterior means and 
standard deviations of the parameters will be similar to maximum likelihood.  In the analyses 
to follow, I used the Gibbs Sampler (29) to sample from the posterior distribution given by 
equation (6).  Although somewhat computationally intensive (but less intensive than EM), 
the FB approach here provides a very straightforward way to estimate parameters from a 
complex model, especially variance and covariance parameters.   
In the Bayesian paradigm inferences on model parameters (e.g. β1, β2, λ, α, φ) are 
obtained through estimation of their distribution conditional on the observed data, also 
referred to as the posterior distribution of the parameters.  For notational convenience let 
β=(β1, β2) denote the vector of coefficients on both the fully observed and potentially 
missing covariates from the proportional hazards model.  The posterior distribution is 
proportional to the product of the conditional distribution of the data (x and z) given the 
parameters and prior distributions on the model parameters: 
 p(!,",#,$ | y,r,x,z)% p(y,r,x,z | !,",#,$) & p(!) & p(") & p(# ) & p($) . (7) 
The conditional distribution of the data, p(y, r, x, z| β, λ, α, φ) is proportional to the 
likelihood function from the frequentist approach (equation 6) and the terms p(β), p(λ), p(α) 
and p(φ) represent the prior distributions on the model parameters, representing a priori 
expectations on them.  The Bayesian approach then seeks to obtain means and variances for 
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the parameters of interest (β, λ, α, φ) from their marginal posterior distributions.  These 
Bayesian estimates are equivalent to frequentist point estimates for these parameters if non-
informative distributions are specified for the priors (30).  A non-informative distribution is 
one which exhibits little influence on the posterior, allowing the likelihood to dominate.  
To solve for the parameters of this model I used the WinBUGS software program (31, 
32) that makes use of the Gibbs sampler, an algorithm for generating samples from marginal 
posterior distributions without requiring knowledge of the form of the density (29).  The 
Gibbs sampler allows the generation of a large sample of data on the parameters (β, λ, α, φ) 
from which sample means and variances may be calculated in order to make statistical 
inferences.  To obtain an empirical estimate of the joint posterior distribution p(β, λ, α, φ | y, 
r, x, z), the Gibbs sampler generates a series of draws of (β, λ, α, φ) from the corresponding 
full conditional distributions [e.g. p(β |  λ, α, φ, y, r, x, z)].  This sequence of draws on each 
variable ultimately converges in distribution to the marginal posterior distributions of interest 
(e.g. p(β | y, r, x, z)) from which estimates of the mean and variance may be calculated (29).  
Specifically, the steps of the algorithm are as follows: 
0. Specify a set of initial values of the parameters, (! (0)," (0),# (0),$ (0) ) 
1. Set the step counter k=1. 
2. Draw β(k) from the conditional distribution [β |  α(k-1), φ(k-1), λ (k-1),  y, r, x, z] 
3. Draw λ(k) from the conditional distribution [λ |  β(k), α(k-1), φ(k-1),  y, r, x, z] 
4. Draw α(k) from the conditional distribution [α |  β(k) , λ (k), φ(k-1),  y, r, x, z] 
5. Draw φ(k) from the conditional distribution [φ |  β(k),  λ (k), α(k) , y, r, x, z] 
6. Set k=k+1.  Repeat step 2, a total of N times. 
7. The sequence of N “observations” of (β(k) , λ(k), α(k), φ(k)) will then essentially 
consist of a sample from the marginal posterior distributions for each variable.   
From equation 7, one can see that the full conditional distributions in this algorithm 
are proportional to the likelihood multiplied by the prior distribution, for example: 
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 p(! | ",#,$, y,r,x,z)% p(y,r,x,z | !,",#,$) & p(!) .  
For the distributions of the exposures (x, z), probability of missingness (r) and event time (y) 
I use the forms described above.  For the parameters from the proportional hazards regression 
(β, λ), logistic regression (φ) and missing data (α) models I specify prior distributions as 
normal with mean zero and large variance: 
!i ~ N(0,"! ) # i = 1,..., p
$i ~ N(0,"$ ) # i = 1,..., s
% i ~ N(0,"% ) # i = 1,...,q
 
with σ. on the order of 1,000,000 while the each of the baseline hazards from the proportional 
hazards regression, λj, are assumed to follow independent Gamma distributions with 
common parameters.  I ran the Gibbs sampler for several thousand iterations to achieve 
convergence (usually 25,000-30,000 iterations, depending on the complexity of the model), 
and then an additional 25,000-30,000 iterations after convergence to generate a sample for 
inference.  Estimates of regression parameters are obtained by calculating the mean value for 
each sample of parameters (e.g. the mean of the sample for each of the β parameters), with 
the 2.5th and 97.5th percentiles defining the 95% credible intervals, the Bayesian analog to 
frequentist confidence intervals (30).  For substantive interpretation I exponentiate (anti-log 
transform) the parameters and limits on the credible intervals.  Although the credible 
intervals are theoretically distinct from frequentist confidence intervals (as they represent the 
interval which has a 95% probability of containing the true parameter value), the use of non-
informative priors yields interval estimates that are similar to standard frequentist confidence 
intervals. 
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Confounding  
Model selection procedures have not been developed for missing data problems, and most 
importantly the iterative inclusion and exclusion of covariates into the models will 
fundamentally affect the assumptions regarding the missing data process.  This fact makes it 
impossible to disentangle the confounding effect of an included variable with the effect of the 
associated change in the missing data model.  Consequently, potential confounders were 
examined using a directed acyclic graph and confirmed through a change-in-estimate 
approach on the complete dataset of 1,033 subjects.  Although this method is less than ideal it 
should still successfully identify confounders of the associations of interest.  Potential 
confounders for the body size and physical activity analyses were those variables that are 
thought to be associated with both post-diagnosis weight change and mortality or post-
diagnosis physical activity levels and mortality, respectively.  Separately for all-cause and 
breast cancer specific mortality I used a change-in-estimate approach on the complete dataset 
to identify potential confounding variables for the final analysis.  Using a Cox proportional 
hazards regression model each variable was independently examined for its impact on the 
relationship between exposure and time to death.  Those variables that change the natural 
logarithm of the ratio of the adjusted to unadjusted hazard ratio (lnCoHR = ln[adjusted 
HR/unadjusted HR]) by 10% or more were included in a multivariate model. 
For the analysis of post-diagnosis weight change potential confounders included those 
variables potentially associated with both post-diagnosis weight change and survival (33-38): 
post-diagnosis physical activity (metabolic equivalent task hours per week, MET-hrs/wk; 
continuous), total energy at baseline interview (kcal/day; continuous), menopausal status 
(premenopausal, postmenopausal), stage (in situ, invasive), chemotherapy regimen (yes/no), 
radiation therapy (yes/no), hormone therapy (yes/no), nodal involvement (yes/no), tumor size 
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greater than 2 cm (yes/no), estrogen receptor positive tumor (ER status; yes/no) and 
progesterone receptor positive tumor (PR status; yes/no).  The final confounder list included 
age, chemotherapy regimen, tumor size, ER status and PR status, which was also consistent 
with identification of confounders using the analysis of a directed acyclic graph.  In addition 
to weight change, other covariates with significant amounts of missing data included 
chemotherapy, tumor size, ER status and PR status with 32.2%, 31.6%, 34.0% and 34.3% 
missing out of the 1,508 cases, respectively.  Models for the variables chemotherapy, ER 
status, PR status and tumor size were included in the selection model along with the model 
for weight change.  Treatment and tumor characteristics were unlikely to be non-ignorably 
missing and therefore did not require specification of models for their missing data 
mechanisms.  Variables with minor amounts of missing data included menopausal status 
(1.99% missing), pre-diagnosis BMI (1.13% missing), adult weight change (from age 20 to 1 
year before diagnosis; 1.66% missing), education (0.40% missing) and income (0.27% 
missing); so these few subjects were excluded from the analysis as these amounts were 
unlikely to influence the results.  The analysis of weight change ultimately included 1,436 
women, 292 who died during follow-up with 156 of these deaths attributed to breast cancer. 
For post-diagnosis physical activity, potential confounders included variables that 
have been shown to be related to both survival and post-diagnosis physical activity levels, 
and included age, pre-diagnosis body mass index (BMI, weight in kg/squared height in 
meters) in the year prior to diagnosis, chemotherapy treatment (yes/no), radiation therapy 
(yes/no) and hormone therapy (yes/no) (39, 40).  I also considered menopausal status at 
diagnosis (premenopausal/postmenopausal), total energy intake in the year prior to the 
baseline interview, stage (in situ vs. invasive), ER status (yes/no), PR status (yes/no), tumor 
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size (< 2 cm vs. >= 2 cm) and nodal involvement (yes/no).  The final models included age, 
chemotherapy treatment, radiation treatment, hormone therapy and tumor size, which were 
also consistent with assessment of confounding using a directed acyclic graph.  In addition to 
physical activity, other covariates with significant amounts of missing data included 
chemotherapy, radiation treatment, hormone therapy and tumor size with 32.2%, 33.0%, 
32.1%, 31.6% missing, respectively.  For each of these variables, models were incorporated 
into the analysis to impute their values, similar to the model required for physical activity 
levels.  Other variables with missing data included baseline physical activity (0.93%) 
menopausal status (1.99% missing), pre-diagnosis BMI (1.13% missing), adult weight 
change (from age 20 to 1 year before diagnosis; 1.66% missing), education (0.40% missing) 
and income (0.27% missing).  These small amounts were unlikely to influence the results and 
so the additional cost of estimating models for each of these variables exceeded any benefit.   
I therefore excluded subjects with any of these variables missing.  Our final analysis then 
included 1,423 women (94.4% of the original 1,508 cases). Among these women, 291 died 
during the follow-up with 156 of these deaths due to breast cancer. 
Effect Measure Modification 
Given the low number of events and the influence of missing data, the power for examining 
effect modification in this study was limited and therefore I examined interactions in an 
exploratory and descriptive manner using stratified analysis.  For the analysis of post-
diagnosis weight change, I examined effect modification by baseline body mass index (BMI; 
<25 kg/m2 vs. >= 25 kg/m2), adult weight gain from age 20 years to 1 year before reference 
date (>3 kg loss, maintain within 3 kg and >3 kg gain) as well as the interaction with time 
(before and after 2 years post-diagnosis), which additionally captured possible departure 
from the proportionality assumption.  For the physical activity analysis I stratified results by 
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pre-diagnosis physical activity levels (0 MET-hours/week, 0.1-9.0 MET-hours/week, >9.0 
MET-hours/week), baseline (BMI <25 kg/m2 vs. >= 25 kg/m2) and various measures of time 
(before and after 1 year post-diagnosis; before and after 2 years post-diagnosis).  Formal tests 
for interactions were not conducted as these were considered exploratory and p-values are 
not calculated in the Bayesian paradigm. 
Sensitivity Analysis 
One benefit of the selection model approach is the ability to use it to easily perform 
sensitivity analysis by altering the form of the models for probability of missingness.  As in 
Herring et al. (23) I compared the results from models with assumptions (1) that the 
probability of missing is independent of observed and unobserved data (MCAR) using a 
complete-case analysis in Stata v. 10.0, as well as (2) that the probability of missing is 
dependent on observed covariates, but not unobserved data (MAR), formally omitting 
specification of the probability of missingness (equation (3)) and (3) that the probability of 
missing is dependent upon observed and missing data (non-ignorable missing), requiring 
explicit specification of equation (3).   
The results of this sensitivity analysis are presented in chapter 3.  I only conducted a 
complete sensitivity analysis on the analysis of post-diagnosis weight change, and I estimated 
models that assumed a non-ignorably missing data mechanism for the detailed weight change 
and physical activity chapters (chapters 4 and 5).  It was encouraging that results from the 
weight change analysis appeared largely invariant to changes in the MAR and NMAR 
assumptions, as we believed weight change to be more likely to be non-ignorably missing 
given that it is such a sensitive issue. 
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Study Power 
Although the final analysis was performed in a Fully Bayesian framework, and I did not 
conduct formal hypothesis testing, since the proposed analysis will yield estimates similar to 
the frequentist approach, a power analysis may provide a general idea of the ability of this 
study to detect certain effect sizes with credible intervals that exclude the null.  Given the 
significance of missing data for this study and the fact that power calculations do not exist for 
missing data models, I show power calculations for two different scenarios:  for the 
minimum sample size (e.g. if a complete case analysis were to be conducted among those 
completing the follow-up questionnaire, n=1033) and for the maximum sample size (e.g. 
assuming complete follow-up data for the entire cohort, n=1436 for weight change analysis 
and n=1423 for physical activity analysis, after omitting subjects with missing data on 
confounders as described above) which will provide the most useful information for this 
analysis.  A significance level of 5% will be assumed for hypothesis tests and calculations are 
based on the logrank test using the sample size routine in Stata 10.0 (Stata Corporation, 
College Station, TX).  For each of the aims, I assumed distributions of weight change and 
physical activity levels recently published in similar follow-up studies, applied to the 
expected sample sizes in this cohort. 
Aim 1.  Determine if post-diagnosis changes in bodyweight are associated with breast 
cancer survival:  Power calculations for this aim are based on a comparison of survival rates 
between those in the weight maintenance group and those in the group corresponding to the 
highest gain.  Applying the distribution of weight change observed in the analysis by Caan et 
al. (14) (>5% loss: 17%, maintenance within 5%: 47% , 5-10% gain: 16%, >10% gain: 19%) 
to the sample sizes presented here, for the complete data sample of 1,033 subjects I calculate 
that there will be 489 and 200 subjects in the maintenance and highest gain group, 
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respectively.   For the full sample of 1,436 subjects I calculated 679 and 278 subjects in the 
maintenance and highest gain group, respectively.   
Table 2 shows power calculations comparing survival times using a 2-sided log-rank 
test to compare survival in these groups; as I expect a deleterious effect of increasing weight 
the comparisons are presented assuming hazard ratios greater than 1.0.  Power to compare 
maintainers to those with the greatest weight gain was excellent for modest associations 
(>95% power to detect a HR of at least 1.5). 
Aim 2.  Determine if post-diagnosis levels of physical activity are associated with 
breast cancer survival: Power calculations for this aim will be based on a comparison of 
survival rates between those in the group of lowest post-diagnosis physical activity and those 
in the group corresponding to the highest level of post-diagnosis physical activity and as 
before, I present results comparing to a larger group consisting of the two greatest levels of 
activity combined.  I used the distribution of post-diagnosis physical activity levels reported 
by Irwin et al. (17) (0 MET-hours/week: 17%, 0.1-9.0 MET-hours/week: 43% , >9.0 MET-
hours/week: 40%) applied to the sample sizes here.  These calculations yield 171 subjects in 
the lowest level, 416 subjects in the highest level for the complete data sample of 1,033.  For 
the full sample of 1,423 subjects I calculated 236 and 573 subjects in the lowest and highest 
activity group, respectively.  Power calculations for this aim will be presented assuming a 
protective effect of increasing activity, or for hazard ratios less than 1.0.  As shown in table 
3, power to compare the lowest to those with the highest levels of post-diagnosis physical 
activity was excellent for modest associations (>92% power to detect a HR of 0.75 or less).   
Strengths and Limitations 
The primary strength of this study is that the question of how post-diagnosis levels in body 
size and physical activity levels affect survival after breast cancer diagnosis is largely 
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unresolved.  Results from this analysis address important public health questions, which will 
impact on lifestyle recommendations for women who are diagnosed with the disease.  The 
physical activity questionnaire used in this study is comprehensive in that it allows study 
subjects to specify activities in an open-ended format and allows for accurate assessment of 
activity over a wide span of time (8); consequently, it is considered to be the best assessment 
tool for population-based studies of physical activity and breast cancer etiology (41).  
Another significant advantage of this study is the novel approach employed to account for the 
missing follow-up data in this cohort.  This technique is unique and is applicable to outcomes 
other than survival. An additional benefit of this approach is that it allows a straightforward 
method for conducting sensitivity analyses to evaluate the effect of different missing data 
assumptions (MCAR, MAR or non-ignorable) on the parameter estimates.  Use of the Gibbs 
Sampler through software such as BUGS (31), although computationally intensive, is 
straightforward and should be accessible to the methodologically astute epidemiologist. 
The cases for this study form a population-based cohort, and although not 
generalizable to the entire United States population will yield valuable data on the 
relationship between lifestyle factors and breast cancer survival.  A notable weakness of this 
study is that the assessments used for the primary exposures (height, weight, physical 
activity) are self-reported and as such may tend to be reported with error.  Anthropometric 
measures in particular tend to be mis-reported with heavier people tending to underreport 
weight, while lighter people tend to overreport (42).  Lastly, the presence of a substantial 
portion of missing data is a weakness of this dataset proposed for this work.  Techniques to 
account for missing data are useful, however not a substitute for having the data that was not 
observed.  Although an analytical approach is not as ideal as having the data it is an 
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appropriate strategy, yielding statistically unbiased estimators and making efficient use of 
existing resources. 
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Summary 
To examine the association between post-diagnosis changes in body size, levels of physical 
activity and survival after diagnosis with breast cancer I used data from the Long Island 
Breast Cancer Study Follow-up, a population-based cohort of 1,508 women diagnosed with 
breast cancer during 1996 and 1997 from Long Island, New York.  Data was collected 
shortly after diagnosis and again approximately five years later and includes anthropometric 
and physical activity data as well as sociodemographic, medical and lifestyle variables.  Date 
and cause of death were ascertained using the National Death Index.  Out of the 1,508 
subjects completing the baseline interview only 1,033 completed the follow-up assessments 
resulting in a large proportion of missing exposure data.  To address this issue I outlined a 
selection model from the biostatistics literature that provides a flexible framework in which 
to model the missing data process.  I used time-to-event models to relate post diagnosis 
changes in body size and post diagnosis levels of physical activity to time of death and 
specify a model to describe the distribution of the exposures in the total study population.  A 
model to explain the probability that an observation is missing is also specified; by 
modifying the form of this model I performed sensitivity analysis to explore the impact of 
different assumptions on the mechanisms that lead to the missing data.  
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Table 2.1.   Selected characteristics of breast cancer cases at diagnosis (n=1,508), Long 
Island Breast Cancer Study Project, 1996-1997. 
 
Variable Cases  Percent 
Age at diagnosis (yrs)   
<40 89 5.9 
40-<50 318 21.1 
50-<60 410 27.2 
60-<70 353 23.4 
>=70 338 22.4 
Menopsausal Status   
Premenopausal 472 31.9 
Postmenopausal 1,006 68.1 
Missing 30  
Race   
White 1,411 93.8 
Other 94 6.2 
Missing 3  
Hispanic Ethnicity   
Yes 57 3.8 
No 1,448 96.2 
Missing 3  
Education   
Less than High School 183 12.2 
High School 538 35.8 
At Least Some College 781 51.8 
Missing 6  
Marital Status   
Ever Married 1,443 95.8 
Never Married 64 4.2 
Missing 1  
Parity   
Nulliparous 198 13.1 
Parous 1310 86.9 
Alcohol use   
Never 588 39.0 
Ever 920 61.0 
Smoking   
Never 675 44.8 
Former 543 36.0 
Current 290 19.2 
Missing 47  
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Table 2.1 (continued).   Selected characteristics of breast cancer cases at diagnosis 
(n=1,508), Long Island Breast Cancer Study Project, 1996-1997. 
 
Family History Breast Cancer   
No First Degree 1,166 79.8 
First Degree 295 19.2 
Hormone Replacement Therapy Use   
Never 1,096 72.9 
Ever 408 27.1 
Missing 4  
BMI at reference date   
<25 683 45.8 
25-29.9 476 31.9 
>=30 332 22.3 
Missing 17  
Stage   
In situ 235 15.6 
Invasive 1,273 84.4 
Nodal Involvement   
No 463 77.6 
Yes 134 22.5 
Missing 911  
Tumor size   
< 2 cm 749 76.2 
>= 2 cm 234 23.8 
Missing 453  
ER status   
Negative 265 26.6 
Positive 730 73.4 
Missing 513  
PR status   
Negative 355 35.8 
Positive 636 64.2 
Missing 517  
Radiation Treatment   
Yes 625 60.9 
No 401 39.1 
Missing 482  
Chemotherapy Treatment   
Yes 423 41.4 
No 599 58.6 
Missing 486  
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Table 2.1 (continued).   Selected characteristics of breast cancer cases at diagnosis 
(n=1,508), Long Island Breast Cancer Study Project, 1996-1997. 
 
Hormone Therapy Treatment   
Yes 616 61.1 
No 393 38.9 
Missing 499  
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Table 2.2.   Power to detect varying hazard ratios for weight change, calculations based on 
the log-rank test statistic, assuming 5% significance level, complete data (n=1033 total; 
maintenance n=489; highest gain n=200) and full sample (n=1436 total; maintenance n=679; 
highest gain n=278). 
 
 Power 
 Highest level vs. Lowest level 
Min. Detectable Hazard 
Ratio 
Complete 
Data 
Full  
Sample 
1.33 95% 99% 
1.5 99% 99%% 
1.75 100% 100% 
Table 2.3.  Power to detect varying hazard ratios for post-diagnosis levels of physical 
activity categorized to three levels, calculations based on the log-rank test statistic, complete 
data (n=1033 total; inactive: 0 MET-hours/week n=171; highest activity: >9.0 MET-
hours/week n=416) and full sample (n=1423 total; inactive: 0 MET-hours/week n=236; 
highest activity: >9.0 MET-hours/week n=573). 
 
 Power 
 Highest level vs. Lowest level 
Min. Detectable Hazard 
Ratio 
Complete 
Data 
Full  
Sample 
0.75 92% 98% 
0.67 99% 99% 
0.50 100% 100% 
0.33 100% 100% 
0.25 100% 100% 
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CHAPTER 3 
A PROPORTIONAL HAZARDS REGRESSION MODEL WITH NON-IGNORABLY 
MISSING TIME-VARYING COVARIATES 
Abstract 
Missing covariate data is common in observational studies of time to an event, especially 
when covariates are repeatedly measured over time.  Failure to account for the missing data 
can lead to bias or loss of efficiency, especially when the data are non-ignorably missing.  
Previous work has focused on the case of fixed covariates rather than those that are 
repeatedly measured over the follow-up period, so here we present a selection model that 
allows for proportional hazards regression with time-varying covariates when some 
covariates may be non-ignorably missing.  We develop a fully Bayesian model and obtain 
posterior estimates of the parameters via the Gibbs sampler in WinBUGS. We illustrate our 
model with an analysis of post-diagnosis weight change and survival after breast cancer 
diagnosis in the Long Island Breast Cancer Study Project (LIBCSP) follow-up study.  Our 
results indicate that post-diagnosis weight gain is associated with lower all-cause and breast 
cancer specific survival among women diagnosed with new primary breast cancer.  Our 
sensitivity analysis showed only slight differences between models with different 
assumptions on the missing data mechanism yet the complete case analysis yielded markedly 
different, and sometimes implausible results. 
Introduction 
Studies of survivorship are often plagued by missing covariate data, especially when 
assessments are made longitudinally and deal with lifestyle or behavioral characteristics that 
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may be sensitive in nature.  A formal treatment of missing data requires consideration of the 
process that leads to the incomplete observations, such as the taxonomy suggested by Little 
and Rubin (1).  Data is considered missing completely at random (MCAR) if the probability 
that data is missing is independent of both observed and unobserved data.  Under this 
scenario the observed data essentially constitutes a random sample of values from all subjects 
and thus a complete-case analysis, which uses data only on those subjects with no missing 
observations, will yield unbiased parameter estimates.  If the probability that data is missing 
depends only upon fully observed variables then the data is referred to as missing at random 
(MAR).  The missing data mechanism is often called ignorable in this case.  The most 
problematic situation arises when the probability that data is missing depends upon 
unobserved values of the missing variable, which is what we suspect for our data.  When the 
probability that a variable is missing depends upon its unobserved value then the data is 
referred to as not missing at random (NMAR) and the missing data mechanism is referred to 
as non-ignorable.  Valid estimation under non-ignorable missingness requires simultaneously 
accounting for the probability that data is missing, the distribution of the values of the 
missing variable and the relationship between the potentially incomplete variable to the 
outcome of interest. 
The majority of the literature on missing covariates in proportional hazards regression 
has focused on frequentist methods for baseline MAR covariates (2-10).  The Bayesian 
approach to survival analysis with covariate data that is MAR is described in detail by 
Ibrahim, Chen and Sinha (11).  Frequentist methods for non-ignorably missing covariates in 
survival analysis have been presented by Leong, Lipsitz and Ibrahim (12) and Herring, 
Ibrahim and Lipsitz (13), however both of these methods apply only to baseline (fixed) 
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covariates, and the method by Leong and colleagues requires them to also be dichotomous.  
The selection model outlined by Herring et al. (13) specifies the joint distribution of the 
survival times, missing covariates and missingness indicator through a series of one 
dimensional conditional distributions and uses a Monte Carlo Expectation Maximization 
(MCEM) algorithm for parameter estimation.  Here, we propose a model that extends this 
approach by allowing the covariate values to vary over time, and we present a 
computationally easier alternative to the MCEM algorithm for parameter estimation. 
The motivation for developing this model was lies in our interest in identifying 
factors that may be associated with survival among women with breast cancer.  Our objective 
is to evaluate how post-diagnosis changes in weight over time affect survival through an 
analysis of data from the follow-up to the LIBCSP (14).  An issue for this analysis is that a 
significant portion of the study subjects are missing data for one or more follow-up 
assessments of bodyweight making bias or loss of efficiency of serious concern if we limit 
our investigation to only those subjects with complete data.  Specifically, given the stigma 
associated with being overweight, we suspect that those subjects with missing data on body 
size may tend to be heavier than those who responded, making this subset of subjects a less 
than representative sample of the study population.  In this case standard proportional 
hazards models would be inappropriate.  With repeated measurements of body size at and 
after diagnosis, our primary covariate of interest is time-varying, requiring us to develop the 
model we present here.  To our knowledge there has been no previous work addressing 
inference for selection models with non-ignorably missing time-varying covariates. 
The following section of the paper will outline our notation and describe the selection 
model in general.  We then describe specific models for each of the conditional distributions: 
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the missingness indicator given time-to-event and covariates, the time-to-event model given 
covariates and the distribution of the missing covariates.  We then describe our estimation 
approach and then illustrate our model with an example of an analysis of changes in 
bodyweight over time and survival after breast cancer diagnosis, using data from the follow-
up to the Long Island Breast Cancer Study (14).  We conclude with a discussion of the results 
and the methodology. 
The Selection Model 
Here we outline a selection model for proportional hazards regression with time varying 
covariates, which is defined by the joint distribution of the event times, missing covariates 
and the mechanism that describes the probability of missingness.  This joint distribution is 
specified through a series of conditional distributions:  (1) the probability the covariate data 
is missing conditional on event time and (possibly unobserved) covariates, (2) the 
distribution of event time conditional on covariates and (3) the marginal distribution of the 
missing covariates dependent only on fully-observed variables.  We begin by outlining the 
notation for the model. 
Assume we have data on a sample of n  independent subjects and for subject i  denote 
the event time by T
i
 and censoring time by C
i
.  For each of the n  subjects we observe the 
variable yi = min(Ti ,Ci )  and indicator of failure ! i  which takes on the value 1 if yi  
corresponds to an occurrence of an event (i.e. T
i
! C
i
), and 0 if it represents a censored 
observation (i.e. T
i
> C
i
).  We further assume independence between T
i
 and C
i
.  Each 
subject provides a series of longitudinal measurements for p + q  variables where for the kth  
measurement we denote the vector of p  completely observed variables by 
 
xik = (xik1,…, xikp )  
and q  variables with potentially missing values by 
 
zik = (zik1,…, zikq )  measured at times vik  
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for 
 
k = 1,…,K
i
, where K
i
! 1.  Elements of the z
ik
 vector are missing for only some subjects 
at some of the measurement points so associated with each variable in z
ik
 is an indicator of 
missingness for that variable contained in the vector 
 
rik = (rik1,…,rikq )  where rikl = 1  if zikl  is 
missing and r
ikl
= 0  otherwise, for 
 
l = 1,…,q  and 
 
k = 1,…,K
i
.  The notation x
i
, z
i
, and r
i
 
will refer to matrices of size K
i
! p , Ki ! q , and Ki ! q  respectively, representing the set of 
all K
i
 measurements for each vector of variables for each subject i . 
In general, estimation of a proportional hazards regression of y  on [x z]  using 
complete covariate data (only where r
ikl
= 1) will yield biased estimates of the regression 
parameters as it does not account for the distribution of the missing variables and more 
importantly the possibility that the reason they are missing may be related to their 
unobserved values.  The selection model allows us to specify the joint distribution of 
(ri , yi ,zi | xi )  allowing us to account for these relationships with the goal of obtaining 
unbiased estimates of the regression parameters.  In general, the complete data joint 
distribution of (ri , yi ,zi | xi )  may be expressed as a series of conditional densities: 
 p(ri , yi ,zi | xi ,!,",#) = pr (ri | yi ,zi ,xi ,#) $ py (yi | zi ,xi ,!) $ pz (zi | xi ," )  (1) 
The parameters !  and !  index the distribution of the missing data mechanism and the 
missing covariates and are nuisance parameters which are not of inferential interest.  The 
remainder of this section describes the specification of these conditional densities and the 
form of the complete data likelihood in detail. 
Models for the missing data mechanism 
The assumption of nonignorability of the missing data process requires specification of the 
distribution of the probability of missingness, which is assumed to be dependent upon the 
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unobserved value the corresponding variable would have taken if it were observed.  We 
follow Ibrahim, Lipsitz and Chen (15) and Stubbendick and Ibrahim (16) by modeling the 
missing data mechanism r
i
 as a series of one dimensional conditional distributions, which is 
effective at reducing the number of nuisance parameters while maintaining correlation 
between the longitudinal observations and allowing for non-monotone patterns of 
missingness (16, 17).  For the joint distribution of r
i
, we specify a distribution for each r
ikl
 
sequentially conditioning over the other missingness indicators at measurement k , previous 
missingness indicators for all variables at all measurements prior to k , the corresponding 
vector of completely observed and possibly missing covariates, x
ik
 and z
ik
, respectively, 
event time yi  and vector of parameters !kl : 
 
p
r
(ri | yi ,xi ,zi ) = p(riKiq | riKi 1,…,riKi (q!1),ri(Ki !1),…,ri1,xiKi ,ziKi , yi ,"Kiq ) #!
# p(riKi 1 | ri(Ki !1)1,…,ri11,xiKi ,ziKi , yi ,"Ki 1) #!
# p(ri(Ki !1)q | ri(Ki !1)1,…,ri(Ki !1)(q!1),ri(Ki !2),…,
ri1,xi(Ki !1),zi(Ki !1), yi ,"(Ki !1)q ) #!
# p(ri(Ki !1)1 | ri(Ki !2)1,…,ri11,xi(Ki!2 ),zi(Ki !2), yi ,"(Ki !1)1) #!
# p(ri1q | ri11,,…,ri1(q!1),xi1,zi1, yi ,"1q ) #!# p(ri11 | xi1,zi1, yi ,"11)
 (2) 
Sequentially conditioning on previous measurements approximates a correlation structure 
similar to what would be obtained using random effects models without the need to specify 
the random effect (16, 18).  A series of logistic regressions may be used to model these 
conditional distributions as each r
ikl
 is dichotomous.  The contribution to the complete-data 
likelihood for subject i  corresponding to the missing data mechanism is thus given by 
equation (2). 
Although the specification above appears quite complicated, in practice the number of 
measurements K
i
 are likely to be small and it may be realistic to assume that only some 
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subset of the variables in z  are non-ignorably missing, and therefore the number of variables 
requiring specification of missingness models is fewer than q .  Although it may be tempting 
to include a large number of variables and cross-products into the missing data models the 
analyst should strive for the most parsimonious specification possible as these models can 
easily become unidentifiable (13, 17, 19).  Herring et al. (13) and Ibrahim, Zhu and Tang 
(20) suggest a strategy for model selection for the missing data mechanism of these models 
to help avoid issues of identifiability. 
Model for the time-to-event 
We consider here a Cox piecewise exponential hazard model to describe the relationship 
between event time and the covariates.  To define the piecewise exponential model, we 
divide the time axis into J  discrete intervals (s
j!1
, s
j
]  for 
 
j = 1,…, J  with s
0
= 0  and s
J
 
greater than the maximum of the {yi} .  The measurement times for the covariate vector are 
assumed to fall at the boundaries of the intervals although it is possible for a measurement to 
span multiple intervals (e.g. if measurements on [x z]  are taken every 2 years but the 
intervals (s
j!1
, s
j
]  correspond to 1 year each).  Thus, since the number of covariate 
measurements K
i
! J  then we define a notation so the indexes on each of the covariates 
match the index for the intervals of the piecewise exponential model.  Then for subject i  
within interval j , we define 
 
x
ij
*
= (x
ij1
*
, x
ij2
*
,…, x
ijp
*
!)  where xijl
*
= xikl  and  zij
*
= (z
ij1
*
, z
ij2
*
,…, z
ijp
*
!)  
where zijl
*
= zikl  for k  and l  such that vik ! s j"1 < vi,k+1 .  For example, assume that covariate 
measurements are made at year 1 and year 3, yet the intervals for the piecewise exponential 
model correspond to one year each.  Then the covariate values at the second year (x
i2
* ) will 
be carried forward from the first year, while those from the third year will reflect the 
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measurements taken at that time.  Thus x
ij
*  denotes the p !1  vector of fully observed 
covariate values and z
ij
*  denotes the q !1  vector of possibly missing covariate values 
corresponding to the j th  interval for 
 
j = 1,…, J .  We then define the piecewise exponential 
hazards model with the hazard function: 
 !(yi | xij
* ,zij
* ,"1,"2 ,! j ) = ! j exp xij
* #"1 + zij
* #"2( ) for y $(s j%1, s j ]  
where !
1
 is the p !1  vector of coefficients on the vector of covariates x
ij
*  and !
2
 is the 
q !1  vector of coefficients on the vector of covariates z
ij
* .  The density for the observed 
failure time yi  is then: 
 py (yi | xij
* ,zij
* ,!1,!2 ," j ) = " j exp(xij
* #!1 + zij
* #!2 )( )
$i
exp(%&i (yi ))
exp(xij
* #!1 +zij
* #!2 )  
for yi !(s j"1, s j ]  with cumulative hazard function: 
! j (yi ) = (yi " s j"1)# j exp(xij
* $%1 + zij
* $%2 ) + (sg " sg"1)#g exp(xig
* $%1 + zig
* $%2 )
g=1
j"1
&
'
()
*
+,
. 
We further let 
 
! = (!
1
,…,!
J
")  denote the J !1 vector of baseline hazards ! j  and let !ij  be 
an indicator of if subject i  died or was censored in interval j  (i.e. yi !(s j"1, s j ]).  The i
th  
contribution to the complete data likelihood for the piecewise exponential model is then: 
 
py (yi | xi ,zi ,!1,!2 ,") = " j exp(xij
* #!1 + zij
* #!2 )( )
$ij%i
j=1
J
& '
exp ($ij) j (yi )exp(xij
* #!1 + zij
* #!2 ){ }
 (3) 
 where xij
*
! = xik  and zij
*
! = zik  with k  and j  such that vik ! s j"1 < vi,k+1 .  If we define 
tij = min(yi , s j+1) ! s j  if yi ! s j  and 0 if yi < s j  to be the length of the overlap from the 
beginning of interval j  to the end of the interval or until failure time yi , then it can be shown 
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that the likelihood function given by equation (3) is equivalent to one where !
ij
"
i
 follows a 
Poisson distribution with mean tij!(yi | xij
*
,zij
*
,"
1
,"
2
,! j ) . 
Models for Missing Covariates 
For the joint distribution of the missing covariates z
i
 we again follow the strategy suggested 
by Lipsitz and Ibrahim (21), Ibrahim et al. (15) and Stubbendick and Ibrahim (16) by 
specifying a sequence of one dimensional conditional distributions.  We specify a model for 
each zikl sequentially conditioning over the other z  variables at measurement k , all z  
variables at previous times, the corresponding vector of completely observed covariates, x
ik
, 
event time yi , and  ! = (!11,…,!Kiq ")  where each ! kl  is a vector of parameters indexing the 
distribution for each covariate l for measurement k.  The joint distribution of the z  variables 
for subject i is then:  
 
p
z
(zi | yi ,xi ) = p(ziKiq | ziKi 1,…, ziKi (q!1),zi(Ki !1),…,zi1,xiKi , yi ,"Kiq ) #!
# p(ziKi 1 | zi(Ki !1)1,…, zi11,xiKi , yi ,"Ki 1) #!
# p(zi(Ki !1)q | zi(Ki !1)1,…, zi(Ki !1)(q!1),zi(Ki !2),…,zi1,xi(Ki !1), yi ," (Ki !1)q ) #!
# p(zi(Ki !1)1 | zi(Ki !2)1,…, zi11,xi(Ki !2), yi ," (Ki !1)1) #!
# p(zi1q | zi11,,…, zi1(q!1),xi1, yi ,"1q ) #!# p(ri11 | xi1,zi1, yi ,"11)
 (4) 
Expression of the distribution of covariates this way allows considerable flexibility in choice 
of distribution for each zikl, accommodating continuous and categorical variables, as well as 
offering a convenient way to account for intra-subject correlation without specification of a 
random effect.  Once again, one should strive for a parsimonious specification of this joint 
distribution to avoid specification issues.  Equation (4) then represents the ith  contribution to 
the marginal likelihood for z . 
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Estimation 
Substitution of equations (2), (3) and (4) into (1) yields the complete data likelihood: 
 
 
!(!
1
,!
2
,",#,$) = p(ri , yi ,zi | xi ,!1,!2 ,",$,# )
i=1
n
%
= p
r
(ri | yi ,zi ,xi ,$)py (yi | zi ,xi ,!1,!2 ,")pz (zi | xi ,# )
i=1
n
%
 
with densities p
r
(!) , p
y
(!)  and p
z
(!)  defined above.  Previous work with similar models has 
made use of the EM algorithm to obtain the parameter estimates (13).  However here we 
illustrate a Fully Bayesian (FB) approach using vague priors on the parameters !
1
, !
2
, ! , 
!  and !  which will produce estimates equivalent to the frequentist analysis using EM and 
also yield variance estimates that are much easier to obtain than with the EM framework.  
The FB framework is also less computationally demanding than the EM framework for this 
model. 
The joint posterior distribution of the parameters is proportional to the product of the 
conditional distribution of the observed data given the parameters and the joint prior 
distribution of the model parameters p(!
1
,!
2
,",#,$) : 
p(!
1
,!
2
,",#,$ | y,r,x,z)% p(yi ,ri ,xi ,zi | !1,!2 ,#,& ,$,")dzi( )
zi
' (
i=1
n
) p(!1,!2 ,",#,$).
 (5) 
If non-informative priors are specified for (!
1
, !
2
, ! , ! , ! ) then the posterior means and 
standard deviations of the parameters will be similar to maximum likelihood.  We use the 
Gibbs Sampler (22) to sample from the posterior distribution given by equation (5).  
Although somewhat computationally intensive (but less intensive than EM), the FB approach 
here provides a very straightforward way to estimate parameters from a complex model, 
especially variance and covariance parameters. 
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Example 
We apply this model to an analysis of data from the follow-up study to the LIBCSP, to 
evaluate whether time-varying post-diagnosis changes in body size are related to survival 
among women with newly diagnosed breast cancer. 
Description of the Long Island Breast Cancer Follow-up Study 
The details of the LIBCSP are discussed elsewhere (14) but briefly, the parent study is a 
population based case-control study of breast cancer among women in Nassau and Suffolk 
counties on Long Island, New York conducted between August 1996 and July 1997.  Cases 
consisted of 1,508 women with newly diagnosed in situ or invasive breast cancer; of these, 
1,414 women agreed to be contacted at a later date for follow-up interviews.  For those who 
agreed to participate in the follow-up, the case subjects or their proxy were contacted by mail 
approximately 5 years after initial diagnosis of breast cancer and informed consent was 
obtained via telephone follow-up calls.  Of the 1,414 women who initially agreed to 
participate, 316 subsequently refused or were unable to be contacted.  Of the remaining 1,098 
subjects who agreed to the follow-up interview, only 1,033 case subjects or proxies (68.5% 
of the original 1,508 women) actually completed the interviewer-administered questionnaire 
(23).  The follow-up interview ascertained information similar to that gathered in the baseline 
questionnaire but relevant to the time period since diagnosis including treatment, 
reproductive history, smoking and alcohol use, and as well as body size and physical activity.  
Date and cause of death were ascertained for all 1,508 women using the National Death 
Index (24) with median follow-up time of 8.8 years (range: 0.2-9.4 years). 
Relevant to this analysis, the follow-up questionnaire ascertained body size (weight in 
pounds and height in inches) at diagnosis, one year post-diagnosis and at time of response to 
questionnaire for those subjects still living, or one year prior to death for interviews 
 100 
completed by proxy for subjects who were deceased at the follow-up but living longer than 
one year (specific timing for final follow-up measurement varied between 2 and 7 years post 
diagnosis).   Overall refusal to participate in the follow-up interview and non-response to 
specific questions among people still alive at each timepoint resulted in percentages of 
missing data on body size of 47.6%, 49.4% and 33.9% at baseline, 1-year post diagnosis and 
final follow-up.  Our concern is that heavier women may not have responded to the 
questionnaire in general, or to the body size questions specifically, due to self-conscious 
feelings or other reasons related to the amount of their weight, creating a non-ignorable 
mechanism for missing body size data.  With the body size variables we calculate percent 
change in body weight between the year prior to diagnosis and kth  measurement 
(100*(weight at measurement k  - weight one year before diagnosis)/weight one year before 
diagnosis) for k =1 (at baseline), 2 (at one year) and 3 (at time of interview or one year prior 
to death). 
Other fixed covariates included in this analysis (measured only once, at diagnosis) are 
indicators of chemotherapy regimen (yes/no), tumor size greater than 2 centimeters (yes/no), 
estrogen receptor positive tumor (ER status, yes/no) and progesterone receptor positive tumor 
(PR status, yes/no).  Each of these covariates also exhibited a significant amount of missing 
data with 32.2%, 31.6%, 34.0% and 34.3% missing, respectively.  The overlap between these 
variables with missing values was small, and since a complete case analysis requires all 
variables to be observed the resulting completely observed dataset, which excluded those 
with missing post-diagnosis change in bodyweight or a missing value for any covariate 
contained 499 subjects.  Note, however, that the percentage missing for any one of these 
variables was moderate.  Other important covariates included menopausal status, education, 
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adult weight change and body mass index (BMI) one year prior to diagnosis, which were 
each missing for less than 2% of subjects.  We also include data on age at diagnosis, which is 
fully observed for all women.  For the small amount of missing data on menopausal status, 
education, adult weight change and prediagnosis BMI we will exclude these subjects from 
the analysis, however for the remaining 1,455 subjects we will specify a selection model to 
account for the significant amount of missing data on follow-up body size, treatment and 
tumor characteristics.  Out of the 1,455 women included in this analysis, 292 died during the 
follow-up period with 156 of those deaths attributed to breast cancer. 
Selection Model 
We model the time since diagnosis for subject i  (denoted dur
i
) as a piecewise exponential 
model with J =10 one-year intervals.  Percent change in bodyweight for subject i  in interval 
j  corresponding to measurement k , denoted as pcwt
ij
*= pcwtik  for s j!1 "(vik ,vi,(k+1) ] , was 
categorized into four categories using indicator functions I
(a,b)
(x)  where I
(a,b)
(x)=1 if 
x !(a,b)  and 0 otherwise.  The four categories represent those who lost more than 5% of 
their pre-diagnosis body weight ( pcwt
ij
*
< !5 ), those who maintained within 5% of their pre-
diagnosis bodyweight ( pcwt
ij
*
! "5  and pcwt
ij
*
! 5 ), those who gained between 5% and 10% 
of their pre-diagnosis weight ( pcwt
ij
*
> 5  and pcwt
ij
*
< 10 ) and those who gained 10% or 
more of their prediagnosis bodyweight pcwt
ij
*
! 10 , omitting the category corresponding to 
those maintaining weight as the referent group.  We also include fixed covariates continuous 
age at diagnosis (dxagei ), indicators for chemotherapy treatment (chemoi ), ER status 
( erstat
i
), PR status ( prstat
i
) and tumor size > 2 centimeters ( tumor
i
), yielding the hazard 
function for our time to event model: 
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!(duri | xij ,zij ,"1,"2 ,! j ) = ! j exp("11dxagei + "21I#$,#5 (pcwtij
* ) +
"22I5,10 (pcwtij
* ) + "23I10,$ (pcwtij
* ) + "24chemoi +
"25erstati + "26 prstati + "27tumori )
 (6) 
 
for duri !(s j"1, s j ] .  For our analysis we assume that only percent change in weight ( pcwtik ) 
is potentially non-ignorably missing, while chemotherapy treatment (chemo
i
) and tumor 
characteristics tumor size > 2 centimeters ( tumor
i
), ER status (erstat
i
) and PR status 
( prstat
i
) are ignorably missing as we believe that their missingness is unlikely to be related 
to either unknown or known variables.  Therefore only one missing data mechanism need be 
specified: r
ik
=1 if subject i  was missing body size responses at measurement k  for 
 
k = 1,…,K
i
 where K
i
=1, 2 or 3 and r
ik
=0 if the value was present.  Then, from equation (2) 
for K
i
=3 we have: 
 
p
r
(ri | yi ,xi ,zi ,!) = p(ri3 | ri2 ,ri1,dxagei , pcwti3,ti3,!3) "
p(ri2 | ri1,dxagei , pcwti2 ,ti2 ,!2 ) "
p(ri1 | dxagei , pcwti1,ti1, yi ,!1)
 (7) 
where dxagei  is age at diagnosis and tik  is time in years since diagnosis to measurement k , 
both fully observed.  The modification of equation (7) for K
i
=1 or 2 is straightforward.  We 
specify each of the conditional distributions on the right hand side of equation (6) with a 
logistic regression model. 
Using equation (4) we express the joint distribution of the missing time-varying 
covariates percent change in weight ( pcwtik ) for  k = 1,…, 3 , and fixed (baseline) covariates 
chemotherapy treatment (chemo
i
), tumor size > 2 centimeters ( tumor
i
), ER status ( erstat
i
), 
PR status ( prstat
i
), as functions of continuously measured year of follow-up (for the 3rd 
measurement,v
i3
) menopausal status at diagnosis (menpstat
i
), BMI in the year prior to 
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diagnosis (bmirefi ), income reported at diagnosis ( incomei ), years of education completed 
( education
i
) and age at diagnosis (dxagei ) as: 
p
z
* (zi | yi ,xi ,!) = p(pcwti3 | pcwti2 , pcwti1,chemoi ,dxagei ,menpstati ,bmirefi ,vi3," 7 ) #
p(pcwti2 | pcwti1,chemoi ,dxagei ,menpstati ,bmirefi ,"6 ) #
p(pcwti1 | chemoi ,dxagei ,menpstati ,bmirefi ,"5 ) #
p(chemoi | dxagei ,incomei ,educationi ," 4 ) # p(erstati | dxagei ," 3) #
p(prstati | dxagei ,"2 ) # p(tumori | dxagei ,incomei ,educationi ,"1).
 (8) 
We model the conditional distributions of percent change in weight as linear regression 
models while the dichotomous treatment and tumor characteristic variables are modeled as 
using logistic regression models.  Note that in the case of the linear regression models the 
parameter vector !
l
 contains not only slope, but variance terms as well.  The choice of 
covariates for the models for percent change in bodyweight were determined based on 
consensus of previous studies on postdiagnosis weight change among breast cancer patients 
(25, 26).  The models for treatment variables were selected in the interest of parsimony and 
to represent those variables we believe to be associated with access to care.  An alternative 
option for the models for percent change in weight would be to generate a single four-level 
ordinal categorical variable for pcwtik  with the corresponding indicator variables in the 
piecewise exponential model, and ordinal logistic regression models for the categorical 
variable in the joint distribution given by equation (8).  However, given the inherently 
continuous nature of the underlying variable the method presented here yields an equivalent 
and more intuitive specification. 
We selected noninformative priors for the unknown parameters in the model.  For the 
slope parameters for the regression models (!
1
, !
2
, !
1
, !
2
, !
3
, !
4
, !
5
, !
6
, !
7
, !
1
, !
2
, 
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!
3
) we specified independent normal distributions with zero mean and precision of 10-5 and 
for the baseline hazards (! ) and variance parameters for the linear regression models we 
specified vague gamma distributions.  Estimation was performed using the Gibbs sampler in 
WinBUGS 1.4 (27) run for 25,000 iterations with an additional 25,000 burn-in.  To evaluate 
the robustness of our model to assumptions on the missing data mechanism we also estimated 
this model assuming that the longitudinal body size variable was MAR, therefore omitting 
the specification for the missing data mechanism, equation (7).  For comparison, we also 
estimated a complete-case analysis using maximum likelihood for an equivalent piecewise 
exponential model using Stata v. 10.0 (College Station, TX).  Each set of models was 
estimated for both all-cause and breast-cancer specific mortality. 
In table 3.1 we report the parameters from the piecewise exponential model under the 
various missing data assumptions for all-cause mortality.  Post-diagnosis weight loss appears 
to be associated with poor survival across all missing data assumptions as this is likely 
indicative of women with more advanced disease or otherwise less than robust health.  Post 
diagnosis weight gain is also positively associated with all-cause mortality for all model 
assumptions. However the associations in the complete case analysis in relation to moderate 
weight gain (5-10% of prediagnosis weight) are markedly attenuated compared to those that 
account for the missing data.  The magnitudes of the associations with post diagnosis weight 
change are similar between the MAR and NMAR models, although the estimate of effect for 
more moderate gain (5-10%) appears attenuated in the NMAR model compared to the MAR 
model, with the confidence interval for both estimates including the value corresponding to a 
null effect.  Most notable is that the credible interval for larger weight gain (>10%) excludes 
the null effect in both missing data models yet includes it in the complete case analysis.  In 
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both missing data models, compared to women who maintain their prediagnosis weight, 
moderate weight gain is associated with a modest increase in risk of death (MAR posterior 
log-hazard ratio (lnHR): 0.31, 95% credible interval: -0.42, 0.99; NMAR posterior lnHR: 
0.18, 95% credible interval: -0.55, 0.84) while larger gain is associated with a much greater 
risk of death (MAR posterior lnHR: 1.15, 95% credible interval: 0.50, 1.76; NMAR posterior 
lnHR: 0.72, 95% credible interval: 0.06, 1.36).  Estimates of effect for the covariates appear 
nearly identical between the missing data models, and the same direction and similar 
magnitude compared to the complete case analysis. 
Table 3.2 shows the results for breast cancer related deaths.  Compared to the models 
for all-cause mortality, we observe similar patterns across the different missing data 
assumptions.  The effect of moderate weight gain is attenuated, while the effect of larger 
weight gain is intensified in the models that account for missing data. 
Discussion 
We have presented a model for the analysis of time-to-event data with time-varying 
covariates when data on some covariates may be missing and have proposed an easy to 
implement solution strategy.  We employed this model in an analysis of the association of 
longitudinal changes in bodyweight and survival after diagnosis with breast cancer in a large, 
population-based case-control study where we were concerned that data on post-diagnosis 
changes in body size may be non-ignorably missing.  Our findings from the analysis suggest 
that weight gain after diagnosis is associated with greater mortality, both from any cause and 
specifically for death due to breast cancer with greater weight gain associated with a larger 
effect.  Through sensitivity analysis we found that results from the complete case analysis are 
significantly attenuated compared to results from our selection model.  In the case of breast 
cancer specific mortality, the results are contrary to what we expect, while the models that 
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account for the missing data produce estimates that appear more reasonable.  Overall, models 
assuming an ignorable and non-ignorable missing data mechanism yielded equivalent 
conclusions although slight differences in parameter estimates were observed, especially for 
women with modest weight gain. 
Models for missing data can be useful analytic tools yet there are no substitutes for 
complete data.  The assumptions on the missing data mechanism are untestable and in some 
cases selection models similar to the one we illustrate have shown to be quite sensitive to 
misspecification (13).  When employing selection models careful consideration must be 
given to the form of the model for the missing data mechanism—the desire for a thorough 
and accurate specification of the model must be balanced with parsimony as convergence can 
become problematic for models with many parameters. Although computationally intensive, 
the Bayesian approach to parameter estimation that we employed is easy to implement and 
accessible to analysts with a wide variety of computational ability. The ideal situation would 
be to completely observe data on all subjects, however this is unlikely to ever happen in 
reality, especially in longitudinal population-based studies.  For cases where there is concern 
about the potential for covariate data to be missing at random, techniques such as the one we 
propose here offer a practical means of analyzing such incomplete datasets. 
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Table 3.1.  Coefficient estimates (posterior log-hazard ratios) and 95% credible intervals 
from piecewise exponential proportional hazards model for all-cause mortality in the Long 
Island Breast Cancer Study Project under different missing data assumptions. 
 
 β  (95% credible interval) 
Variable 
Complete Case* 
(n=499) 
MAR† 
(n=1461) 
NMAR§ 
(n=1461) 
Change in bodyweight    
>5% loss 1.39 (0.84, 1.94) 1.55 (1.14, 1.98) 1.30 (0.91, 1.72) 
5-10% gain 0.04 (-0.89, 0.96) 0.31 (-0.42, 0.99) 0.18 (-0.55, 0.84) 
>10% gain 0.77 (-0.01, 1.55) 1.15 (0.50, 1.76) 0.72 (0.06, 1.36) 
Chemotherapy treatment 0.51 (-0.02, 1.04) 0.68 (0.32, 1.03) 0.73 (0.36, 1.10) 
ER positive tumor -0.67 (-1.25, -0.08) -0.50 (-0.84, -0.15) -0.50 (-0.85, -0.15) 
PR positive tumor -0.27 (-0.85, 0.29) -0.28 (-0.62, 0.05) -0.28 (-0.60, 0.04) 
Tumor size > 2cm 0.71 (0.25, 1.18) 0.69 (0.40, 0.99) 0.68 (0.38, 0.97) 
Age at diagnosis 0.05 (0.03, 0.08) 0.05 (0.03, 0.06) 0.04 (0.03, 0.06) 
* Complete case analysis reports log-hazard ratios and 95% confidence intervals from maximum likelihood.  
Excludes subjects with missing data on one or more covariates. 
† Specifies model for distribution of missing covariates. 
§ Specifies model for distribution of missing covariates and missing data indicator for change in bodyweight. 
 
Table 3.2.  Coefficient estimates (log-hazard ratios) and 95% credible intervals from 
piecewise exponential proportional hazards model for breast cancer mortality in the Long 
Island Breast Cancer Study Project under different missing data assumptions. 
 
 β  (95% credible interval) 
Variable 
Complete Case* 
(n=499) 
MAR† 
(n=1461) 
NMAR§ 
(n=1461) 
Change in bodyweight    
>5% loss 2.10 (1.24, 2.95) 1.83 (1.24, 2.47) 1.70 (1.10, 2.32) 
5-10% gain 0.39 (-0.98, 1.76) 0.18 (-0.99, 1.21) 0.12 (-1.02, 1.14) 
>10% gain 0.79 (-0.40, 1.98) 1.07 (0.20, 1.90) 1.48 (0.87, 2.11) 
Chemotherapy treatment 0.70 (-0.05, 1.44) 1.06 (0.54, 1.59) 1.12 (0.59, 1.65) 
ER positive tumor -0.23 (-1.08, 0.63) -0.37 (-0.85, 0.11) -0.37 (-0.84, 0.10) 
PR positive tumor -0.47 (-1.29, 0.35) -0.40 (-0.85, 0.05) -0.39 (-0.84, 0.06) 
Tumor size > 2cm 1.21 (0.59, 1.84) 1.12 (0.73, 1.49) 1.09 (0.70, 1.47) 
Age at diagnosis 0.02 (-0.01, 0.06) 0.02 (0.00, 0.03) 0.02 (0.01, 0.04) 
* Complete case analysis reports log-hazard ratios and 95% confidence intervals from maximum likelihood.  
Excludes subjects with missing data on one or more covariates. 
† Specifies model for distribution of missing covariates. 
§ Specifies model for distribution of missing covariates and missing data indicator for change in bodyweight. 
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CHAPTER 4 
POST-DIAGNOSIS CHANGE IN BODYWEIGHT AND SURVIVAL AFTER 
BREAST CANCER DIAGNOSIS 
Abstract 
Weight gain after diagnosis is common among women with breast cancer, yet results have 
been inconsistent among the few studies examining its effects on survival.  This study 
examines these effects among 1,436 women diagnosed with a first primary breast cancer in 
1996-1997, on Long Island, NY.  Shortly after diagnosis and again after approximately 5 
years, subjects were interviewed to assess factors related to breast cancer, including 
anthropometric measures.  Weight was assessed at each decade of life from age 20 years, one 
year before, at and one year after diagnosis and at the time of follow-up.  Mortality through 
the end of 2005 was assessed using the National Death Index.  Proportional hazards 
regression with time-varying covariates was used while employing a selection model to 
account for missing data.  Compared to women who maintained their pre-diagnosis weight 
(+/- 5%), those who gained more than 10% after diagnosis had worse survival [hazard ratio 
(HR) (95% credible interval): 2.08 (1.05-3.94)].  The effect was more pronounced during the 
first 2 years after diagnosis [>5% gain, before 2 years, all-cause HR: 2.94 (0.49-17.43); after 
2 years HR: 1.46 (0.83-2.49)].  For breast-cancer mortality, the association with post-
diagnosis weight gain was stronger among women overweight before diagnosis [HR: 2.15 
(0.71-6.17)] compared to ideal weight before diagnosis [HR: 1.18 (0.35-4.06)], and for 
women who had gained > 3 kilograms over adulthood before diagnosis [HR: 3.82 (2.04-
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7.37)] compared to no gain weight before diagnosis [HR: 1.13 (0.24-5.18)].  These results 
suggest the importance of weight maintenance for women after breast cancer diagnosis. 
Introduction 
For the more than 2 million female breast cancer survivors in the United States (1) the 
identification of modifiable factors that may positively influence the survivorship experience 
is imperative. Of particular interest is the effect of changes in body size after diagnosis on 
survival, as many women gain weight after being diagnosed with breast cancer (2, 3).  
Weight gain among women with breast cancer is often observed in response to treatment 
with chemotherapy, as well as among women with younger age at diagnosis, lower pre-
diagnosis BMI, those who are premenopausal, and present with later disease stage at 
diagnosis (2-7).  Higher levels of adipose tissue are associated with greater circulating levels 
of hormones such as estrogen, insulin and related growth factors, which increase proliferation 
of mammary cells and are associated with breast carcinogenesis (8-10). 
The prognostic significance of obesity at or before diagnosis (3) is well established, 
however, the question of how changes in bodyweight after diagnosis affect survival has been 
addressed by relatively few studies with inconsistent results (3, 11-13).  Since pre-diagnosis 
body size is often associated with post-diagnosis changes (2-7), it is unclear if the observed 
increase in risk associated with pre-diagnosis body size is merely a reflection of any adverse 
effect of post-diagnosis changes in body composition, and thus the observed reduction in 
survival for pre-diagnosis body size is only an artifact of its correlation with post-diagnosis 
changes.  Alternatively, it is possible that both pre-and post-diagnostic weight changes 
adversely influence survival independently of each other, or even synergistically.  
Furthermore, none of the previous studies have employed longitudinal measures of post-
diagnosis weight change, thus have been unable to examine if the effect may vary over time. 
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The objective for this analysis was to examine the effect of post-diagnosis body size 
changes over time on survival after breast cancer diagnosis using data from a large, 
population-based cohort of women with a recent diagnosis of breast cancer on Long Island, 
New York, and determine if the adverse effects of pre-diagnosis body size are attenuated 
after accounting for post-diagnosis weight change.  Additionally, possible modification of the 
effect of post-diagnosis weight change was examined by stratification on baseline body size, 
pre-diagnosis adult weight gain and timing of post-diagnosis weight change. 
Methods 
For this analysis we used data from the follow-up to the Long Island Breast Cancer Study 
Project (LIBCSP).  The parent LIBCSP is a population-based case-control study of breast 
cancer conducted on Long Island, New York (14) with a follow-up study of case women to 
determine factors associated with survival after breast cancer diagnosis.  The study was 
approved by the Institutional Review Board of participating institutions.  
Study Population.  Cases were English speaking adult women with a first primary in 
situ or invasive breast cancer diagnosed between August 1, 1996 to July 31, 1997, from 
Nassau and Suffolk counties in New York.  Potentially eligible women were identified 
through pathology departments of participating hospitals and their physicians were contacted 
to confirm the diagnosis and obtain permission to contact the patients for participation in the 
study.  A total of 1,508 eligible cases (82.1%) agreed to participate in the parent study and 
completed the baseline questionnaires.  Signed informed consent was obtained for all 
subjects prior to data collection. 
During the parent case-control study 94 women refused to be contacted at a later date 
for participation in the follow-up study.  For those who agreed to participate in the follow-up, 
the case subjects or their proxy were contacted by mail approximately 5 years after initial 
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diagnosis of breast cancer and informed consent was obtained via telephone follow-up calls.  
Of the 1,414 women who initially agreed to participate in the follow-up study, 60 
subsequently refused at the initial mail contact, 65 refused when contacted by telephone, 18 
refused due to illness, 22 were unable to complete the interview, 55 were lost to follow-up 
and 96 were deceased with no identifiable proxy to complete the interview.  Of the remaining 
1,098 subjects who agreed to the follow-up interview, 65 were only able to provide 
information on their first course of treatment for their original breast cancer diagnosis.  
Ultimately 1,033 case subjects (68.5% of the original 1,508 women) actually completed the 
follow-up interview (15).  The follow-up interview ascertained information similar to that 
gathered in the baseline questionnaire but relevant to the time period since diagnosis. 
Outcome Assessment.  The outcome for this study, date and cause of death, was 
determined by the National Death Index (NDI) (16), a centralized database of death records 
maintained by the National Center for Health Statistics which is considered the standard 
source of mortality data for epidemiologic research (17).  For women who were determined 
to be deceased from the NDI records we constructed two indicators: (1) breast cancer related 
death (breast cancer listed as primary or secondary cause of death, International 
Classification of Disease code 174.9 or C-50.9) and (2) death from any cause.  These 
indicators, combined with time of death, form the outcomes for this analysis.  Of the 1,508 
cases from the parent study, there were a total of 308 deaths as of December 31, 2005, and 
the largest single cause of death was attributed specifically to breast cancer (n = 164).  
Body Size Assessment. At baseline the initial questionnaire (18) collected self-
reported data on height in inches and body weight in pounds at age 20 years and at 1 year 
prior to date of diagnosis.  The baseline questionnaire also collected weight in pounds by 
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decade of life from 20 years through 70 years of age.  The follow-up questionnaire assessed 
self-reported height, body weight in pounds at diagnosis, one year after diagnosis and at time 
of follow-up interview or one year before death for interviews on deceased subjects 
completed by proxy.  This yielded three assessments of body size at and after diagnosis. 
Percent change in body weight was calculated between the year prior to diagnosis and 
at diagnosis, 1-year post diagnosis and at time of follow-up interview as 100*(weight at 
follow-up measurement - weight one year before diagnosis)/weight one year before 
diagnosis.  Weight change was categorized as >5% loss, maintain within 5%, 5-10% gain and 
greater than 10% weight gain; these categories were used to compare our results to other 
reports (11) and correspond to categories of weight loss used in weight management 
recommendations aimed at cancer patients (19).  To avoid small counts within strata when 
assessing effect modification, weight change was categorized as >5% loss, maintain within 
5% and >5% gain.  Other body size variables used in our analysis included BMI 1 year 
before diagnosis (<25 kilograms/meters2 (kg/m2), 25-30 kg/m2 and >=30 kg/m2) and adult 
weight change, which reflected change in body weight from age 20 up to 1 year before 
diagnosis (>3 kg loss, maintenance within 3 kg and >3 kg gain).  These categorizations of 
pre-diagnosis body size reflect those used in previous analyses of this data (20). 
Covariates.  Risk factor information was assessed by structured questionnaire, which 
was administered by trained interviewers during in-home visits [at baseline, 
(http://epi.grants.cancer.gov/LIBCSP/projects/Questionnaire.html)] or telephone (at follow-
up).  Information collected included known and suspected risk and prognostic factors for 
breast cancer, including menopausal status, education, income, anthropometric measures, and 
physical activity.   
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For case women who signed a medical record release form (97.7%), tumor stage and 
estrogen and progesterone receptor (ER/PR) status were ascertained from the medical records 
as part of the parent case-control study. For the follow-up, signed medical record release 
forms were obtained again, and medical records were abstracted for 598 women to obtain the 
details regarding complete course of treatment for the first primary breast cancer diagnosis.  
The abstracted treatment data were then compared to the self-reported information obtained 
as part of the telephone follow-up interview.  Kappa coefficients comparing self-report and 
medical records were high for all three treatment modalities examined: radiation therapy 
κ=0.97, chemotherapy κ=0.96 and hormone therapy κ=0.92 (20), and thus the self-reported 
data are included in these analyses.  Data on tumor size was obtained from the New York 
State Cancer Registry. 
At baseline, approximately 98% of the respondents completed a self-administered 
modified Block food frequency questionnaire (FFQ) that took an average of approximately 
30 minutes to complete (14).  The FFQ assessed frequency and relative portion size for 101 
food items in the year before the baseline interview. 
Statistical Analysis.  Non-response to specific questions among people still alive at 
each timepoint, coupled with the overall non-response to the follow-up interview, resulted in 
percentages of missing data on weight of 47.6%, 49.4% and 33.9% at time of diagnosis, 1-
year post diagnosis and final follow-up, respectively among all 1,508 women.  Given such 
substantial percentages of missing data, and the sensitivity of assessing body size, there was 
concern that body size data may be not missing at random (NMAR), a condition which arises 
when the probability that data is missing is dependent upon the unobserved values (21, 22).  
In this study, the potential issue was that nonresponse to the follow-up questionnaire may be 
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more likely among heavier women, who may be more psychologically sensitive to questions 
regarding bodyweight or who may be in poor health caused by being overweight.  To address 
this issue a selection model for the analysis of survival data with non-ignorably missing time-
varying covariates was used (23).  A proportional hazards regression was specified to 
estimate the effect of post-diagnosis weight change over time on survival (all-cause and 
breast cancer specific).  The main variables in this model included post-diagnosis change in 
body size (>5% loss, maintain within 5% (referent category), 5-10% gain, >10% gain), BMI 
one year before diagnosis (<25 kg/m2 (referent category), >= 30 kg/m2) and adult weight 
change from age 20 (> 3 kg loss, maintain within 3 kg (referent category), > 3 kg gain), and 
were adjusted for age (continuous).   
For models of effect modification post-diagnosis weight change was categorized as 
>5% loss, maintain within 5% and >5% gain and included its product with time (< 2 years, 
>= 2 years), BMI one year before diagnosis (categorized as <25 kg/m2 and >= 25 kg/m2) and 
adult weight gain from age 20 years to 1 year before diagnosis (any loss or maintain within 3 
kg, gain >= 3kg).  The time interaction of two years was chosen since recent studies of post-
diagnosis weight change assessed women at approximately this time (11, 12) and to 
distinguish the possible effects of weight gain shortly after diagnosis.  Collapsing the 
categories for the measures of pre- and post-diagnosis body size was to prevent unestimable 
effects due to small counts within categories.   
Potential confounders in this analysis included those variables potentially associated 
with both post-diagnosis weight change and survival: post-diagnosis physical activity 
(metabolic equivalent task hours per week, MET-hrs/wk; continuous), total energy at 
baseline interview (kcal/day; continuous), menopausal status (premenopausal, 
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postmenopausal), stage (in situ, invasive), chemotherapy regimen (yes, no), radiation therapy 
(yes, no), hormone therapy (yes, no), nodal involvement (yes, no), tumor size greater than 2 
cm (yes, no), estrogen receptor positive tumor (ER status; yes, no) and progesterone receptor 
positive tumor (PR status; yes, no).  The final models included those confounders that altered 
the estimates of the hazard ratios for change in bodysize by >10% in a complete case analysis 
using Stata (version 10.0, College Station, TX) as selection models are impractical for the 
usual algorithm used for confounder identification.  The final confounder list included age, 
chemotherapy regimen, tumor size, ER status and PR status, which was also consistent with 
identification of confounders using the analysis of a directed acyclic graph.   
In addition to the proportional hazards model, the selection model requires 
specification of a model for the missing covariates and the dichotomous indicator of the 
missing data.  The change in body size variable at each follow-up measurement was modeled 
as a linear regression dependent upon previous change in body size variables, as well as age, 
chemotherapy indicator, menopausal status and BMI before diagnosis, variables established 
in the literature to be consistently associated with post-diagnosis weight change (2-7).  In 
addition to weight change, other covariates with significant amounts of missing data included 
chemotherapy, tumor size, ER status and PR status with 32.2%, 31.6%, 34.0% and 34.3% 
missing out of the 1,508 cases, respectively.  Chemotherapy and tumor size were modeled as 
logistic regressions against age, income (< $20,000; $20,000-49,999; $50,000-89,999 and >= 
$90,000) and education (high school or less, some college, college graduate and post-
college), while hormone receptor status indicators were modeled as logistic regressions as a 
function of age.  Treatment and tumor characteristics were unlikely to be non-ignorably 
missing and therefore did not require specification of models for their missing data 
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mechanisms.  The probability that data was missing for change in body size at any given 
observation is modeled as a logistic regression with age, weight change at the current and all 
previous observations, and missingness indicator at all previous observations.  The 
parameters of these ancillary models are not of inferential interest and are only needed to 
provide unbiased estimates of the survival model.  Variables with minor amounts of missing 
data included menopausal status (1.99% missing), pre-diagnosis BMI (1.13% missing), adult 
weight change (from age 20 to 1 year before diagnosis; 1.66% missing), education (0.40% 
missing) and income (0.27% missing); so, we excluded these few subjects from the analysis 
as these amounts were unlikely to influence our results.   
This analysis ultimately included 1,436 women, 292 who died during our follow-up 
with 156 of these deaths attributed to breast cancer.  Median survival time was 8.80 years 
after diagnosis with a range from 0.23 to 9.41 years.  Most women were postmenopausal at 
time of diagnosis. Women in this cohort were between 25.1 to 98.1 years of age with average 
of 58.8 years.  Less than half of the women received chemotherapy treatment, and most 
tumors were either ER-positive or PR-positive.  Less than 20% of the tumors were 2 cm or 
larger.  Sociodemographic and anthropometric characteristics of the study sample are shown 
in table 1. 
A fully Bayesian approach to parameter estimation was employed by specifying 
vague prior distributions on the model parameters and the Gibbs sampler in WinBUGS 1.4 
(24) was used to sample from their posterior distribution.  The sampler was run for 60,000 
iterations with the first 20,000 discarded as a burn-in sample, retaining every 5th iteration to 
reduce serial correlation.  Posterior hazard ratios (HR) were calculated by exponentiating the 
mean of the samples for the beta coefficients (log-hazard ratios) from the proportional 
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hazards model and posterior credible intervals were calculated by exponentiating the 2.5th 
and 97.5th percentiles of these samples.  The use of vague priors yields posterior point 
estimates and credible intervals that are similar to those from standard frequentist analysis. 
Results 
As shown in table 1, among women with complete data on at least one follow-up measure of 
body size, some 55% were able to maintain their pre-diagnosis body size.  However, among 
the nearly 22% of women who reported gaining weight after diagnosis, mortality was 
increased, as shown in table 2.  The effect estimates for mortality associated with moderate 
post-diagnosis weight gain [all-cause posterior HR: 1.19 (0.58-2.31) and breast cancer-
specific posterior HR: 1.13 (0.36-3.11)] were increased even after adjustment for pre-
diagnostic BMI and adult weight gain, and similar to those from the unadjusted models that 
were reported previously (23).  With these additional adjustments, mortality risk was doubled 
for large post-diagnosis weight gain [all-cause posterior HR: 2.08 (1.05-3.94), and breast 
cancer-specific posterior HR: 2.14 (0.86-5.06)], although the estimate for breast-cancer 
specific mortality was attenuated compared to the unadjusted models (see table 2).  Among 
women who lost weight after diagnosis, the adverse effect on survival remained, with 
increased effect estimates for all-cause [HR: 3.56 (2.39-5.48)] and breast-cancer specific 
mortality [HR: 4.29 (2.42-7.82)], even after adjusting for weight loss prior to diagnosis.  
In these models that consider post-diagnosis weight change, being overweight (BMI 
25.0-29.9 kg/m2) at time of diagnosis was not strongly associated with an increased risk of 
either all-cause mortality [HR: 0.89 (0.65-1.20)] or breast cancer-specific deaths [HR: 1.05 
(0.69-1.60)].  Although the adverse effects associated with obesity at diagnosis (BMI >= 30 
kg/m2) are still evident [all-cause mortality HR: 1.25 (0.91-1.71); breast cancer-specific 
mortality HR: 1.35 (0.87-2.08)], the magnitude of the effect is attenuated from the 
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pronounced effects previously reported for this study population (20).  Similarly, once the 
effects of post-diagnosis weight change are considered, the adverse effects associated with 
pre-diagnostic adult weight loss conveyed a moderate effect on all-cause [HR: 1.63 (0.90-
2.98)], but not breast cancer-specific mortality [HR: 1.04 (0.36-2.76)], and adult weight gain 
prior to diagnosis showed little effect on either outcome. 
Effect modifications due to timing of post-diagnosis weight gain, pre-diagnosis BMI 
and pre-diagnosis adult weight change are presented in table 3.  Across all of these models 
the greatest increases in risk are seen among women who lost weight after diagnosis, which 
again may reflect poorer health in general.  The deleterious effects of post-diagnosis weight 
gain appear stronger when weight is gained shortly after diagnosis [within first 2 years of 
diagnosis, all-cause posterior HR: 3.02 (0.51-17.44) and breast cancer-specific HR: 2.31 
(0.40-12.78)], although the wide credible intervals indicate imprecise estimates.  Weight gain 
after two years shows similar effects for both all-cause and breast cancer-specific mortality, 
with moderate increases in risk of death compared to women who maintained their weight.  
The effect of post-diagnosis weight gain is slightly greater among overweight and obese 
women (BMI >= 25 kg/m2) than among women of ideal weight (BMI < 25 kg/m2), with the 
difference being greatest for breast cancer-related deaths [BMI < 25 kg/m2, posterior HR: 
1.18 (0.35-4.06) and BMI >= 25 kg/m2, posterior HR: 2.15 (0.71-6.17)].  Among women 
who maintained or lost weight before diagnosis, the effect of post-diagnosis weight gain was 
slightly lower compared to women who gained weight as an adult, however once again this 
difference was greatest when only deaths due to breast cancer were considered [pre-diagnosis 
weight maintainers, posterior HR: 1.13 (0.24-5.18) and pre-diagnosis weight gainers, 
posterior HR: 3.82 (2.04-7.37)]. 
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Discussion 
Previously reported findings (23) on weight change after diagnosis in this cohort of 1,436 
women diagnosed with in situ or invasive breast cancer focused on the methodologic 
approach for considering time varying non-ignorably missing covariate data in a survival 
analysis.  That previous analysis (23) did not include adjustments for pre-diagnosis levels of 
BMI or adult weight change; nor did it consider effects associated with the timing of the 
weight gain relative to diagnosis, namely those that occurred soon after diagnosis, 
presumably during chemotherapy, versus weight gain that occurred later, after the first course 
of treatment is completed. The unadjusted results of the previous analysis suggested a 
moderate 19% increase in all-cause mortality among women gaining between 5-10% of their 
pre-diagnosis bodyweight, with a much larger 105% increase among women who gained 
more then 10%; similar increases in risk were noted for breast cancer-specific mortality.  The 
greatest risk – over three-fold—was found among women who lost weight after diagnosis, 
yet this is likely to reflect adverse effects associated with advanced disease or otherwise poor 
health. 
In the analysis presented here, even after adjusting for pre-diagnosis body size 
variables in this analysis, moderate increases in risk of all-cause and breast cancer-specific 
mortality were still observed among women who gained between 5-10% of their pre-
diagnosis weight at any time after diagnosis. Large increases in mortality risk were found for 
both outcomes among women who gained more than 10% of their pre-diagnosis weight after 
diagnosis.  When pre-diagnosis anthropometric measures of adiposity were included in the 
models the effects for larger weight gain were somewhat attenuated from the analysis that did 
not include pre-diagnosis body size, primarily for breast-cancer specific mortality, although 
the effects were essentially unchanged for moderate weight gain.  The effect of weight gain 
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on mortality appeared stronger within the first 2 years after diagnosis compared to after 2 
years, although study power was limited to draw firm conclusions regarding this difference.  
The effect of post-diagnosis weight gain on breast cancer specific mortality was also stronger 
among women who had gained weight as an adult before diagnosis.  
Fat mass is thought to affect breast cancer etiology since visceral adipose tissue is 
metabolically active (25) and affects a number of pathways that are involved in 
carcinogenesis.  Visceral adipose tissue is associated with increases in sex hormones such as 
estradiol and decreases in related binding proteins, especially sex hormone binding globulin 
(SHBG) (26) as well as insulin and insulin like growth factors (10, 27) which can promote a 
hormonal environment that encourages proliferation of both normal and cancerous mammary 
cells (8-10).  Weight gain after adolescence is primarily associated with accumulation of this 
metabolically active adipose tissue and therefore changes in body size may be an 
etiologically relevant exposure (28).  This issue is of particular concern as weight gain after 
diagnosis in breast cancer patients is well documented, with the amount ranging from 
approximately 1 kg to more than 10 kg within the first two years (3). 
The relationship between breast cancer survival and post-diagnosis changes in body 
size is far less studied than the relationship with pre-diagnostic body size.  Only a handful of 
studies have directly examined the relationship between weight change post-diagnosis and 
survival with inconsistent results (11-13, 29-33).  Findings have generally been null when 
modest increases in weight have been considered (31-33), although significant decreases in 
survival have been noted when larger changes in weight or BMI were studied, often in 
subgroup analyses (12, 29, 30).  Caan and colleagues failed to find an association between 
post-diagnosis weight change and survival, however the authors did note an association with 
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pre-diagnosis body size (11).  Nichols et al. found results more similar to those reported here, 
namely that weight gain of at least 5 kg was associated with an increase in all-cause, breast 
cancer specific and cardiovascular mortality.  Generally, studies with null findings have been 
limited by small sample size (31-33) and short follow-up (31, 33), possibly explaining the 
lack of associations.  Additionally, timing of follow-up measures is likely to contribute to the 
differences in findings.  Our study was able to utilize anthropometric measures from 
diagnosis to death or censoring, allowing us to estimate the effect of this time-varying 
exposure as well as estimate differences in effect across relevant time periods.  We observed 
that the deleterious effect of post-diagnosis weight gain was more pronounced closer to 
diagnosis, which was not assessed in other recent studies that used body size measures at 
least 2 years post diagnosis (11, 12). 
Our findings regarding weight loss are consistent with recent reports by Caan et al. 
(11) and Nichols et al. (13) who observed that weight loss was associated with significantly 
greater mortality after breast cancer diagnosis, both reporting hazard ratios over 2 in the 
greatest category of weight loss for death from any cause.  Data from the Nurses’ Health 
Study also showed a greater risk of death among those who lost weight, although the 
associations were not statistically significant (12).  Recent recommendations regarding 
weight loss for breast cancer patients (34) have been made based on the observation that 
greater BMI at diagnosis is associated with poor survival, however post-diagnosis weight 
loss is not supported, and appears to be contradicted, by recent observational reports, 
including this one.  As stated previously, it is unclear if this observed association between 
weight loss and survival is due to a distinct effect of the weight loss, or the fact that those 
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who are near death are likely to be losing weight.  This issue could be clarified by studies 
that include data on intent of weight loss among breast cancer survivors.  
Obesity at diagnosis and weight gain pre-diagnosis are established indicators of 
poorer prognosis as discussed in several recent reviews (3, 34-36), although most of the 
studies conducted to date have not accounted for post-diagnosis changes in body size.  
Similarly, a recent report that utilized the Long Island breast cancer cohort observed hazard 
ratios ranging from 1.63 to 2.85 for women who were obese before diagnosis (20). However, 
in the analysis reported here, once the effects of post-diagnosis changes in weight on 
mortality are considered, the associations with pre-diagnosis anthropometric measures are 
attenuated.  Our new findings suggest that the effect of pre-diagnosis body size may be 
driven, at least partly, by its association with post diagnosis weight change.  Additionally, our 
observation of a more pronounced adverse effect for post-diagnosis weight gain among 
women who also gained weight as an adult before diagnosis underscore the importance of 
avoiding increases in adiposity at any point in a woman’s life trajectory.  
Strengths of this study include its population-based study design and relatively large 
sample size.  Also, an innovative analytical approach to the treatment of missing exposure 
and confounder data was employed.  Complete case analysis is common since it is 
automatically carried out by most software packages, however it usually reduces statistical 
efficiency, and can yield biased effect estimates in all but the most rigid conditions.  Ad hoc 
adjustment for missing data is still common in epidemiology, such as some variant of the 
“missing indicator” method or improper imputation, which can perform even worse than 
complete case analysis (22).  Formal treatment of missing data is crucial to accurate 
inference, and the selection model approach employed here can account for potentially non-
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ignorably missing covariates, which is when bias and statistical efficiency are of greatest 
concern (21).  Even though the methodology used here is theoretically sound, it is important 
to keep in mind that even the most rigorous statistical model is no substitute for having the 
data that was unobserved.  Missing data models rely on untestable assumptions and can be 
quite sensitive to changes in specification (37).   
A significant strength of this analysis is that data from multiple assessments of 
change in body size over the follow-up experience were utilized, starting at and near 
diagnosis, which allowed for determination of differential effects based on timing of weight 
change which, as of yet, has gone unaddressed.  A limitation of this analysis is the use of 
self-reported body size measures, which leaves open the potential for measurement error.  
However, self-reported anthropometric measures have been shown to be highly correlated 
when compared to measurements taken in a clinic setting (38).  Data from the NHANES III 
study showed that in addition to self reported and measured weight being highly correlated, 
older women, who make up most of this cohort, tend to report their weight accurately (39).  
Also, self- and interviewer-obtained measurements have shown nearly identical associations 
in a recent analysis of pre-diagnosis BMI and survival after breast cancer diagnosis in a 
similar cohort (40).  The use of proxy interviews could also be a source of bias, however 
these accounted for a small portion of our study sample (<8%), and a recent detailed report 
comparing the use of proxy and case assessments illustrated that proxy assessments of 
anthropometric measures yielded nearly identical associations compared to those completed 
by the case subject (41).  The results from our stratified models should be interpreted as 
exploratory given that statistical power was reduced for subgroup analysis.  Additionally, the 
categorization of pre-diagnosis BMI and pre-diagnosis weight gain yielded a different 
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percentage of cases in each subgroup, notably 80% of the cohort appeared in the upper 
category of pre-diagnosis weight gain, which likely contributed to the differences noted, as 
BMI and weight gain are highly correlated. 
In summary, these findings suggest that weight maintenance after breast cancer 
diagnosis should be encouraged, especially among women who have gained weight as an 
adult before diagnosis. The time period immediately after diagnosis may be especially 
relevant for weight maintenance, when treatment-related weight gain is common.  Although 
the associations with pre-diagnosis BMI were attenuated in our study, maintenance of a 
healthy weight should nevertheless be encouraged at all times as it may promote weight 
maintenance after diagnosis, and conveys other health benefits. 
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Table 4.1.  Characteristics of 1,436 women newly diagnosed with a first primary breast 
cancer between 1996-1997 on Long Island, NY, with follow-up assessments between 2002-
2004. 
 
Variable N (%) 
Deaths through December 31, 2005  
All cause 292 (20.3) 
Breast-cancer specific 156 (10.8) 
Weight change from 1-year before diagnosis 
to date of diagnosis 
 
>5% loss 197 (26.0) 
Maintain ±5% 458 (60.4) 
5-10% gain 72 (9.5) 
>10% gain 31 (4.1) 
Missing 678 
Weight change from 1-year before diagnosis 
to 1-year post diagnosis 
 
>5% loss 168 (23.1) 
Maintain ±5% 400 (55.0) 
5-10% gain 95 (13.1) 
>10% gain 64 (8.8) 
Missing 709 
Weight change from 1-year before diagnosis 
to time of follow-up interview 
 
>5% loss 200 (21.2) 
Maintain ±5% 414 (43.9) 
5-10% gain 161 (17.1) 
>10% gain 168 (17.8) 
Missing 493 
ER status  
Positive 701 (73.6) 
Negative 252 (26.4) 
Missing 483 
PR status  
Positive 609 (64.2) 
Negative 340 (35.8) 
Missing 487 
Chemotherapy  
Yes 404 (41.4) 
No 573 (58.7) 
Missing 459 
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Table 4.1 (continued).  Characteristics of 1,436 women newly diagnosed with a first 
primary breast cancer between 1996-1997 on Long Island, NY, with follow-up assessments 
between 2002-2004. 
 
Variable N (%) 
Tumor size  
< 2 cm 749 (76.2) 
>= 2 cm 234 (23.8) 
Missing 453 
BMI 1 year before diagnosis  
<18.5 kg/m2 25 (1.7) 
18.5-24.9 kg/m2 639 (44.5) 
25.0-29.9 kg/m2 455 (31.7) 
>=30.0 kg/m2 317 (22.1) 
Weight change from age 20 to 1 year before 
diagnosis 
 
< 3kg gain or any loss 240 (16.7) 
> 3kg gain 1,196 (83.3) 
Age at diagnosis  
(mean: 58.8 yrs, sd: 12.6 yrs) 
 
20-29.9 10 (0.7) 
30-39.9 77 (5.4) 
40-49.9 306 (21.3) 
50-59.9 381 (26.5) 
60-69.9 340 (23.7) 
70-79.9 274 (19.1) 
80-89.9 45 (3.1) 
90+ 3 (0.2) 
Menopausal Status  
Premenopausal 462 (32.2) 
Postmenopausal 974 (67.8) 
Education  
High school or less 688 (47.9) 
Some college 342 (23.8) 
College graduate 186 (13.0) 
Post college education 220 (15.3) 
Income  
< $20,000 174 (12.1) 
$20,000-49,999 560 (39.0) 
$50,000-89,999 427 (29.7) 
>=$90,000 275 (19.2) 
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Table 4.2.  Hazard ratios (and 95% credible intervals) for the association between post-diagnosis changes in body weight and all-
cause and breast cancer-specific mortality among women newly diagnosed with a first primary breast cancer in 1996-1997 in Long 
Island, NY and followed through 2005. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Model 1 adjusted for age at diagnosis, chemotherapy treatment, ER status, PR status and tumor size.  These results presented 
previously (23). 
† Model 2 includes covariates from Model 1 as well as BMI 1 year prior to breast cancer diagnosis and weight change from age 20 
up to 1 year before breast cancer diagnosis. 
 Hazard ratio (95% credible interval) 
 All-cause Mortality 
(292 deaths/1,436 subjects) 
Breast Cancer-specific Mortality 
(156 deaths/1,436 subjects) 
 Model 1* Model 2† Model 1* Model 2† 
Post-diagnosis 
weight change  
    
>5% loss 3.68 (2.47-5.57) 3.56 (2.39-5.48) 5.46 (3.01-10.14) 4.29 (2.42-7.82) 
±5% maintain (ref) 1. 1. 1. 1. 
5-10% gain 1.19 (0.58-2.31) 1.23 (0.59-2.39) 1.13 (0.36-3.11) 1.13 (0.37-3.09) 
>10% gain 2.05 (1.06-3.90) 2.08 (1.05-3.94) 4.37 (2.38-8.25) 2.14 (0.86-5.06) 
BMI 1 year before 
diagnosis 
    
<25 kg/m2 (ref)  1.  1. 
25-30 kg/m2  0.89 (0.65-1.20)  1.05 (0.69-1.60) 
>=30 kg/m2  1.25 (0.91-1.71)  1.35 (0.87-2.08) 
Weight change from 
age 20 to 1 year 
before diagnosis 
    
>3kg loss  1.63 (0.90-2.98)  1.04 (0.36-2.76) 
±3kg maintain (ref)  1.  1. 
> 3kg gain  0.93 (0.63-1.41)  1.09 (0.62-2.01) 
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Table 4.3.  Hazard ratios (and 95% credible intervals) for the association between post-diagnosis changes in body weight and all-
cause and breast cancer-specific mortality, stratified by time, pre-diagnosis BMI and pre-diagnosis adult weight change among 
women newly diagnosed with a first primary breast cancer in 1996-1997 on Long Island, NY, and followed through 2005. 
 
 Hazard ratio* (95% credible interval) 
 All-cause Mortality 
(292 deaths/1,436 subjects) 
Breast Cancer-specific Mortality 
(156 deaths/1,436 subjects) 
 Time Since Diagnosis Time Since Diagnosis 
Post-diagnosis  
weight change  Before 2 years After 2 years Before 2 years After 2 years 
>5% loss 7.87 (2.47-37.41) 3.39 (2.25-5.21) 5.74 (1.82-23.15) 4.23 (2.24-8.33) 
±5% maintain (ref) 1. 1. 1. 1. 
>5% gain 2.94 (0.49-17.43) 1.46 (0.83-2.49) 2.38 (0.40-13.90) 1.50 (0.64-3.62) 
     
 Pre-diagnosis BMI Pre-diagnosis BMI 
Post-diagnosis  
weight change < 25 >= 25 < 25 >= 25 
>5% loss 4.50 (2.52-8.22) 3.27 (2.02-5.73) 4.42 (1.94-10.59) 4.85 (2.22-11.62) 
±5% maintain (ref) 1. 1. 1. 1. 
>5% gain 1.47 (0.70-3.13) 1.69 (0.80-3.61) 1.18 (0.35-4.06) 2.15 (0.71-6.17) 
     
 Pre-diagnosis adult weight gain Pre-diagnosis adult weight gain 
Post-diagnosis  
weight change < 3 kg >= 3kg < 3 kg >= 3kg 
>5% loss 4.10 (1.30-12.57) 4.78 (3.06-7.65) 4.04 (0.77-19.47) 5.86 (3.13-11.21) 
±5% maintain (ref) 1. 1. 1. 1. 
>5% gain 1.96 (0.73-4.84) 2.58 (1.63-4.18) 1.13 (0.24-5.18) 3.82 (2.04-7.37) 
* Models adjusted for pre-diagnosis BMI, pre-diagnosis adult weight gain, age at diagnosis, chemotherapy treatment, ER status, 
PR status and tumor size. 
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CHAPTER 5  
POST-DIAGNOSIS PHYSICAL ACTIVITY LEVELS AND SURVIVAL AFTER 
BREAST CANCER DIAGNOSIS AMONG WOMEN ON LONG ISLAND, NY. 
Abstract 
Physical activity is associated with physiological responses thought to beneficially affect 
survival after breast cancer diagnosis, yet results of epidemiologic studies undertaken to 
evaluate this hypothesis have been inconsistent. Effects of post-diagnosis activity on 
survival, including stratification by time since diagnosis and by pre-diagnosis body size, were 
examined in a cohort of 1,423 women diagnosed with in situ or invasive breast cancer in 
1996-1997 on Long Island, New York.  Subjects were interviewed soon after diagnosis and 
again after approximately 5 years to assess breast cancer-related factors, including 
recreational physical activity before and after diagnosis. Date and cause of death through 
2005 were determined from the National Death Index.  Adjusted estimates were obtained 
using a proportional hazards regression with time-varying covariates and a selection model to 
account for missing data. Survival was improved among women who were highly active after 
diagnosis (>9.0 MET-hours/week) compared to inactive women (0 MET-hours/week) for all-
cause [hazard ratio (HR) (95% credible interval): 0.23 (0.15-0.39)] and breast cancer-specific 
mortality [HR: 0.22 (0.13-0.36)], even with adjustment for pre-diagnosis activity.  The 
beneficial effect of physical activity on breast cancer-specific mortality was evident in all 
subgroups examined, including: (1) within the first 2 years since diagnosis [HR: 0.17 (0.04-
0.58)] as well as 2+ years since diagnosis [HR: 0.17 (0.08-0.33)]; and (2) among women who 
were overweight in the year prior to diagnosis [HR: 0.13 (0.04-0.32)] as well as those who 
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were not overweight [HR: 0.23 (0.01-0.47)]. These findings show that post-diagnosis 
physical activity is associated with improved survival among women with breast cancer.  
Introduction 
Higher levels of physical activity have been linked to a decreased risk of developing breast 
cancer (1), which is believed to reflect the ability of physical activity to decrease circulating 
estrogen, improve insulin sensitivity and improve immune function as well as favorably  
influence adiposity (2).  As these mechanisms are also believed to influence prognosis after a 
diagnosis of breast cancer, physical activity has gained interest as a potential modifiable 
lifestyle factor that may improve survival among women with breast cancer.  Several recent 
studies have found that increased physical activity after diagnosis of breast cancer is 
associated with better survival (3-6), yet the magnitude of these effects is inconsistent and 
none have addressed if timing of physical activity relative to diagnosis alters these effects.  
These questions have important public health and clinical implications for the 150,000 
women who are diagnosed with breast cancer every year as well as the 2+ million breast 
cancer survivors in the United States (7). 
To assess the effect of physical activity after diagnosis on survival among women 
with breast cancer we conducted an analysis using data from a large, population-based cohort 
of women on Long Island, New York who were recently diagnosed with breast cancer.  We 
also considered possible modification of these effects by timing, pre-diagnosis physical 
activity levels and baseline body size. 
Methods 
This study employs data from the follow-up to the Long Island Breast Cancer Study Project 
(LIBCSP), a population-based case-control study of breast cancer risk (8).  The follow-up 
study followed newly diagnosed breast cancer cases from the parent study with the objective 
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of assessing factors associated with survival after diagnosis.  Both the parent and follow-up 
studies were approved by the Institutional Review Board of participating institutions.  
Study Population.  Participants in the follow-up study were English speaking adult 
women with a first primary in situ or invasive breast cancer diagnosed in 1996-1997 from 
Nassau and Suffolk counties in New York and enrolled in the parent LIBCSP case-control 
study.  Incident breast cancer cases were identified through pathology departments of 
participating hospitals and their physicians were contacted to confirm the diagnosis and 
obtain permission to contact the patients.  Of the 1,837 eligible cases, a total of 1,508 
(82.1%) agreed to participate and provided signed informed consent.  Of these, 1,414 women 
agreed to be contacted at a later date for participation in the follow-up.  These women were 
contacted by mail approximately 5 years after diagnosis and informed consent was obtained 
by telephone with 1,098 women ultimately consenting to the follow-up interview.  Of the 316 
who subsequently refused to participate, 60 (19%) refused at mail contact, 65 (21%) refused 
at telephone contact, 18 (6%) would not participate due to illness, 22 (7%) were unable to 
complete the interview, 55 (17%) were lost to follow-up and 96 (30%) were deceased with 
no identifiable proxy.  Of those agreeing to participate, 1,033 subjects (68.5% of the original 
1,508 women) completed the follow-up interview (9), which gathered information relevant 
since diagnosis. 
Outcome Assessment.  Date and cause of death through December 31, 2005 were 
established using the National Death Index (NDI) (10), which is considered a standard source 
of mortality data for epidemiologic research (11).  With data from the NDI, for the 1,508 
cases from the parent study, we constructed a variable indicating death from any cause 
(n=308) as well as a variable indicating death due to breast cancer (n=164), which was 
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determined if breast cancer was listed as the primary or secondary cause of death, using 
International Classification of Disease code 174.9 or C-50.9.  Cases without a death record in 
the NDI database were determined to be alive as of December 31, 2005.  These variables 
indicating cause of death or censoring, along with the variable indicating length of time since 
diagnosis, were the outcomes for our analysis. 
Physical Activity Assessment.  Recreational physical activity was assessed through 
personal interviews, using a modification of the instrument developed by Bernstein and 
colleagues developed in a previous study of physical activity and breast cancer (12).  The 
baseline questionnaire included a screening question asking “Have you ever participated in 
any physical activities or exercises on a regular basis—that is for at least 1 hour per week for 
3 months or more in any year?” (13); those subjects answering affirmatively were considered 
having ever participated in physical activity.  These subjects were then asked to list each 
activity separately, and then answer more detailed questions for each one: 
1) “In what activity did you (first/next) participate on a regular basis?” 
2) “Looking at the calendar, at what age did you start (ACTIVITY) regularly?” 
3) “At what age did you stop (ACTIVITY)?” 
4) “For how many years did you (ACTIVITY) regularly?  For how many months 
each year did you do this?” 
5) “On average, about how many hours per week did you actually (ACTIVITY)?” 
For the subjects with detailed physical activity data the number of months per year of 
each activity was converted to number of hours per week.  Where an activity was reported 
without a corresponding duration, 12 months per year was imputed for non-seasonal 
activities while the average number of months per year was imputed for seasonal activities.  
For each activity a metabolic equivalent of energy expenditure (MET) score was assigned 
using a database derived from previously published values (14).  The MET is a standard unit 
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of energy expenditure for physical activity research (15) and is defined as the energy 
expended while sitting quietly, approximately one kilocalorie per kilogram of bodyweight 
per hour.  When an activity reported by the study subjects did not have a corresponding 
MET-score published then a similar activity with a published MET value was chosen.  For 
each activity the MET value was then multiplied by duration of activity in number of hours 
per week, which was added across all activities for each subject and averaged to arrive at a 
measure of the average total number of MET-hours per week for each subject. 
In the follow-up questionnaire, subjects were asked if they had participated in any 
physical activities or exercises on a regular basis for at least 1 hour a week for 3 months or 
more in any year since the date of diagnosis.  If an affirmative answer was recorded then 
detailed questions regarding type, duration, frequency and age at commencement were asked, 
as described in the baseline questionnaire, for any number of activities, with the time period 
queried relevant to the time since the diagnosis.  From this we calculated an average number 
of MET-hours per week in the time since diagnosis averaged over the entire follow-up 
period, and for women with complete data on when activities started and stopped, we also 
calculated the average number of MET-hours per week for each year from diagnosis up to 
the time of the follow-up interview, as described above.  This yielded a maximum of 7 
follow-up measures of physical activity, beginning in the year of diagnosis. 
Covariates.  Self-reported data on potential covariates were gathered through 
interviewer-administered questionnaires at baseline (in person) and at follow-up (by 
telephone) and included assessment of menopausal status, education, income, treatment 
modalities and other factors known and suspected to influence the development and 
prognosis of breast cancer including anthropometric measures (height in meters and weight 
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in kilograms in the year before diagnosis) and lifetime physical activity assessments.  
Approximately 98% of the respondents completed a self-administered modified Block food 
frequency questionnaire (FFQ) during the baseline interview, which assessed frequency and 
portion size for 101 food items in the year prior (8). Data on tumor stage and estrogen and 
progesterone receptor (ER/PR) status were gathered from medical records of the 1,402 
women who signed a medical record release form at the time of the baseline questionnaire. 
Treatment for the first primary diagnosis of breast cancer and other tumor characteristics 
were gathered from medical records for 598 of the women who signed a medical record 
release at the time of the follow-up questionnaire. The treatment data gathered from the 
medical record matched closely the self-reported data from the follow-up questionnaire 
(kappa coefficients: radiation therapy κ=0.97, chemotherapy κ=0.96 and hormone therapy 
κ=0.92 (16)), and thus the self-reported data are used in these analyses. Data on tumor size 
was obtained from the New York State Cancer Registry. 
Statistical Analysis.  Due to nonresponse to the follow-up questionnaire 33.5% 
(n=506) of the study sample were missing information on post-diagnosis physical activity 
levels.  In addition, there was missing information on start and stop dates for 10.6% (n=160) 
of the sample, which prevented matching these activities to specific timepoints.  However, 
since these women provided information on absolute duration, it was possible to calculate an 
average physical activity level over the entire follow-up period.  For women with complete 
data on when activities began and ended, physical activity levels were also created for each 
year after diagnosis. 
To account for missing data in this study we utilized a selection model for the 
analysis of survival data with time-varying covariates (17).  The selection model accounts for 
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the possibility that data may be not missing at random (NMAR), a condition where the 
probability that data is missing is dependent upon the unobserved data.  The model requires 
specification of (1) the outcome model, here described with a proportional hazards 
regression, (2) linear and logistic regression models for the missing covariates and (3) a 
model describing the probability that data is missing.  
The main exposure for this analysis was post-diagnosis physical activity, which was 
categorized into 0 MET-hrs/wk (referent category), 0.01-9.00 MET-hrs/wk and >9 MET-
hrs/wk.  For each year of follow-up, the corresponding physical activity variable pertained to 
activity undertaken in the year prior, which would reflect the etiologically relevant exposure 
period of recent activity.  Within the selection model, the missing physical activity data at 
each time period was modeled as a linear regression as a function of age at diagnosis, 
chemotherapy and radiation treatment, menopausal status at diagnosis, body mass index 
(BMI, weight in kg/squared height in meters) 1-year before diagnosis and lagged physical 
activity measurements back to diagnosis.  Potential confounders for this analysis included 
variables that have been shown to be related to both survival and post-diagnosis physical 
activity levels, and included age, pre-diagnosis body mass index  in the year prior to 
diagnosis, chemotherapy treatment, radiation therapy treatment and hormone therapy (18, 
19).  We also considered menopausal status at diagnosis, total energy intake in the year prior 
to the baseline interview, stage (in situ vs. invasive), estrogen receptor (ER) status, 
progesterone receptor (PR) status, tumor size (< 2 cm vs. >= 2 cm) and nodal involvement 
(yes vs. no).  In the final models we included those confounders that changed the effect 
estimates of the physical activity-survival association by >10% using a complete case 
analysis.  The final models included age, chemotherapy treatment, radiation treatment, 
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hormone therapy and tumor size, which were also consistent with assessment of confounding 
using a directed acyclic graph.  MET-hrs/wk of physical activity at each timepoint was 
modeled as a linear regression with age, chemotherapy treatment, radiation therapy, 
chemotherapy-radiation therapy interaction, menopausal status, pre-diagnosis BMI and all 
previous measures of MET-hrs/wk.  In addition to physical activity, other covariates with 
significant amounts of missing data included chemotherapy, radiation treatment, hormone 
therapy and tumor size with 32.2%, 33.0%, 32.1%, 31.6% missing, respectively.  For each of 
these variables, a logistic regression model was specified with age, income (< $20,000; 
$20,000-49,999; $50,000-89,999 and >= $90,000) and education (high school or less, some 
college, college graduate and post-college).  Within the selection model, the probability that 
physical activity data was missing was modeled as a logistic regression with age and physical 
activity assessments. 
Other variables with missing data included baseline physical activity (0.93%) 
menopausal status (1.99% missing), pre-diagnosis BMI (1.13% missing), adult weight 
change (from age 20 to 1 year before diagnosis; 1.66% missing), education (0.40% missing) 
and income (0.27% missing).  These small amounts were unlikely to influence our results 
and so the additional cost of estimating models for each of these variables exceeded any 
benefit, therefore we excluded subjects with any of these variables missing.   
Our final analysis then included 1,423 women (94.4% of the original 1,508 cases). 
Among these women, 291 died during the follow-up with 156 of these deaths due to breast 
cancer.  Median survival time was 8.80 years with times ranging from 0.23 to 9.41 years.  
Table 1 shows descriptive statistics for sociodemographic and select prognostic factors for 
the subjects in our analysis.  Most women in the study were postmenopausal at diagnosis and 
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ages ranged from 25 to 91 years.  Less than half of the women reported receiving 
chemotherapy treatment after their diagnosis, while the majority received radiation therapy or 
hormone therapy.   
The model was estimated within a Fully Bayesian framework, specifying vague prior 
distributions on the model parameters and using the Gibbs sampler in WinBUGS 1.4 (20) to 
sample from their posterior distribution.  We ran the sampler for 50,000 iterations, discarding 
the first 25,000 as a burn-in sample and retained every 5th iteration to reduce serial 
correlation.  Posterior hazard ratios (HR) and corresponding 95% credible intervals were 
calculated by exponentiating the mean of the samples for the log-hazard ratios from the 
proportional hazards model (beta coefficients) and the 2.5th and 97.5th percentiles of these 
samples, respectively.  Specifying vague priors on the regression parameters yields posterior 
point estimates and credible intervals that are similar to those from frequentist analysis. 
Results 
As shown in Table 5.1, most women with breast cancer (76.1%) reported some form of 
recreational physical activity after diagnosis, with the majority of those with complete data 
reporting more than 9 MET-hours per week. This level of activity is equivalent to 
approximately 108 minutes per week of brisk walking (4 miles per hour, a moderate-intensity 
activity) or 68 minutes per week of jogging at 5 miles per hour (a vigorous-intensity activity) 
(21). 
Table 5.2 displays the association between mortality and the average physical activity 
over the entire post-diagnosis follow-up period. Moderate levels (0.1-9.0 MET-hours/week) 
were associated with improved survival compared to women who were inactive (0 MET-
hours/week) for both all-cause [HR (95% credible interval): 0.41 (0.27-0.62)] and breast 
cancer-specific mortality [HR: 0.40 (0.25-0.68)], adjusted for pre-diagnostic activity levels 
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and other relevant factors listed in the methods section.  The beneficial effects were even 
greater for the highest level of activity [>9.0 MET-hours/week vs. 0 MET-hours/week; all-
cause HR: 0.21 (0.15-0.30), breast cancer-specific mortality HR: 0.12 (0.07-0.20)].   
Table 5.3 shows the estimates for the effects of average post-diagnosis levels of 
activity on survival stratified by levels of pre-diagnosis physical activity.  Strong beneficial 
effects for the highest physical activity levels undertaken after diagnosis were observed 
across groups, regardless of the average activity level undertaken before diagnosis.  There is 
a slight suggestion, however, of a stronger inverse association for moderate activity among 
women who were inactive before diagnosis [among women who expended 0 MET-
hours/week before diagnosis, comparing 0.1-9.0 MET-hours/week vs. 0 MET-hours/week, 
all-cause mortality HR: 0.31 (0.15-0.59)] compared to those who were moderately active or 
highly active before diagnosis [among women who expended 0.1-9.0 MET-hours week 
before diagnosis, HR: 0.49 (0.23-1.01); among women who expended >9.0 MET-hours week 
before diagnosis HR: 0.56 0.25-1.36)].  Similar patterns were observed for breast-cancer 
specific mortality. 
When we considered variable, yearly physical activity levels over time (table 5.4), 
results for the most-active women were similar to the estimates obtained when we considered 
only average physical activity levels.  For example, for >9.0 MET-hours/week vs. 0 MET-
hours/week, the hazards ratio was 0.23 (0.15-0.39) for all-cause mortality, and 0.22 (0.13-
0.36) for breast cancer specific mortality.  A stronger inverse association, however, was 
noted for those who were moderately active when variable levels were taken into 
consideration, especially for breast-cancer specific mortality [0.1-9.0 MET-hours/week vs. 0 
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MET-hours/week, all-cause mortality HR: 0.35 (0.15-0.70), and breast cancer specific 
mortality HR: 0.22 (0.13-0.36)]. 
In table 5.5 we present results stratified by timing of effect to determine if activity 
before or after diagnosis, or both, is most relevant to enhancing survival. This approach also 
facilitates comparison of our results to those of other studies, who assessed activity around 2 
years or more post-diagnosis.  For all-cause mortality, the beneficial effect of variable, yearly 
physical activity was somewhat greater within the 2 years immediately after diagnosis [>9.0 
MET-hours/week vs. 0 MET-hours/week HR: 0.15 (0.03-0.47)] than 2+ years post-diagnosis 
[>9.0 MET-hours/week vs. 0 MET-hours/week HR: 0.25 (0.15-0.39)], although there are 
substantial reductions in mortality for both time periods.  In contrast, these differences by 
time since diagnosis were not observed when only deaths due to breast cancer were 
considered [>9.0 MET-hours/week vs. 0 MET-hours/week, with 2 years HR: 0.17 (0.04-
0.58), and after 2 years HR: 0.17 (0.08-0.33)]. Additionally, after 2 years, the effect of 
moderate activity was nearly equal to the effect of high activity for both all-cause and breast 
cancer-specific mortality. 
To further isolate the effects of post-diagnosis activity from pre-diagnosis activity, we 
also stratified our analyses by the time period just before and after 1-year post-diagnosis, 
with the former reflecting recent pre-diagnosis physical activity, and the latter corresponding 
to post-diagnosis activity.  As shown in table 5.5, higher physical activity levels appear to 
have similar effects on all-cause mortality regardless of timing [before 1-year post-diagnosis 
HR comparing high activity to inactivity: 0.21 (0.03-0.93); after 1-year post-diagnosis HR 
comparing high activity to inactivity: 0.25 (0.15-0.40)].  However, for breast cancer related 
deaths, activity after diagnosis [HR comparing high activity to inactivity: 0.16 (0.09-0.29)] 
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appeared to be slightly more beneficial than activity before [HR comparing high activity to 
inactivity: 0.43 (0.06-2.32)], although both time periods showed substantial reductions in 
mortality in relation to varying physical activity levels.   
As shown in table 5.5, results were also stratified by body size at the time of 
diagnosis, a well-established indicator of prognosis among women with breast cancer. Post-
diagnosis activity improved survival for both overweight and non-overweight women, 
although the effect appeared to be slightly stronger among women who were not overweight 
in the year prior to diagnosis [BMI < 25 kg/m2 in the year before diagnosis, all-cause 
mortality HR comparing high activity to inactivity: 0.09 (0.03-0.22)] than those who were 
overweight [BMI >= 25 kg/m2 in the year prior to diagnosis, all-cause mortality HR 
comparing high activity to inactivity: 0.41 (0.24-0.70)].  
Discussion 
We observed that greater levels of physical activity undertaken after diagnosis were 
associated with substantially lower risk of death from any cause as well as death due to breast 
cancer in a large, population-based cohort of women who were diagnosed with a first 
primary breast cancer in 1996-1997.  Enhanced survival associated with post-diagnosis 
physical activity was evident over several different scenarios: (1) when activity levels were 
considered as average levels over the entire follow-up versus when yearly variations were 
considered; and (2) when adjustments were made for pre-diagnosis levels of activity and 
body size, and other parameters relevant to prognosis.  The beneficial effect of physical 
activity appeared slightly stronger in the time period following a diagnosis than activity 
undertaken before diagnosis, and also among women who were not overweight in the year 
before diagnosis for both all-cause and breast cancer specific mortality.  Nevertheless, the 
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risk of death was substantially reduced among women who were physically activity after 
diagnosis in all subgroups that we examined.   
Physical activity is associated with several metabolic consequences that may favor 
survival from both breast cancer and cardiovascular disease (22), which were the first and 
second most common cause of death, respectively, in our cohort of women with breast 
cancer.  Especially relevant to cancer, higher levels of physical activity are associated with 
reduction in hormones believed to function as tumor promoters, such as estrogen and insulin.  
The primary mechanism for these effects is through a reduction in adipose tissue (23, 24), 
especially metabolically active visceral fat (25), which is a significant source of endogenous 
estrogen, especially among postmenopausal women (26).  Independent of its effect on 
adiposity, greater physical activity is also associated with an increase in the amount of sex 
hormone binding globulin (SHBG) and improvement in insulin sensitivity (27).  While 
hormonal pathways offer the most convincing explanations for a protective effect of physical 
activity on carcinogenesis, moderate physical activity may improve the immune response 
over both sedentary and exceptionally active individuals (28), possibly by promoting killer-
cell, macrophage and cytokine activity (29, 30) as well as upregulating antioxidant enzyme 
activity (31), which may protect against DNA damage. 
Until recently, studies of the effect of physical activity on survival after breast cancer 
diagnosis focused on pre-diagnostic activity, and results were inconsistent.  Two small 
studies of pre-diagnosis physical activity and survival failed to find associations with breast 
cancer prognosis (32, 33), although protective effects were noted by Abrahamson et al. (34) 
and Irwin et al. (5).  Only recently have a handful of investigations been conducted on the 
effects of post-diagnosis physical activity (3-6) with most reporting an approximately 40-
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50% reduction in risk of death among highly active women (3, 4, 6).  However, the most 
recent report, by Irwin and colleagues (5), observed a very strong protective effect of being 
physically active 2 years after diagnosis; for women who expended 9 or more MET-
hours/week compared to those who were inactive mortality was reduced by two-thirds (all-
cause mortality HR: 0.33, 95% CI: 0.15-0.73), which is similar to the magnitude of effect we 
observed when considering the effect of this same level of activity after 2 years (all-cause 
mortality HR: 0.27).   
While our findings are in general agreement with a protective effect of increasing 
physical activity on mortality among breast cancer survivors, our associations were generally 
stronger in magnitude than those reported by previous studies.  Although the categorization 
of physical activity levels differed across studies, a more likely potential explanation may be 
the significant differences in study design.  Our study followed women forward from date of 
diagnosis, while the previous analyses included women who were well into their survivorship 
experience, usually around 2 to 3 years post-diagnosis but as much as 4 years in one study 
(6), and over 10 years in another (3, 35).  Excluding women who do not survive past the first 
several years could induce length-biased sampling (36) and create a sample of subjects who 
are more likely to survive regardless of their activity levels.  These cohorts are thus not 
generally representative of all women who are diagnosed with breast cancer.  Additionally, 
the instrument we used for physical activity assessment allowed us to obtain longitudinal 
measures of physical activity over the entire follow-up period, while most previous studies 
utilized data from single time periods (e.g. in the year prior to interview).  Timing of physical 
activity assessments is important, as previous research has suggested that among breast 
cancer survivors, physical activity levels tend to decline during the first year, but show an 
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upward trend after one year, although only about half of the women return to their pre-
diagnosis activity levels by 3 years (19).  Failing to fully capture the return to higher levels of 
physical activity among those who survive longer could partly explain the differences in 
reported associations. 
Strengths of our study include its large size and population-based study design that 
included women with breast cancer from the time of diagnosis.  Additionally, we were able 
to ascertain physical activity longitudinally from date of diagnosis through time of the 
follow-up interview, which allowed for evaluation of the effect of temporal changes on the 
effect of physical activity on survival.   
We also employed a novel and rigorous modeling approach to deal with missing data, 
which is far superior to the ad hoc methods often employed in epidemiologic analyses (37).  
Excluding subjects with any missing data, referred to as complete case analysis, has the 
potential to induce bias in parameter estimates and results in reduction in statistical 
efficiency.  Methods that use a category for missing data or improper methods of imputation 
can often perform worse than complete case analysis and are similarly not recommended 
(37).  The Bayesian imputation technique applied here is theoretically sound, amenable to 
sensitivity analysis and applicable to a wide range of outcome models, including linear and 
logistic regression (38).   
Potential limitations of the study reported here are worthy of mention. These include 
the use of self-reported physical activity (39), however the comprehensive instrument we 
used was developed specifically for the study of physical activity and breast cancer (12) and 
has been successfully used in other studies (40, 41).  The use of proxy interviews is also a 
potential source of bias for physical activity data (42), however the number of proxy 
 151 
interviews in our dataset was small (<8%).  Additionally, a recent report found that data 
gathered by proxy interview provided nearly identical associations compared to index reports 
of physical activity (43), suggesting that proxy interviews of physical activity data are 
reliable.  It is also possible that the strong inverse associations noted could be due to healthier 
women being more physically active while those who were sicker were more inclined to be 
less active.  However, this source of bias is unlikely to entirely explain the effects entirely as 
we adjusted for tumor characteristics and treatment, and additionally the results were robust 
when considering physical activity later in the survivorship experience, when such effects 
would likely be attenuated as those with more severe disease would be likely to have died 
within the first several years.  Also, we had limited power to detect effect modification, 
therefore our stratified analyses should be interpreted as exploratory, and should be 
confirmed by other studies.  Although a formal methodology was employed to address 
missing data, the ideal situation would be to have a data set with all variables fully observed 
that is representative of all breast cancer survivors.  Models for missing data may be sensitive 
to model specification (44), which could have potentially influenced these results.   
In summary, our results indicate that physical activity undertaken after diagnosis with 
breast cancer increases survival among women with breast cancer.  We found some 
suggestion that the beneficial effect may vary slightly by the time since diagnosis, as well as 
by body size just before diagnosis, however a protective effect was consistently seen in all 
stratified analyses.  Since most women, especially those with a breast cancer diagnosis, do 
not achieve the recommended amount of physical activity each day (19), these findings 
suggest that this is an important area for public health interventions.   
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Table 5.1.  Characteristics of 1,436 women diagnosed with a first primary breast cancer in 
1996-1997 on Long Island, NY, with follow-up assessments in 2002-2004. 
 
 N (%) 
Deaths as of December 31, 2005  
All cause 291 (20.5) 
Breast-cancer specific 156 (11.0) 
Physical activity over entire follow-
up* period after diagnosis 
 
0 MET-hrs/wk 226 (23.9) 
0.1-9.0 MET-hrs/wk 182 (19.2) 
>9 MET-hrs/wk 538 (56.9) 
Missing 477 
Physical activity before diagnosis*  
0 MET-hrs/wk 582 (40.9) 
0.1-9.0 MET-hrs/wk 355 (25.0) 
>9 MET-hrs/wk 486 (34.1) 
Physical activity 1 year after 
diagnosis* 
 
0 MET-hrs/wk 213 (27.1) 
0.1-9.0 MET-hrs/wk 94 (11.9) 
>9 MET-hrs/wk 480 (61.0) 
Missing 619 
Physical activity 2 years after 
diagnosis* 
 
0 MET-hrs/wk 193 (25.1) 
0.1-9.0 MET-hrs/wk 96 (12.5) 
>9 MET-hrs/wk 480 (62.4) 
Missing 602 
Physical activity 3 years after 
diagnosis* 
 
0 MET-hrs/wk 183 (23.8) 
0.1-9.0 MET-hrs/wk 96 (12.5) 
>9 MET-hrs/wk 490 (63.7) 
Missing 560 
Physical activity 4 years after 
diagnosis* 
 
0 MET-hrs/wk 177 (23.2) 
0.1-9.0 MET-hrs/wk 89 (11.7) 
>9 MET-hrs/wk 496 (65.1) 
Missing 542 
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Table 5.1 (continued).  Characteristics of 1,436 women diagnosed with a first primary breast 
cancer in 1996-1997 on Long Island, NY, with follow-up assessments in 2002-2004. 
 
Physical activity 5 years after 
diagnosis* 
 
0 MET-hrs/wk 183 (24.7) 
0.1-9.0 MET-hrs/wk 83 (11.2) 
>9 MET-hrs/wk 474 (64.0) 
Missing 524 
Physical activity 6 years after 
diagnosis* 
 
0 MET-hrs/wk 349 (62.3) 
0.1-9.0 MET-hrs/wk 30 (5.4) 
>9 MET-hrs/wk 181 (32.3) 
Missing 668 
ER status  
Negative 251 (26.6) 
Positive 694 (73.4) 
Missing 478 
PR status  
Negative 338 (35.9) 
Positive 603 (64.1) 
Missing 482 
Chemotherapy  
No 568 (58.8) 
Yes 398 (41.2) 
Missing 457 
Radiation therapy  
No 379 (39.1) 
Yes 591 (60.9) 
Missing 453 
Hormone therapy  
No 367 (38.5) 
Yes 586 (61.5) 
Missing 470 
Tumor size  
< 2 cm 442 (80.5) 
>= 2 cm 107 (19.5) 
Missing 874 
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Table 5.1 (continued).  Characteristics of 1,436 women diagnosed with a first primary breast 
cancer in 1996-1997 on Long Island, NY, with follow-up assessments in 2002-2004. 
 
BMI 1 year before diagnosis  
<18.5 kg/m2 25 (1.8) 
18.5-24.9 kg/m2 633 (44.5) 
25.0-29.9 kg/m2 451 (31.7) 
>=30.0 kg/m2 314 (22.1) 
Weight change from age 20 to 1 year 
before diagnosis 
 
< 3kg gain or any loss 238 (16.7) 
> 3kg gain 1,185 (83.3) 
Age at diagnosis 
(mean: 58.8 yrs, sd: 12.7 yrs) 
 
20-29.9 10 (0.7) 
30-39.9 77 (5.4) 
40-49.9 302 (21.2) 
50-59.9 377 (26.5) 
60-69.9 337 (23.7) 
70-79.9 272 (19.1) 
80-89.9 45 (3.2) 
90+ 3 (0.2) 
Menopausal Status at diagnosis  
Premenopausal 456 (32.0) 
Postmenopausal 967 (68.0) 
Education  
High school or less 683 (48.0) 
Some college 339 (23.8) 
College graduate 185 (13.0) 
Post college education 216 (15.2) 
Income at diagnosis  
< $20,000 174 (12.2) 
$20,000-49,999 555 (39.0) 
$50,000-89,999 420 (29.5) 
>=$90,000 274 (19.3) 
* Average MET-hours per week for recreational physical activity over relevant interval.  
Note that the total number of subjects available for each assessment declines over time as 
subjects leave the cohort due to death or censoring. 
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Table 5.2.  Hazard ratios (and 95% credible intervals) for the association between all-cause 
and breast cancer-specific mortality, and average post-diagnosis physical activity levels 
(MET-hrs/wk) over the entire follow-up period, among a cohort of women with a first 
primary breast cancer on Long Island, NY, and followed through December 31, 2005.   
Post-diagnosis 
Physical Activity Hazard ratio* (95% credible interval) 
Average 
Met-hrs/wk 
All-cause 
Mortality 
Breast Cancer-
Specific Mortality 
0 1. 1. 
0.1-9.0 0.41 (0.27-0.62) 0.40 (0.25-0.68) 
>9.0 0.21 (0.15-0.30) 0.12 (0.07-0.20) 
* Models adjusted for age, chemotherapy treatment, radiation therapy, hormone therapy, 
tumor size and pre-diagnosis physical activity levels (MET-hrs/wk).  
Table 5.3.  Hazard ratios (and 95% credible intervals) for the association between all-cause 
and breast cancer specific mortality and average post-diagnosis physical activity levels (PA) 
over entire follow-up period, stratified by pre-diagnosis physical activity (PA) levels, among 
women diagnosed with a first primary breast cancer in 1996-1997 on Long Island, NY, and 
followed through December 1, 2005. 
 Hazard ratio* (95% credible interval) 
Post-diagnosis 
Physical Activity 
All-cause Mortality 
(292 deaths/1,436 subjects) 
Average 
Met-hrs/wk 
Pre-diagnosis PA  
0 Met-hrs/wk 
Pre-diagnosis PA 
0.1-9.0 Met-hrs/wk 
Pre-diagnosis PA 
>9.0 Met-hrs/wk 
0 1. 1. 1. 
0.1-9.0 0.31 (0.15-0.59) 0.49 (0.23-1.01) 0.56 (0.25-1.36) 
>9.0 0.26 (0.15-0.44) 0.21 (0.09-0.43) 0.21 (0.10-0.45) 
    
Post-diagnosis 
Physical Activity 
Breast Cancer-Specific Mortality 
(156 deaths/1,436 subjects) 
Average 
Met-hrs/wk 
Pre-diagnosis PA  
0 Met-hrs/wk 
Pre-diagnosis PA 
0.1-9.0 Met-hrs/wk 
Pre-diagnosis PA 
>9.0 Met-hrs/wk 
0 1. 1. 1. 
0.1-9.0 0.26 (0.10-0.60) 0.49 (0.19-1.18) 0.48 (0.19-1.29) 
>9.0 0.13 (0.05-0.30) 0.17 (0.07-0.39) 0.08 (0.02-0.23) 
* Models adjusted for age, chemotherapy treatment, radiation therapy, hormone therapy and 
tumor size. 
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Table 5.4.  Hazard ratios (and 95% credible intervals) for the association between all-cause 
and breast-cancer specific mortality and post-diagnosis physical activity levels (met-hrs/wk) 
assessed yearly over entire follow-up, among women diagnosed with a first primary breast 
cancer in 1996-1997 on Long Island NY, and followed through December 31, 2005.   
Post-diagnosis 
Physical Activity Hazard ratio* (95% credible interval) 
Yearly  
Met-hrs/wk 
All-cause  
Mortality 
Breast Cancer-
Specific Mortality 
0 1. 1. 
0.1-9.0 0.35 (0.15-0.70) 0.23 (0.06-0.59) 
>9.0 0.23 (0.15-0.39) 0.22 (0.13-0.36) 
* Models adjusted for age, chemotherapy treatment, radiation therapy, hormone therapy and 
tumor size. 
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Table 5.5.  Hazard ratios (and 95% credible intervals) for the association between all-cause 
and breast cancer-specific mortality and yearly post-diagnosis physical activity (PA) levels, 
stratified by time since diagnosis and pre-diagnosis BMI, among women diagnosed with a 
first primary breast cancer in 1996-1997 on Long Island, NY, and followed through 
December 31, 2005. 
 Hazard ratio* (95% credible interval) 
Post-
diagnosis PA 
All-cause Mortality 
(292 deaths/1,436 subjects) 
Breast Cancer Mortality 
(156 deaths/1,436 subjects) 
 Time since diagnosis: Time since Diagnosis: 
Yearly  
Met-hrs/wk 
 
0-2 years 
 
2+ years 
 
 0-2 years 
 
2+ years 
0 1. 1. 1. 1. 
0.1-9.0 0.39 (0.11-1.11) 0.27 (0.06-0.74) 0.22 (0.03-0.92) 0.18 (0.03-0.66) 
>9.0 0.15 (0.03-0.47) 0.25 (0.15-0.39) 0.17 (0.04-0.58) 0.17 (0.08-0.33) 
     
 Time since diagnosis: Time since Diagnosis: 
Yearly  
Met-hrs/wk 
 
0-1 year 
 
1+ year 
 
0-1 year 
 
1+ year 
0 1. 1. 1. 1. 
0.1-9.0 0.61 (0.15-1.99) 0.21 (0.05-0.59) 0.54 (0.08-2.71) 0.11 (0.02-0.47) 
>9.0 0.21 (0.03-0.93) 0.25 (0.15-0.40) 0.43 (0.06-2.32) 0.16 (0.09-0.29) 
     
 BMI one year before diagnosis BMI one year before diagnosis 
Yearly  
Met-hrs/wk 
 
 < 25 
 
 >= 25 
 
 < 25 
 
 >=25 
0 1. 1. 1. 1. 
0.1-9.0 0.17 (0.03-0.60) 0.48 (0.19-1.13) 0.07 (0.00-0.46) 0.31 (0.07-0.95) 
>9.0 0.09 (0.03-0.22) 0.41 (0.24-0.70) 0.13 (0.04-0.32) 0.23 (0.01-0.47) 
* Models adjusted for age, chemotherapy treatment, radiation therapy, hormone therapy and 
tumor size
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CHAPTER 6 
DISCUSSION 
Summary 
A statistical model to address potentially non-ignorably missing time-varying covariates in 
survival analysis was developed.  This technique, and a slight modification, was applied to 
two analyses of a large, population-based follow-up study of women with a recent diagnosis 
of breast cancer to assess if post-diagnosis weight change and physical activity levels were 
associated with survival.   
The results showed that women who had gained weight after diagnosis had worse 
survival when deaths from all causes as well as deaths specifically due to breast cancer were 
considered.  When considering post-diagnosis weight change, the effects for pre-diagnosis 
body size that have been consistently associated with poorer prognosis in the recent 
literature, body mass index (BMI) before diagnosis and adult weight gain before diagnosis, 
were noticeably attenuated, suggesting that most of their reported effect is mediated through 
weight change after diagnosis.  In a stratified analysis, the effect was greater when the post-
diagnosis weight gain occurred closer to diagnosis, when chemotherapy-related weight gain 
is of concern, compared to the time farther from diagnosis, however the estimates were not 
very precise.  Additionally, weight gain after diagnosis appeared to be more deleterious for 
women who are heavier before diagnosis or who have gained weight as an adult before 
diagnosis.   
Being physically active after diagnosis was associated with better survival, even with 
adjustments included for the effects of activity undertaken before diagnosis. In addition, the 
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inverse association with activity was noted regardless of the timing of the outcome relative to 
the date of diagnosis.  Further, the effect may be more pronounced among women who are 
leaner before diagnosis, but again the estimates were imprecise. 
The findings for both the change in weight and physical activity analyses are in 
general agreement with other recent reports (1-8), although the magnitude of the associations 
reported here are stronger.  Recent reports of weight change and survival in similar 
populations have been mixed (5-7), although methodology has differed substantially across 
reports, with notable differences in study design, exposure assessment and definition of 
cutpoints for categorization of exposures.  Nevertheless, two of these three previous studies 
report some degree of a positive association between weight gain and survival, even if only 
in subgroups of women (5, 7).  The findings of this work generally agree with a U-shaped 
relationship between weight change and survival that have been described among the general 
population, with greater risk of mortality observed for those who lose or gain substantial 
amounts of weight, and the lowest risk of death observed for those who maintain, or gain 
little weight (9).  Although weight gain and absolute obesity likely represent somewhat 
different exposures, as one can gain weight and not necessarily become obese, it is worth 
noting that in the general population, a similar pattern has been reported with excess deaths 
among the underweight (body mass index, BMI < 18.5) and obese (BMI ≥ 30.0), compared 
to those in the normal weight (BMI ≥  18.5 and < 25) and overweight (BMI ≥ 25 and < 30) 
categories (10). 
Recent analyses of physical activity and survival among women with breast cancer 
have consistently reported inverse associations (1-4, 8), although the effects reported here are 
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stronger.  Possible reasons for the larger effect sizes found in the analyses undertaken here as 
compared to previous reports are discussed below.  
Missing Data 
A particular strength of this work was the development and application of a theoretically 
sound approach to the treatment of missing data.  Missing covariate data is quite common in 
epidemiologic research, especially in longitudinal studies when subjects may be lost to 
follow-up, fail to remember, or simply refuse to answer certain questions.  This issue is 
especially problematic when the variables of interest are sensitive in nature and so the 
likelihood that they are missing is dependent upon their actual (unobserved) value, in which 
case the data are not missing at random (NMAR).  The text by Little and Rubin (11) provides 
a comprehensive overview of missing data in general and proposes the taxonomy of missing 
completely at random (MCAR), where the probability that data is missing is independent of 
observed or unobserved data, missing at random (MAR), when the probability that data is 
missing is dependent on observed data, and NMAR, when the probability that data is missing 
depends upon the unobserved missing values.  Several authors have recently reviewed the 
issue of missing data in the context of epidemiologic and public health research (12, 13) 
including a discussion of proper and improper analytic approaches.  Since most statistical 
software packages automatically exclude any subject with missing data on one or more 
variable such complete case analyses are common, although when there is a significant 
amount of missing data they result in a loss of statistical efficiency and under many 
circumstances can yield significantly biased estimates.  The results presented in chapter 3 
underscore the dangers associated with complete case analysis in particular: not only were 
the effect estimates for weight change attenuated from the more complete selection model 
results, but weight gain showed an inverse association, and ER-positive status showed a 
 165 
positive association with breast cancer mortality, which are in direct contrast to associations 
found in the more comprehensive approach that was developed for this analysis as well as 
with clinical evidence.  Ad hoc methods are also widely employed, as many investigators still 
utilize some variant of the “missing indicator” method (12), where subjects with missing 
values are assigned to a unique category representing those with missing data, or improper 
imputation, where missing values are estimated from sample means, predicted from 
regression models or simply carried forward from previous observations (in longitudinal 
studies) and then treated as “true” data with no adjustment for the fact that such predicted 
values carry with them a degree of uncertainty.  Both of these methodologies are to be 
avoided as they can induce significant bias and, in the case of improper imputation, 
underestimate standard errors (12, 14, 15).   
The approach taken for this study was to extend the selection model proposed by 
Herring et al. (16) to allow for time-varying covariates, which to the best of my knowledge 
has not been addressed in the previous statistics literature.  The method presented in chapter 
3 is very flexible, can address both MAR and NMAR data and easily lends itself to 
sensitivity analyses to explore changes in these assumptions and model specifications.  
Sensitivity analysis is especially important in cases where NMAR is suspected since 
selection models can be quite sensitive to changes in specification (16) and missing data 
methods in general rely heavily on untestable assumptions. 
Formal approaches to regression analysis with missing covariate data include 
maximum likelihood, multiple imputation, weighted estimating equations and Fully Bayesian 
(FB), which are described in general by Ibrahim et al. (17).  The approach taken for this 
analysis was FB, which requires specification of models for the outcome, missing covariates 
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and the missing data mechanism (in the case of NMAR covariates), as well as prior 
distributions on each of the parameters for the aforementioned models.  The Bayesian 
framework offers considerable flexibility since sensitivity analyses to assumptions of the 
missing data mechanism are easily conducted.  Additionally, estimation is readily 
accomplished through use of the Gibbs sampler in WinBUGS (18) which is computationally 
quicker and requires considerably less coding than comparable likelihood-based techniques.  
Although the outcome for this study was survival, this method can easily be applied to any 
outcome, including binary data for the analysis of case-control studies.  Bayesian methods 
are becoming more accepted in the analysis of epidemiologic data (19-24) and the technique 
outlined here should be accessible to many practicing epidemiologists with moderate 
quantitative training. 
Study Design 
An additional strength of this analysis is that it utilized data from a population-based cohort 
of women who were followed forward from the date of diagnosis of breast cancer.  Most of 
the recent studies of both post-diagnosis weight change (5-7) and post-diagnosis physical 
activity (1-4) have been limited to designs where follow-up recruitment and exposure 
assessments were made several years after the date of diagnosis.  In one study population that 
has yielded two reports (1, 7), single post-diagnosis exposure assessments were made an 
average of nearly 6 years, and as much as 16 years after diagnosis.  According to recent 
SEER statistics, among women who were diagnosed with breast cancer in 1996, a total of 
8.8% died during the first 2 years and 13% died in the first 5 years, while only an additional 
6.2% (19.2% total) died in the second five years after diagnosis (25).  Although absolute 
survival rates have improved over the years, mostly due to more effective treatments, this 
pattern remains consistent:  those who survive past the first several years are more likely to 
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continue surviving.  Such samples are unlikely to represent the general population of breast 
cancer survivors. 
An important issue surrounding previous study designs is the timing of exposure 
assessments.  Body size and physical activity were typically assessed only once, near the 
time of enrollment (e.g. 2 or more years after diagnosis), and often not at uniform points 
within a given study.  Capturing the longitudinal patterns of both body size and physical 
activity are important among breast cancer survivors as changes in body composition are 
associated with length of time on treatment regimens, especially chemotherapy (26), and 
weight gain usually peaks around the first year after diagnosis.  Additionally, among women 
with breast cancer, physical activity levels tend to decline during the first year and increase 
thereafter, although only about half of the women have returned to their pre-diagnosis levels 
by 3 years (27).  Given the association between physical activity and body size, this could 
also have implications not only for assessment of physical activity as an independent 
prognostic factor, but also for weight change.  If these factors are not measured consistently 
and at relevant intervals from the date of diagnosis then important changes could be missed 
and bias could result, especially when coupled with sampling issues discussed above.  This 
study is the first to utilize multiple assessments of both body size and physical activity, which 
allowed the assessment of how weight change and physical activity levels at various times in 
the survival experience affect prognosis.   
Exposure Assessment 
Self-reported exposures, such as body size and physical activity, are often of concern given 
issues related to measurement error and recall bias.  Sensitive questions such as weight are 
often believed to be under-reported by heavier individuals and over-reported by lighter 
individuals (28), however a study of women of similar age to this population showed that 
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self-reported anthropometric measures are highly accurate and comparable to measurements 
obtained in a clinic setting (29).   
Validity of self-reported physical activity questionnaires are also often in question 
(30), however the instrument used for this study was developed for studies of physical 
activity and breast cancer (31) and its semi open-ended format offers an extremely 
comprehensive assessment of type, duration and frequency of recreational physical activity 
over broad periods of time.  Although a prospective assessment of physical activity may have 
provided more accurate short-term assessments, the use of alternative assessments such as 
activity diaries or even objective measurement tools such as pedometers or accelerometers 
would not have been able to be utilized to the extent to assess long-term physical activity 
patterns in such a large study population. 
Study Limitations 
While this study has several notable strengths, its limitations should also be acknowledged.  
The study population consisted of primarily white women of generally higher socioeconomic 
status compared to the rest of the nation and thus their experiences may not be representative 
of the survival experience of all women who are diagnosed with breast cancer, in particular 
those of other racial or socioeconomic groups.  Consequently, these results may not be 
generalizable to all women with breast cancer.  
Due to sparseness of the data that made model convergence difficult, I was unable to 
examine the joint effects of physical activity and weight change.  As physical activity and 
body size are linked, it would have been informative to examine each variable as a 
confounder, and more interestingly a potential effect modifier for the other.  Although this 
was a limitation of this study, the analysis presented here illustrated the beneficial effect of 
physical activity regardless of baseline body size, which appears to be a marker for post-
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diagnosis weight change.  Furthermore, baseline body size was not a confounder for the 
analysis of post-diagnosis physical activity, nor was baseline physical activity a confounder 
for post-diagnosis weight change, which could be consistent with independent effects of each 
factor. 
This analysis could have benefited from assessment of changes in more specific 
measures of adiposity, such as percent body fat, or changes in measures of fat patterning, 
such as waist-to-hip ratio, which are believed to be strongly associated with metabolically 
active central adiposity.  To date, no study has examined the effect of post-diagnosis changes 
in fat patterning on survival after breast cancer, and so it is unclear if this, or weight change, 
is a more useful predictor of mortality.  Although this would have yielded additional insight, 
this analysis did focus on weight change, which is also strongly associated with changes in 
central adiposity among adults (32). 
This analysis could have also benefited from more complete and detailed stage and 
treatment data.  Although I was able to adjust for tumor characteristics and gross measures of 
treatment regimen they did have significant amounts of missing data and the additional 
resolution afforded by TNM stage and more detailed treatment assessment could help reduce 
the potential for residual confounding by these variables in this analysis.  While this 
additional information would have yielded more complete control of confounding, it is 
extremely unlikely that including detailed stage or treatment variables would have 
significantly attenuated the associations I observed. 
Future Directions 
The literature on the association of obesity and survival would benefit from additional work 
examining the effects of fat patterning and overall body composition, as it is believed that 
visceral fat is more detrimental than subcutaneous adipose tissue.  Although adult weight 
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gain is often associated with an increase in visceral fat, treatment regimens and reductions in 
activity levels seen among breast cancer patients are also associated with changes in body 
composition such as loss of lean body mass in addition to a gain in adiposity (33).  Increase 
in percent body fat due to reduction in lean body mass may not be fully captured by weight 
change, if total weight remains the same.  A more detailed inspection of changes in body 
composition could further highlight areas for intervention. 
Studies of physical activity and breast cancer survival have, to date, focused on 
general measures of activity, usually MET-hours per week or simply hours per week in 
various activities.  Future work should assess the effects of different types of activities, 
including resistance and aerobic training.  Additionally, complementary and alternative 
therapies are increasing in popularity among breast cancer patients (34), including therapies 
that incorporate physical activity, such as yoga and pilates (35-37).  Each form of exercise 
tends to influence different physiological processes, with resistance training associated with 
increases in lean body mass (38, 39) and glycemic control (40, 41), while aerobic activity is 
associated with reduction in body size and favorable changes in risk factors for 
cardiovascular disease (42).  Yoga and pilates have also shown potential for helping women 
regain mobility (37), and manage stress and fatigue (35, 36).  The identification of differential 
effects of each type of activity could assist in designing post-diagnostic rehabilitation 
programs for breast cancer patients as well as public health interventions for these women in 
general. 
Another area that warrants attention is the identification of a “healthy lifestyle 
pattern” that could be associated with improved survival.  Diet, exercise and weight 
management all interact with each other in a manner that impacts the metabolic environment 
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affecting both cancer and cardiovascular disease, especially insulin resistance (42).  There 
has been recent work on identifying dietary patterns that may be associated with survival 
among cancer patients (43, 44), however this approach could also be applied to identification 
of a general behavioral pattern among breast cancer survivors, such as a combined diet and 
physical activity pattern of those with the lowest mortality.  This approach has been explored 
recently by one group that explored survival by a combination of fruit and vegetable intake 
and physical activity and they found that survival was highest among women with high fruit 
and vegetable intake and high physical activity than among any other combination of these 
behaviors (3).  Unfortunately such interactions were not possible to explore in the study on 
which this dissertation is based as only 679 (45%) of the case women completed a follow-up 
food frequency questionnaire. 
As intriguing as these dietary intake findings are, research focused on disentangling 
the effects of a healthy lifestyle on breast cancer survival would benefit from more rigorous 
methodologies for data reduction, such as factor analysis (44), reduced rank regression (42) 
or Bayesian hierarchical models (19, 45).  This information could not only lend itself to 
targeted public health messages, but also enhance our understanding of the biology of 
survival after a diagnosis of breast cancer. 
Conclusion 
Findings from this population-based cohort of women with breast cancer, which utilized a 
statistical approach developed specifically for this study, indicate that survival is hampered 
among women who gain or lose weight after diagnosis, but enhanced among those who are 
physically active post-diagnosis even if they were overweight or inactive before diagnosis. 
Future studies should focus on determining which specific combination of characteristics of a 
healthy lifestyle after diagnosis, including consideration of changes in dietary intake, 
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increase survival among women with breast cancer.  Intervention studies could also be 
undertaken to identify effective methods to assist women newly diagnosed with breast cancer 
to maintain their weight and engage in physical activity during the post-diagnosis period, 
including during the time period that they are receiving treatment for their disease. 
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APPENDIX 
WinBUGS CODE 
The software used to estimate the models for these analyses was WinBUGS version 1.4 (1); 
to invoke WinBUGS I used the R programming language as a front end to pass the data and 
parameters (http://www.stat.columbia.edu/~gelman/bugsR/) which offers a very convenient 
approach to using the WinBUGS program.  Below is an example of the WinBUGS code used 
to estimate the non-ignorably missing data models discussed in chapter 3 (model 2 in table 
3.2).  The data elements for each subject are: dur (length of follow up for each subject), death 
(indicator of censoring or death), fu.years (time of final follow-up assessment), dpwt.fu (a 
vector of the three assessments of weight change), bmiref (BMI one year before diagnosis), 
wtchg20.cat (adult weight change), chemo (chemotherapy indicator), erstat (ER positive 
indicator), prstat (PR positive indicator), tumor2 (indicator tumor size >2cm), dxage 
(continuous age in years at diagnosis), income, educ (education level), postmenp (indicator 
of postmenopausal status).  The parameters of the model are: N=1436, the total number of 
subjects; J=10, the number of intervals for the proportional hazards model and eps=10-6 is a 
parameter that allows for definition of strict inequalities with the step function. 
model select; 
   { 
    # Partition time axis 
      for (k in 1:J+1) { 
            a[k] <- 10*(k-1)/J; # I chose 10, evenly spaced intervals 
      } 
 
   for (i in 1:N) { 
      for (k in 1:J) { 
 
      # Indicator if event-time in interval k 
      d[i,k]<- death[i]*step(dur[i]-a[k]+eps)*step(a[k+1] - dur[i]); 
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      # length of overlap of dur[i] with interval k 
      delta[i,k] <- (min(dur[i], a[k+1]) - a[k])*step(dur[i]-a[k]); 
 
      # Assign exposure to correct interval 
      dpwt[i,k] <- dpwt.fu[i,1]*step(1.0-a[k]-eps) +     
             dpwt.fu[i,2]*(step(a[k]-1.0)*(step(fu.years[i]-a[k]-eps) +  
                                            equals(fu.years[i],1.0))) 
             + dpwt.fu[i,3]*step(a[k]-fu.years[i])* 
                                            step(fu.years[i]-1.0-eps);  
      # Assign dpwt to categories 
      dpwt0[i,k] <- step(-5 - dpwt[i,k]+eps); # > 5% loss in bodyweight 
      dpwt1[i,k] <- step(dpwt[i,k] + 5)*step(5 - dpwt[i,k]);  
                # change +/- 5% [Maintenance, REF] 
      dpwt2[i,k] <- step(dpwt[i,k] - 5 + eps)*step(10 - dpwt[i,k]);  
                # change in bodyweight > than 5% and <=10% 
      dpwt3[i,k] <- step(dpwt[i,k] - 10 + eps);  
                # change in bodyweight > 10% 
 
      # [T|X,Z]--model for time to event conditional upon observed  
      # and unobserved variables 
 
      theta[i,k] <- lambda[k]*exp(beta[1]*dpwt0[i,k] +  
                beta[2]*dpwt2[i,k] + beta[3]*dpwt3[i,k] +  
                beta[4]*step(bmiref[i]-25.0)*step(30.0-bmiref[i]-eps) + 
                beta[5]*step(bmiref[i]-30.0) +  
                beta[6]*equals(wtchg20.cat[i],0) +  
                beta[7]*equals(wtchg20.cat[i],2) +  
                beta[8]*chemo[i] + beta[9]*erstat[i] +  
                beta[10]*prstat[i] + beta[11]*tumor2[i] +  
                beta[12]*dxage[i]) ; 
 
                # define the likelihood 
                d[i,k] ~ dpois(mu[i,k]); 
                mu[i,k] <- delta[i,k]*theta[i,k]; 
 
      } 
 
      # MODEL 2:  Models for missing covariates 
 
      logit(p.r.chemo[i]) <- phi.chemo[1] +  
               phi.chemo[2]*dxage[i] +  
               phi.chemo[3]*(equals(income[i],3)+equals(income[i],4)+ 
                  equals(income[i],5)) +  
               phi.chemo[4]*(equals(income[i],6)+equals(income[i],7)) + 
               phi.chemo[5]*(equals(income[i],8)) +  
               phi.chemo[6]*equals(educ[i],3) + 
               phi.chemo[7]*equals(educ[i],4) +  
               phi.chemo[8]*equals(educ[i],5) ; 
             
      chemo[i] ~ dbin(p.r.chemo[i],1); 
 
      logit(p.r.erstat[i]) <- phi.erstat[1] + phi.erstat[2]*dxage[i]; 
 
      erstat[i] ~ dbin(p.r.erstat[i],1); 
 
      logit(p.r.prstat[i]) <- phi.prstat[1] + phi.prstat[2]*dxage[i] ; 
 
      prstat[i] ~ dbin(p.r.prstat[i],1); 
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      logit(p.r.tumor2[i]) <- phi.tumor2[1] +  
          phi.tumor2[2]*dxage[i] +  
          phi.tumor2[3]*(equals(income[i],3)+equals(income[i],4)+ 
             equals(income[i],5)) +  
          phi.tumor2[4]*(equals(income[i],6)+equals(income[i],7)) + 
          phi.tumor2[5]*(equals(income[i],8)) +  
          phi.tumor2[6]*equals(educ[i],3) + 
          phi.tumor2[7]*equals(educ[i],4) +  
          phi.tumor2[8]*equals(educ[i],5) ; 
 
      tumor2[i] ~ dbin(p.r.tumor2[i],1); 
 
      # Models for missing weight change 
      # 3rd follow-up: 
      mu.dpwt[i,3] <- alpha3[1] + alpha3[2]*dxage[i] +  
                      alpha3[3]*chemo[i] + alpha3[4]*postmenp[i] +  
                      alpha3[5]*bmiref[i] + alpha3[6]*dpwt.fu[i,2] +  
                      alpha3[7]*dpwt.fu[i,1]; 
      dpwt.fu[i,3] ~ dnorm(mu.dpwt[i,3],tau3.dpwt); 
 
      # 2nd follow-up: 
      mu.dpwt[i,2] <- alpha2[1] + alpha2[2]*dxage[i] +  
                      alpha2[3]*chemo[i] + alpha2[4]*postmenp[i] +  
                      alpha2[5]*bmiref[i] + alpha2[6]*dpwt.fu[i,1]; 
 
      dpwt.fu[i,2] ~ dnorm(mu.dpwt[i,2],tau2.dpwt); 
 
      # 2nd follow-up: 
      mu.dpwt[i,1] <- alpha1[1] + alpha1[2]*dxage[i] +  
                      alpha1[3]*chemo[i] + alpha1[4]*postmenp[i] +  
                      alpha1[5]*bmiref[i]; 
 
      dpwt.fu[i,1] ~ dnorm(mu.dpwt[i,1],tau1.dpwt); 
 
      # Missingness models for each follow-up assessment: 
      # 3rd follow-up: 
      logit(p.r.fu[i,3]) <- gamma3[1] + gamma3[2]*dpwt.fu[i,3] +  
                        gamma3[3]*dxage[i] + gamma3[4]*fu.years[i] +  
                        gamma3[5]*p.r.fu[i,1] + gamma3[6]*p.r.fu[i,2]; 
 
      r.fu[i,3] ~ dbin(p.r.fu[i,3],1); 
 
      # 2nd follow-up: 
      logit(p.r.fu[i,2]) <- gamma2[1] + gamma2[2]*dpwt.fu[i,2] +  
             gamma2[3]*dxage[i] + gamma2[4]*p.r.fu[i,1]; 
 
      r.fu[i,2] ~ dbin(p.r.fu[i,2],1); 
 
      # 1st follow-up: 
      logit(p.r.fu[i,1]) <- gamma1[1] + gamma1[2]*dpwt.fu[i,1] +  
                            gamma1[3]*dxage[i] ; 
      r.fu[i,1] ~ dbin(p.r.fu[i,1],1); 
 
   } 
 
   # PRIORS ON PARAMETERS 
   # Parameters for survival model 
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   for (k in 1:J) { lambda[k] ~ dgamma(0.01, 0.01); } 
   for (l in 1:12) { beta[l] ~ dnorm(0, 0.00001); } 
 
   # Parameters for dpwt models 
   for (l in 1:7) { alpha3[l] ~ dnorm(0, 0.00001); } 
   for (l in 1:6) { alpha2[l] ~ dnorm(0, 0.00001); } 
   for (l in 1:5) { alpha1[l] ~ dnorm(0, 0.00001); }                 
 
   # Parameters for missing data models 
   for (l in 1:8) { phi.chemo[l] ~ dnorm(0, 0.00001);} 
   for (l in 1:8) { phi.tumor2[l] ~ dnorm(0, 0.00001);} 
   for (l in 1:2) { phi.erstat[l] ~ dnorm(0,0.00001);} 
   for (l in 1:2) { phi.prstat[l] ~ dnorm(0,0.00001);}  
 
   tau3.dpwt ~ dgamma(0.01, 0.01); 
   tau2.dpwt ~ dgamma(0.01, 0.01); 
   tau1.dpwt ~ dgamma(0.01, 0.01); 
 
   # Parameters for missingness model 
   for (l in 1:6) { gamma3[l] ~ dnorm(0, 0.00001); } 
   for (l in 1:4) { gamma2[l] ~ dnorm(0, 0.00001); } 
   for (l in 1:3) { gamma1[l] ~ dnorm(0, 0.00001); }                 
} 
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